
Supplementary material

Incidence trends of inherited anemias at the global, regional, and national levels over three decades


Supplementary Figure S1. The hierarchical cluster analysis of the temporal trends in incidence rate of
inherited anemias at national level
Supplementary Figure S2. The incidence rate of thalassemias in 2019
Supplementary Figure S3. The percentage change in incident cases of thalassemias between 1990 and
2019. · · · · · · · · · · · · · · · · · · ·
Supplementary Figure S4. The EAPCs in incidence rate of thalassemias from 1990 to 2019. EAPCs
estimated annual percentage change.
Supplementary Figure S5. The incidence rate of thalassemias trait in 2019
Supplementary Figure S6. The percentage change in incident cases of thalassemias trait between 1990 and
2019. · · · · · · · · · · · · · · · · · · ·
Supplementary Figure S7. The EAPCs in incidence rate of thalassemias trait from 1990 to 2019. EAPCs
estimated annual percentage change.
Supplementary Figure S8. The incidence rate of sickle cell disorders in 2019
Supplementary Figure S9. The percentage change in incident cases of sickle cell disorders between 1990
and 2019. · · · · · · · · · · · · · · · · · · ·
Supplementary Figure S10. The EAPCs in incidence rate of sickle cell disorders from 1990 to 2019
EAPCs, estimated annual percentage change.
Supplementary Figure S11. The incidence rate of sickle cell trait in 2019
Supplementary Figure S12. The percentage change in incident cases of sickle cell trait between 1990 and
2019. · · · · · · · · · · · · · · · · · · ·
Supplementary Figure S13. The EAPCs in incidence rate of sickle cell trait from 1990 to 2019. EAPCs
estimated annual percentage change.
Supplementary Figure S14. The incidence rate of G6PD deficiency in 2019. G6PD, glucose-6-phosphate
dehydrogenase.
Supplementary Figure S15. The percentage change in incident cases of G6PD deficiency between 1990
and 2019. G6PD, glucose-6-phosphate dehydrogenase.
Supplementary Figure S16. The EAPCs in incidence rate of G6PD deficiency from 1990 to 2019. EAPCs
estimated annual nercentage change G6PD glucose-6-phosphate dehydrogenase

Supplementary Figure S17. The incidence rate of G6PD trait in 2019. G6PD, glucose-6-phosphate
dehydrogenase
Supplementary Figure S18. The percentage change in incident cases of G6PD trait between 1990 and 2019.
G6PD, glucose-6-phosphate dehydrogenase
Supplementary Figure S19. The EAPCs in incidence rate of G6PD trait from 1990 to 2019. EAPCs,
estimated annual percentage change. G6PD, glucose-6-phosphate dehydrogenase
Supplementary Figure S20. The EAPCs in incidence rate of thalassemias from 1990 to 2019, at global,
regional and national level for both sexes combined
Supplementary Figure S21. The EAPCs in incidence rate of thalassemias trait from 1990 to 2019, at global
regional and national level for both sexes combined
Supplementary Figure S22. The EAPCs in incidence rate of sickle cell disorders from 1990 to 2019, at
global, regional and national level for both sexes combined
Supplementary Figure S23. The EAPCs in incidence rate of sickle cell trait from 1990 to 2019, at global,
regional and national level for both sexes combined
Supplementary Figure S24. The EAPCs in incidence rate of G6PD deficiency from 1990 to 2019, at global
regional and national level for both sexes combined
Supplementary Figure S25. The EAPCs in incidence rate of G6PD trait from 1990 to 2019, at global,
regional and national level for both sexes combined
Supplementary Table S1. The incident cases and incidence rates of thalassemias in 1990 and 2019, along
with their temporal trend
Supplementary Table S2. The incident cases and incidence rates of thalassemias trait in 1990 and 2019,
along with their temporal trend
Supplementary Table S3. The incident cases and incidence rates of sickle cell disorders in 1990 and 2019,
along with their temporal trend
Supplementary Table S4. The incident cases and incidence rates of sickle cell trait in 1990 and 2019, along
with their temporal trend
Supplementary Table S5. The incident cases and incidence rates of G6PD deficiency in 1990 and 2019,
along with their temporal trend
Supplementary Table S6. The incident cases and incidence rates of G6PD trait in 1990 and 2019, along
with their temporal trend
Supplementary Table S7. The change of inherited anemias cases and incidence rates between 1990 and
2019 at national level, both sexes


Supplementary Figure S1. The hierarchical cluster analysis of the temporal trends in incidence rate of inherited anemias at national level.



Supplementary Figure S2. The incidence rate of thalassemias in 2019.




Supplementary Figure S3. The percentage change in incident cases of thalassemias between 1990 and 2019.




Supplementary Figure S4. The EAPCs in incidence rate of thalassemias from 1990 to 2019.


EAPCs, estimated annual percentage change.




Supplementary Figure S5. The incidence rate of thalassemias trait in 2019.




Supplementary Figure S6. The percentage change in incident cases of thalassemias trait between 1990 and 2019.




Supplementary Figure S7. The EAPCs in incidence rate of thalassemias trait from 1990 to 2019. EAPCs, estimated annual percentage change.




Supplementary Figure S8. The incidence rate of sickle cell disorders in 2019.




Supplementary Figure S9. The percentage change in incident cases of sickle cell disorders between 1990 and 2019.




Supplementary Figure S10. The EAPCs in incidence rate of sickle cell disorders from 1990 to 2019. EAPCs, estimated annual percentage change.




Supplementary Figure S11. The incidence rate of sickle cell trait in 2019.




Supplementary Figure S12. The percentage change in incident cases of sickle cell trait between 1990 and 2019.




Supplementary Figure S13. The EAPCs in incidence rate of sickle cell trait from 1990 to 2019. EAPCs, estimated annual percentage change.




Supplementary Figure S14. The incidence rate of G6PD deficiency in 2019. G6PD, glucose-6-phosphate dehydrogenase.




Supplementary Figure S15. The percentage change in incident cases of G6PD deficiency between 1990 and 2019. G6PD, glucose-6-phosphate dehydrogenase.




Supplementary Figure S16. The EAPCs in incidence rate of G6PD deficiency from 1990 to 2019. EAPCs, estimated annual percentage change. G6PD, glucose-6-phosphate dehydrogenase.




Supplementary Figure S17. The incidence rate of G6PD trait in 2019. G6PD, glucose-6-phosphate dehydrogenase.




Supplementary Figure S18. The percentage change in incident cases of G6PD trait between 1990 and 2019. G6PD, glucose-6-phosphate dehydrogenase.



Supplementary Figure S19. The EAPCs in incidence rate of G6PD trait from 1990 to 2019. EAPCs, estimated annual percentage change. G6PD, glucose-6-phosphate dehydrogenase.




Supplementary Figure S20. The EAPCs in incidence rate of thalassemias from 1990 to 2019, at global, regional and national level for both sexes combined.




(A) The correlation between EAPCs and thalassemias incidence rate in 1990. (B) The correlation between EAPCs and SDI in 2019. (C) Incidence rate of thalassemias by region from 1990 to 2019 based on SDI levels. EAPCs, estimated annual percentage change. SDI, Socio-Demographic Index.

Supplementary Figure S21. The EAPCs in incidence rate of thalassemias trait from 1990 to 2019, at global, regional and national level for both sexes combined.




(A) The correlation between EAPCs and thalassemias trait incidence rate in 1990. (B) The correlation between EAPCs and SDI in 2019. (C) Incidence rate of thalassemias trait by region from 1990 to 2019 based on SDI levels. EAPCs, estimated annual percentage change. SDI, Socio-Demographic Index.

Supplementary Figure S22. The EAPCs in incidence rate of sickle cell disorders from 1990 to 2019, at global, regional and national level for both sexes combined.




(A) The correlation between EAPCs and sickle cell disorders incidence rate in 1990. (B) The correlation between EAPCs and SDI in 2019. (C) Incidence rate of sickle cell disorders by region from 1990 to 2019 based on SDI levels. EAPCs, estimated annual percentage change. SDI, Socio-Demographic Index.

Supplementary Figure S23. The EAPCs in incidence rate of sickle cell trait from 1990 to 2019, at global, regional and national level for both sexes combined.




(A) The correlation between EAPCs and sickle cell trait incidence rate in 1990. (B) The correlation between EAPCs and SDI in 2019. (C) Incidence rate of sickle cell trait by region from 1990 to 2019 based on SDI levels. EAPCs, estimated annual percentage change. SDI, Socio-Demographic Index.

Supplementary Figure S24. The EAPCs in incidence rate of G6PD deficiency from 1990 to 2019, at global, regional and national level for both sexes combined.



(A) The correlation between EAPCs and G6PD deficiency incidence rate in 1990. (B) The correlation between EAPCs and SDI in 2019. (C) Incidence rate of G6PD deficiency by region from 1990 to 2019 based on SDI levels. EAPCs, estimated annual percentage change. SDI, Socio-Demographic Index.

Supplementary Figure S25. The EAPCs in incidence rate of G6PD trait from 1990 to 2019, at global, regional and national level for both sexes combined.



(A) The correlation between EAPCs and G6PD trait incidence rate in 1990. (B) The correlation between EAPCs and SDI in 2019. (C) Incidence rate of G6PD trait by region from 1990 to 2019 based on SDI levels. EAPCs, estimated annual percentage change. SDI, Socio-Demographic Index.

Supplementary Table S1. The incident cases and incidence rates of thalassemias in 1990 and 2019, along with their temporal trend.

	199	90	20	19	1990-2019
Characteristics	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	EAPC (95%CI)
Global	192.08	3.59	151.9	1.96	-1.9
	(150.02 to 253.13)	(2.8 to 4.73)	(118.84 to 200.99)	(1.54 to 2.6)	(-2.08 to -1.71)
Sex					
Male	111.07 (85.67 to 146.49)	4.12 (3.18 to 5.44)	90.29 (70.08 to 120.52)	2.33 (1.81 to 3.11)	-1.74 (-1.93 to -1.56)
Female	81.01 (63.6 to 105.05)	3.05 (2.39 to 3.96)	61.6 (48.6 to 80.01)	1.6 (1.26 to 2.07)	-2.11 (-2.31 to -1.91)
Region					
Andean Latin	0.01	0.04	0.02	0.04	-0.24
America	(0.01 to 0.02)	(0.03 to 0.05)	(0.02 to 0.03)	(0.03 to 0.04)	(-0.34 to -0.14)
Australasia	0.17	0.82	0.18	0.63	-0.76
	(0.11 to 0.26)	(0.55 to 1.29)	(0.12 to 0.28)	(0.43 to 0.97)	(-0.91 to -0.6)
Caribbean	0.01	0.03	0.01	0.03	0.02
	(0.01 to 0.01)	(0.02 to 0.04)	(0.01 to 0.02)	(0.02 to 0.03)	(-0.07 to 0.11)
Central Asia	2.08	3.01	1.62	1.73	-1.19
	(1.54 to 2.82)	(2.23 to 4.08)	(1.23 to 2.15)	(1.31 to 2.3)	(-1.54 to -0.84)
Central Europe	1.53	1.24	0.58	0.51	-2.58
	(1.03 to 2.33)	(0.84 to 1.89)	(0.41 to 0.89)	(0.36 to 0.78)	(-2.85 to -2.31)
Central Latin	0.03	0.02	0.04	0.02	-0.28
America	(0.02 to 0.05)	(0.01 to 0.03)	(0.02 to 0.06)	(0.01 to 0.02)	(-0.47 to -0.08)
Central Sub-Saharan Africa	0.06 (0.04 to 0.09)	0.11 (0.07 to 0.17)	0.21 (0.12 to 0.32)	0.16 (0.09 to 0.24)	1.11 (0.9 to 1.32)
East Asia	101.64	8.3	60.56	4.11	-2.36
	(72.42 to 144.03)	(5.91 to 11.76)	(43.52 to 86.44)	(2.96 to 5.87)	(-2.86 to -1.85)
Eastern Europe	1.8	0.79	0.96	0.46	-0.43
	(1.25 to 2.64)	(0.55 to 1.17)	(0.7 to 1.37)	(0.33 to 0.65)	(-0.92 to 0.07)

Eastern Sub-Saharan Africa	0.62 (0.44 to 0.86)	0.33 (0.23 to 0.45)	1.28 (0.9 to 1.73)	0.31 (0.22 to 0.42)	-0.38 (-0.49 to -0.27)
High-income Asia Pacific	1.08 (0.78 to 1.57)	0.62 (0.45 to 0.9)	1.07 (0.78 to 1.52)	0.57 (0.42 to 0.81)	-0.26 (-0.8 to 0.29)
High-income	1.1	0.39	1.07	0.29	-0.69
North America	(0.84 to 1.48)	(0.3 to 0.53)	(0.87 to 1.38)	(0.24 to 0.38)	(-0.85 to -0.52)
North Africa and	9.15	2.65	9.76	1.6	-1.66
Middle East	(6.92 to 12.31)	(2.01 to 3.57)	(7.51 to 12.86)	(1.23 to 2.11)	(-1.74 to -1.58)
Oceania	0.4 (0.26 to 0.55)	6.13 (4.05 to 8.51)	0.73 (0.49 to 1.03)	5.5 (3.7 to 7.75)	0.56 (-0.19 to 1.33)
South Asia	27.3 (20.7 to 36.31)	2.49 (1.89 to 3.31)	38.3 (28.42 to 51.93)	2.12 (1.57 to 2.88)	-0.13 (-0.45 to 0.2)
Southeast Asia	41.53 (34.5 to 51.9)	8.9 (7.39 to 11.12)	31.21 (25.91 to 38.32)	4.63 (3.85 to 5.69)	-2.13 (-2.2 to -2.06)
Southern Latin	0.13	0.27	0.12	0.18	-1.18
America	(0.09 to 0.2)	(0.17 to 0.41)	(0.09 to 0.17)	(0.13 to 0.25)	(-1.48 to -0.89)
Southern Sub-Saharan Africa	0.03 (0.02 to 0.05)	0.07 (0.04 to 0.1)	0.08 (0.05 to 0.12)	0.1 (0.06 to 0.15)	1.36 (1.19 to 1.52)
Tropical Latin	0.09	0.06	0.08	0.03	-1.48
America	(0.06 to 0.12)	(0.04 to 0.08)	(0.06 to 0.1)	(0.03 to 0.04)	(-1.59 to -1.38)
Western Europe	2.36 (1.72 to 3.12)	0.61 (0.45 to 0.81)	1.88 (1.42 to 2.43)	0.43 (0.32 to 0.56)	-1.22 (-1.55 to -0.89)
Western Sub-Saharan Africa	0.95 (0.73 to 1.24)	0.49 (0.38 to 0.64)	2.11 (1.6 to 2.69)	0.46 (0.35 to 0.59)	-0.3 (-0.43 to -0.18)

Supplementary Table S2. The incident cases and incidence rates of thalassemias trait in 1990 and 2019, along with their temporal trend.

	1990		20	19	1990-2019
Characteristics	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	EAPC (95%CI)
Global	6910.25 (6002.38 to 8062.8)	129.17 (112.2 to 150.71)	6337.27 (5491.79 to 7335.76)	81.9 (70.98 to 94.81)	-1.35 (-1.47 to -1.23)
Sex					
Male	3798.41 (3302.11 to 4438.7)	141.01 (122.58 to 164.78)	3547.49 (3067.29 to 4121.63)	91.41 (79.03 to 106.2)	-1.24 (-1.37 to -1.12)
Female	3111.84 (2707.23 to 3621.25)	117.16 (101.93 to 136.34)	2789.78 (2430.36 to 3225.03)	72.34 (63.02 to 83.63)	-1.48 (-1.6 to -1.36)
Region					
Andean Latin America	8.72 (7.65 to 9.97)	22.84 (20.05 to 26.11)	10.78 (9.45 to 12.12)	16.94 (14.85 to 19.06)	-0.96 (-1 to -0.93)
Australasia	3.48 (3.07 to 3.96)	17.14 (15.14 to 19.54)	4.22 (3.75 to 4.73)	14.52 (12.91 to 16.29)	-0.5 (-0.62 to -0.38)
Caribbean	5.52 (4.8 to 6.36)	15.65 (13.6 to 18.03)	6.2 (5.39 to 7.13)	13.14 (11.43 to 15.11)	-0.59 (-0.62 to -0.55)
Central Asia	88.11 (76.24 to 102.68)	127.21 (110.07 to 148.24)	87.64 (76.28 to 102.1)	93.7 (81.56 to 109.16)	-0.36 (-0.71 to -0.02)
Central Europe	32.12 (27.34 to 38.65)	26.12 (22.24 to 31.43)	20.95 (17.88 to 24.82)	18.34 (15.65 to 21.73)	-0.82 (-1.09 to -0.56)
Central Latin America	18.68 (13.54 to 25)	11.38 (8.25 to 15.23)	19.14 (14.52 to 24.57)	7.66 (5.81 to 9.83)	-1.39 (-1.43 to -1.35)
Central Sub-Saharan Africa	21.48 (17.89 to 25.41)	38.68 (32.21 to 45.77)	45.21 (37.27 to 53.84)	34.37 (28.34 to 40.93)	-0.39 (-0.55 to -0.24)
East Asia	2592.39 (2205.53 to 3108.19)	211.6 (180.02 to 253.7)	1500.93 (1283.84 to 1777.41)	101.95 (87.21 to 120.73)	-2.29 (-2.83 to -1.74)

Eastern Europe	74.77 (62.24 to 91.6)	33.01 (27.48 to 40.44)	61.16 (51.19 to 74.1)	29.13 (24.38 to 35.29)	0.98 (0.5 to 1.46)
Eastern Sub-Saharan Africa	113.12 (96.03 to 131.05)	59.49 (50.5 to 68.91)	203.88 (173.25 to 236.97)	49.51 (42.07 to 57.55)	-0.81 (-0.9 to -0.71)
High-income Asia Pacific	27.25 (21.04 to 33.88)	15.7 (12.13 to 19.52)	26.05 (20.85 to 31.16)	13.91 (11.13 to 16.64)	-0.18 (-0.72 to 0.37)
High-income North America	90.37 (77.65 to 105)	32.17 (27.64 to 37.38)	88.32 (79.01 to 98.97)	24.23 (21.67 to 27.15)	-0.69 (-0.83 to -0.55)
North Africa and Middle East	673.7 (592.9 to 772.2)	195.26 (171.84 to 223.81)	721.7 (639.68 to 818.46)	118.56 (105.09 to 134.46)	-1.65 (-1.71 to -1.59)
Oceania	15.27 (13.08 to 17.5)	235.95 (202.1 to 270.43)	30.55 (26.35 to 35.11)	230.09 (198.47 to 264.44)	0.19 (-0.03 to 0.41)
South Asia	1939.35 (1658.74 to 2266.66)	176.69 (151.12 to 206.51)	2219.25 (1883.56 to 2617.53)	122.94 (104.34 to 145)	-1.02 (-1.22 to -0.81)
Southeast Asia	862.28 (769.55 to 972.62)	184.72 (164.86 to 208.36)	787.29 (702.45 to 891.94)	116.85 (104.25 to 132.38)	-1.45 (-1.52 to -1.39)
Southern Latin America	5.01 (4.37 to 5.77)	10.1 (8.83 to 11.66)	8.58 (7.41 to 9.78)	12.85 (11.1 to 14.65)	1.39 (1.06 to 1.73)
Southern Sub-Saharan Africa	11.95 (10.14 to 14.04)	22.77 (19.32 to 26.75)	16.64 (13.67 to 19.63)	21.17 (17.4 to 24.99)	-0.16 (-0.25 to -0.08)
Tropical Latin America	28.76 (24.4 to 33.58)	18.81 (15.96 to 21.96)	26.16 (22.34 to 30.07)	11.7 (9.99 to 13.45)	-1.45 (-1.52 to -1.37)
Western Europe	136.73 (118.77 to 156.38)	35.55 (30.88 to 40.66)	122 (106.57 to 138.61)	27.96 (24.43 to 31.77)	-0.77 (-0.94 to -0.59)
Western Sub-Saharan Africa	161.2 (140.25 to 187.33)	83.71 (72.83 to 97.28)	330.63 (287.22 to 379.33)	72.46 (62.94 to 83.13)	-0.56 (-0.67 to -0.45)

Supplementary Table S3. The incident cases and incidence rates of sickle cell disorders in 1990 and 2019, along with their temporal trend.

	1990		20	1990-2019	
Characteristics	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	EAPC (95%CI)
Global	474.73 (373.95 to 596)	8.87 (6.99 to 11.14)	605.01 (466.3 to 780.99)	7.82 (6.03 to 10.09)	-0.31 (-0.42 to -0.19)
Sex					
Male	259.08 (207.08 to 319.81)	9.62 (7.69 to 11.87)	305.82 (236.65 to 393.15)	7.88 (6.1 to 10.13)	-0.41 (-0.53 to -0.29)
Female	215.65 (165.67 to 278.46)	8.12 (6.24 to 10.48)	299.2 (229.39 to 387.34)	7.76 (5.95 to 10.04)	-0.2 (-0.34 to -0.06)
Region					
Andean Latin America	0.06 (0.05 to 0.09)	0.16 (0.12 to 0.22)	0.08 (0.06 to 0.11)	0.12 (0.09 to 0.17)	-0.86 (-0.92 to -0.8)
Australasia	0.5 (0.33 to 0.76)	2.48 (1.62 to 3.73)	0.14 (0.1 to 0.19)	0.47 (0.33 to 0.66)	-7 (-9.16 to -4.79)
Caribbean	3.53 (2.97 to 4.18)	10 (8.42 to 11.85)	3.92 (3.3 to 4.76)	8.31 (6.99 to 10.08)	-0.62 (-0.77 to -0.47)
Central Asia	0.01 (0.01 to 0.02)	0.02 (0.01 to 0.02)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.02)	-0.45 (-0.78 to -0.11)
Central Europe	0.16 (0.12 to 0.21)	0.13 (0.1 to 0.17)	0.11 (0.08 to 0.14)	0.1 (0.07 to 0.13)	-0.84 (-1.05 to -0.64)
Central Latin America	0.48 (0.37 to 0.63)	0.29 (0.22 to 0.38)	0.29 (0.21 to 0.38)	0.12 (0.08 to 0.15)	-3.04 (-3.17 to -2.9)
Central Sub-Saharan Africa	39.66 (31.37 to 49.56)	71.43 (56.5 to 89.27)	73.44 (59.26 to 92.12)	55.83 (45.05 to 70.03)	-0.76 (-0.96 to -0.56)
East Asia	1.13 (0.78 to 1.61)	0.09 (0.06 to 0.13)	0.51 (0.36 to 0.71)	0.03 (0.02 to 0.05)	-3.5 (-4.16 to -2.83)
Eastern Europe	0.02 (0.01 to 0.03)	0.01 (0.01 to 0.01)	0.02 (0.01 to 0.02)	0.01 (0 to 0.01)	0.92 (0.46 to 1.38)

Eastern Sub-Saharan Africa	40.22 (30.96 to 52.61)	21.15 (16.28 to 27.66)	55.47 (43.1 to 71.18)	13.47 (10.47 to 17.28)	-1.51 (-1.63 to -1.38)
High-income Asia	0.01	0.01	0.01	0	-1.48
Pacific	(0.01 to 0.02)	(0 to 0.01)	(0.01 to 0.01)	(0 to 0.01)	(-1.57 to -1.4)
High-income	43.77	15.58	1.7	0.47	-8.16
North America	(32.67 to 58.09)	(11.63 to 20.68)	(1.52 to 1.89)	(0.42 to 0.52)	(-10.49 to -5.77)
North Africa and Middle East	25.73 (22.24 to 30.11)	7.46 (6.44 to 8.73)	19.47 (16.06 to 23.54)	3.2 (2.64 to 3.87)	-3.15 (-3.42 to -2.88)
Oceania	0	0	0	0	0
	(0 to 0)	(0 to 0.01)	(0 to 0)	(0 to 0.01)	(-0.12 to 0.11)
South Asia	111.89	10.19	124.43	6.89	-1.46
	(75.34 to 162.73)	(6.86 to 14.83)	(83.25 to 179.19)	(4.61 to 9.93)	(-1.8 to -1.12)
Southeast Asia	0.1	0.02	0.09	0.01	-1.65
	(0.08 to 0.15)	(0.02 to 0.03)	(0.07 to 0.13)	(0.01 to 0.02)	(-1.72 to -1.59)
Southern Latin	0	0	0	0	-0.93
America	(0 to 0)	(0 to 0.01)	(0 to 0)	(0 to 0)	(-1.08 to -0.79)
Southern Sub-Saharan Africa	0.21 (0.17 to 0.27)	0.41 (0.32 to 0.52)	0.2 (0.15 to 0.26)	0.26 (0.2 to 0.33)	-1.87 (-2.06 to -1.68)
Tropical Latin	0.92	0.6	0.83	0.37	-2.04
America	(0.75 to 1.12)	(0.49 to 0.73)	(0.69 to 1.01)	(0.31 to 0.45)	(-2.19 to -1.89)
Western Europe	8.41 (6.16 to 11.3)	2.19 (1.6 to 2.94)	1.44 (1.11 to 1.84)	0.33 (0.26 to 0.42)	-5.04 (-6.17 to -3.9)
Western Sub-Saharan Africa	197.91 (158.6 to 246.78)	102.77 (82.35 to 128.14)	322.85 (248.23 to 412.82)	70.75 (54.4 to 90.47)	-1.4 (-1.5 to -1.3)

Supplementary Table S4. The incident cases and incidence rates of sickle cell trait in 1990 and 2019, along with their temporal trend.

	19	990	20	1990-2019	
Characteristics	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	EAPC (95%CI)
Global	8662.5 (7659.58 to 9796.58)	161.92 (143.17 to 183.12)	10113.13 (8915.24 to 11439.3)	130.7 (115.22 to 147.84)	-0.65 (-0.73 to -0.57)
Sex					
Male	4481.61 (3959.48 to 5054)	166.37 (146.99 to 187.62)	5133 (4526.28 to 5817.39)	132.26 (116.63 to 149.89)	-0.65 (-0.74 to -0.57)
Female	4180.89 (3684.59 to 4746.43)	157.41 (138.72 to 178.7)	4980.13 (4393.39 to 5628.01)	129.14 (113.92 to 145.94)	-0.65 (-0.73 to -0.57)
Region					
Andean Latin America	16.67 (14.11 to 19.62)	43.66 (36.95 to 51.38)	19.61 (16.68 to 22.99)	30.83 (26.23 to 36.15)	-1.12 (-1.16 to -1.07)
Australasia	8.09 (6.87 to 9.58)	39.9 (33.89 to 47.22)	5.89 (5.07 to 6.91)	20.28 (17.45 to 23.78)	-2.49 (-3.17 to -1.8)
Caribbean	85.42 (76.98 to 94.85)	242.17 (218.24 to 268.88)	87.65 (78.8 to 97.96)	185.84 (167.07 to 207.69)	-0.86 (-0.98 to -0.75)
Central Asia	9.11 (7.29 to 11.19)	13.16 (10.52 to 16.15)	8.82 (7.04 to 10.76)	9.43 (7.53 to 11.5)	-0.46 (-0.8 to -0.13)
Central Europe	30.27 (26.2 to 34.72)	24.61 (21.31 to 28.23)	20.13 (17.32 to 23.09)	17.62 (15.16 to 20.21)	-0.8 (-1.02 to -0.58)
Central Latin America	47.35 (40.41 to 56.26)	28.85 (24.62 to 34.28)	30.8 (26.42 to 36.51)	12.32 (10.57 to 14.6)	-2.79 (-2.9 to -2.69)
Central Sub-Saharan Africa	550.82 (495.39 to 609.03)	992.11 (892.28 to 1096.95)	960.08 (872.88 to 1062.1)	729.86 (663.56 to 807.41)	-0.96 (-1.13 to -0.79)
East Asia	313.85 (258.22 to 377.77)	25.62 (21.08 to 30.84)	164.15 (137.37 to 196.44)	11.15 (9.33 to 13.34)	-2.81 (-3.4 to -2.22)

Eastern Europe	14.12 (11.42 to 17.14)	6.24 (5.04 to 7.57)	11.24 (9.18 to 13.64)	5.35 (4.37 to 6.5)	0.91 (0.43 to 1.39)
Eastern Sub-Saharan Africa	813.24 (732.67 to 906.27)	427.64 (385.28 to 476.56)	1217.76 (1105.38 to 1350.7)	295.73 (268.44 to 328.02)	-1.3 (-1.41 to -1.19)
High-income Asia Pacific	6.41 (4.96 to 8.03)	3.69 (2.86 to 4.63)	4.5 (3.57 to 5.54)	2.4 (1.91 to 2.96)	-1.39 (-1.47 to -1.31)
High-income North America	525.73 (471.79 to 584.4)	187.14 (167.94 to 208.03)	118.78 (111.47 to 126.88)	32.58 (30.58 to 34.8)	-4.16 (-5.13 to -3.18)
North Africa and Middle East	894.65 (826.66 to 975.47)	259.3 (239.59 to 282.72)	843.71 (771.36 to 926.26)	138.61 (126.72 to 152.17)	-2.21 (-2.31 to -2.1)
Oceania	0.31 (0.14 to 0.49)	4.87 (2.15 to 7.57)	0.61 (0.26 to 1.02)	4.6 (1.95 to 7.69)	-0.12 (-0.2 to -0.03)
South Asia	3217.47 (2690.66 to 3833.2)	293.13 (245.13 to 349.23)	3184.15 (2666.87 to 3774.71)	176.39 (147.73 to 209.1)	-1.8 (-1.98 to -1.62)
Southeast Asia	67.6 (57.73 to 79.23)	14.48 (12.37 to 16.97)	58.63 (50.1 to 68.68)	8.7 (7.44 to 10.19)	-1.65 (-1.71 to -1.59)
Southern Latin America	1.95 (1.1 to 2.95)	3.94 (2.22 to 5.95)	1.84 (1.06 to 2.75)	2.76 (1.58 to 4.12)	-0.95 (-1.09 to -0.81)
Southern Sub-Saharan Africa	27.27 (23.72 to 31.4)	51.95 (45.18 to 59.81)	28.44 (24.6 to 32.88)	36.19 (31.3 to 41.85)	-1.23 (-1.3 to -1.16)
Tropical Latin America	79.62 (71.23 to 88.77)	52.08 (46.59 to 58.07)	80.92 (72.94 to 89.7)	36.19 (32.62 to 40.12)	-1.1 (-1.18 to -1.02)
Western Europe	174.09 (153.59 to 197.35)	45.27 (39.94 to 51.31)	107.63 (91.74 to 124.9)	24.67 (21.03 to 28.63)	-1.49 (-1.71 to -1.27)
Western Sub-Saharan Africa	1778.46 (1586.41 to 1983.54)	923.49 (823.77 to 1029.98)	3157.8 (2776.44 to 3575.19)	692.02 (608.45 to 783.49)	-1.03 (-1.14 to -0.92)

Supplementary Table S5. The incident cases and incidence rates of G6PD deficiency in 1990 and 2019, along with their temporal trend.

	19	990	20	019	1990-2019
Characteristics	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	EAPC (95%CI)
Global	7484.69 (6819.44 to 8244.42)	139.9 (127.47 to 154.11)	8956.94 (8050.43 to 10025.58)	115.76 (104.04 to 129.57)	-0.86 (-1.03 to -0.68)
Sex					
Male	5432.72 (4961.98 to 5966.03)	201.68 (184.2 to 221.48)	6531.66 (5873.55 to 7257.53)	168.3 (151.34 to 187)	-0.86 (-0.99 to -0.73)
Female	2051.97 (1854.5 to 2285.62)	77.26 (69.82 to 86.05)	2425.28 (2169.68 to 2729.62)	62.89 (56.26 to 70.78)	-0.83 (-1.16 to -0.5)
Region					
Andean Latin America	18.85 (14.68 to 23.81)	49.38 (38.45 to 62.38)	50.98 (39.97 to 64.12)	80.17 (62.85 to 100.82)	-0.67 (-1.37 to 0.03)
Australasia	1.23 (0.96 to 1.55)	6.09 (4.73 to 7.65)	3.12 (2.42 to 3.87)	10.74 (8.32 to 13.31)	2.27 (1.44 to 3.11)
Caribbean	82.31 (63.87 to 101.95)	233.36 (181.07 to 289.03)	83.9 (64.94 to 103.79)	177.87 (137.67 to 220.04)	-0.92 (-0.97 to -0.86)
Central Asia	27.02 (20.88 to 34.07)	39.02 (30.14 to 49.19)	26.68 (20.67 to 33.79)	28.52 (22.1 to 36.13)	-0.34 (-0.69 to 0.01)
Central Europe	55.25 (46.83 to 65.12)	44.93 (38.09 to 52.95)	40.29 (34.19 to 47.42)	35.27 (29.93 to 41.51)	-1.39 (-1.78 to -1)
Central Latin America	157.78 (134.53 to 185.49)	96.14 (81.97 to 113.02)	104.85 (86.4 to 125.29)	41.93 (34.56 to 50.11)	-2.81 (-2.98 to -2.63)
Central Sub-Saharan Africa	356.1 (276.15 to 442.58)	641.4 (497.38 to 797.15)	593.09 (460.02 to 740.72)	450.87 (349.71 to 563.09)	-1.19 (-1.33 to -1.04)
East Asia	879.28 (844.9 to 914.01)	71.77 (68.96 to 74.61)	742.31 (707.82 to 775.12)	50.42 (48.08 to 52.65)	-0.98 (-1.17 to -0.8)

Eastern Europe	55.85 (52.93 to 58.7)	24.66 (23.37 to 25.92)	46.82 (44.52 to 49.1)	22.3 (21.2 to 23.38)	0.76 (0.28 to 1.23)
Eastern Sub-Saharan Africa	924.64 (800.78 to 1066.89)	486.22 (421.09 to 561.03)	1228.27 (1025.02 to 1453.69)	298.28 (248.93 to 353.03)	-1.62 (-1.86 to -1.37)
High-income Asia Pacific	8.07 (7.02 to 9.27)	4.65 (4.05 to 5.34)	5.78 (5.12 to 6.49)	3.08 (2.73 to 3.47)	-2.02 (-2.25 to -1.78)
High-income North America	231.31 (221.2 to 241)	82.34 (78.74 to 85.79)	178.51 (169.73 to 186.98)	48.97 (46.56 to 51.29)	-1.87 (-2.79 to -0.93)
North Africa and Middle East	689.15 (605.74 to 789.89)	199.74 (175.56 to 228.94)	662.38 (532.51 to 814)	108.82 (87.48 to 133.72)	-1.59 (-1.73 to -1.44)
Oceania	13.81 (12.53 to 15.28)	213.5 (193.61 to 236.16)	23.65 (18.28 to 29.57)	178.15 (137.72 to 222.74)	-0.59 (-0.77 to -0.42)
South Asia	1788.98 (1672.95 to 1917.76)	162.99 (152.42 to 174.72)	2450.22 (2330.59 to 2571.13)	135.73 (129.1 to 142.43)	-1.91 (-2.54 to -1.27)
Southeast Asia	755.15 (678.87 to 837.98)	161.77 (145.43 to 179.52)	486.8 (425.85 to 555.55)	72.25 (63.2 to 82.45)	-2.37 (-2.6 to -2.13)
Southern Latin America	16.21 (12.5 to 20.19)	32.71 (25.23 to 40.75)	14.36 (11.08 to 18.27)	21.51 (16.6 to 27.36)	-1.29 (-1.46 to -1.13)
Southern Sub-Saharan Africa	139.66 (126.31 to 154.22)	266.05 (240.62 to 293.8)	140.31 (126.64 to 154.74)	178.57 (161.17 to 196.94)	-1.17 (-1.32 to -1.03)
Tropical Latin America	94.73 (91.17 to 98.22)	61.97 (59.63 to 64.24)	110.09 (105.7 to 114.41)	49.24 (47.27 to 51.17)	0.08 (-0.43 to 0.6)
Western Europe	114.68 (99.16 to 132.11)	29.82 (25.78 to 34.35)	117.38 (101.36 to 135.77)	26.9 (23.23 to 31.12)	-0.39 (-0.62 to -0.15)
Western Sub-Saharan Africa	1074.62 (994.62 to 1164.8)	558.01 (516.47 to 604.84)	1847.16 (1666.24 to 2043.51)	404.8 (365.15 to 447.83)	-0.94 (-1.03 to -0.85)

Supplementary Table S6. The incident cases and incidence rates of G6PD trait in 1990 and 2019, along with their temporal trend.

	19	990	20	19	1990-2019
Characteristics	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	Incident cases No.×10³(95% UI)	Incidence rates per 100000 (95% UI)	EAPC (95%CI)
Global	17715.84 (17107 to 18350.29)	331.15 (319.77 to 343.01)	18731.78 (17994.33 to 19540.11)	242.09 (232.56 to 252.54)	-1.09 (-1.2 to -0.99)
Sex					
Male	-	-	-	-	-
Female	17715.84 (17107 to 18350.29)	666.99 (644.07 to 690.87)	18731.78 (17994.33 to 19540.11)	485.72 (466.6 to 506.68)	-1.11 (-1.22 to -1.01)
Region					
Andean Latin America	142.97 (128.91 to 157.47)	374.48 (337.67 to 412.47)	150.82 (135.61 to 166.57)	237.16 (213.23 to 261.92)	-1.52 (-1.56 to -1.48)
Australasia	13.68 (12.07 to 15.47)	67.47 (59.5 to 76.31)	10.75 (9.04 to 12.42)	36.98 (31.11 to 42.72)	-1.86 (-2.32 to -1.4)
Caribbean	80.23 (71.83 to 89.37)	227.46 (203.65 to 253.36)	68.44 (61.11 to 76.48)	145.1 (129.55 to 162.15)	-1.5 (-1.6 to -1.41)
Central Asia	153.1 (136.23 to 170.56)	221.03 (196.67 to 246.24)	145.32 (129.31 to 161.92)	155.37 (138.25 to 173.12)	-0.53 (-0.87 to -0.19)
Central Europe	121.72 (112.51 to 131.68)	98.99 (91.49 to 107.09)	77.99 (72.05 to 84.2)	68.28 (63.07 to 73.71)	-0.75 (-1.01 to -0.49)
Central Latin America	700.78 (667.16 to 735.59)	426.98 (406.5 to 448.19)	511.95 (481.29 to 543.18)	204.76 (192.5 to 217.25)	-2.59 (-2.74 to -2.43)
Central Sub-Saharan Africa	535.71 (494.97 to 573.38)	964.91 (891.52 to 1032.74)	887.19 (817.8 to 948.45)	674.44 (621.69 to 721.01)	-1.13 (-1.28 to -0.98)
East Asia	2464.26 (2419.84 to 2505.21)	201.14 (197.52 to 204.48)	1661.29 (1629.32 to 1691.57)	112.84 (110.67 to 114.9)	-2.29 (-2.48 to -2.09)

Eastern Europe	217.63 (211.93 to 222.92)	96.08 (93.57 to 98.42)	169.86 (165.68 to 173.7)	80.9 (78.9 to 82.72)	0.89 (0.39 to 1.39)
Eastern Sub-Saharan Africa	1705.33 (1622.09 to 1785.98)	896.75 (852.99 to 939.17)	2561.51 (2428.82 to 2695.75)	622.06 (589.84 to 654.66)	-1.29 (-1.41 to -1.16)
High-income Asia Pacific	97.43 (91.49 to 103.51)	56.15 (52.73 to 59.66)	60.19 (56.69 to 63.95)	32.14 (30.27 to 34.15)	-2.02 (-2.14 to -1.91)
High-income North America	475.31 (465.69 to 485.13)	169.2 (165.77 to 172.69)	449.23 (439.45 to 458.2)	123.23 (120.54 to 125.69)	-0.91 (-1.06 to -0.75)
North Africa and Middle East	1790.5 (1682.72 to 1899.05)	518.94 (487.71 to 550.4)	1829.64 (1684.07 to 1972.42)	300.57 (276.66 to 324.03)	-1.77 (-1.81 to -1.73)
Oceania	27.29 (24.54 to 29.98)	421.83 (379.26 to 463.38)	61.6 (55.79 to 67.52)	463.96 (420.23 to 508.55)	0.01 (-0.19 to 0.22)
South Asia	4617.95 (4527.5 to 4717.5)	420.72 (412.48 to 429.79)	4923.01 (4831.32 to 5012.66)	272.71 (267.63 to 277.68)	-1.83 (-2.13 to -1.53)
Southeast Asia	1704 (1627.07 to 1781.8)	365.05 (348.57 to 381.71)	1258.5 (1201.71 to 1317.7)	186.78 (178.35 to 195.57)	-2.14 (-2.29 to -1.99)
Southern Latin America	80.8 (71.79 to 90.45)	163.1 (144.92 to 182.58)	67.82 (60.01 to 76.25)	101.6 (89.9 to 114.23)	-1.39 (-1.58 to -1.2)
Southern Sub-Saharan Africa	272.49 (263.39 to 281.79)	519.1 (501.76 to 536.81)	287.73 (277.45 to 297.64)	366.19 (353.1 to 378.79)	-0.99 (-1.08 to -0.89)
Tropical Latin America	407.88 (400.11 to 415.23)	266.8 (261.71 to 271.6)	377.95 (370.96 to 384.64)	169.03 (165.91 to 172.03)	-1.15 (-1.38 to -0.93)
Western Europe	509.43 (477.26 to 543.5)	132.46 (124.1 to 141.32)	457 (427.34 to 488.02)	104.74 (97.94 to 111.85)	-0.65 (-0.74 to -0.56)
Western Sub-Saharan Africa	1597.33 (1537.16 to 1658.99)	829.44 (798.19 to 861.45)	2714 (2586.26 to 2839.77)	594.77 (566.77 to 622.33)	-0.9 (-1.04 to -0.77)

G6PD deficiency is inherited in an X-linked pattern, data on G6PD trait was not collected.

Abbreviations: EAPC, estimated annual percentage change; UI, uncertainty interval. CI, confidence interval. G6PD, glucose-6-phosphate dehydrogenase.

Supplementary Table S7. The change of inherited anemias cases and incidence rates

between 1990 and 2019 at national level, both sexes.

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Afghanistan	Inherited anemias	148 (136 to 161)	427 (392 to 464)	1. 88 (1. 83 to 1. 95)	1298. 78 (1191. 73 to 1413. 21)	1116. 16 (1024. 25 to 1212. 88)	-1. 19 (-1. 4 to -0. 97)
Afghanistan	Thalassemi as	0 (0 to 1)	1 (1 to 2)	1.99 (1.7 to 2.32)	3.89 (3 to 5.14)	3. 47 (2. 68 to 4. 55)	-0.93 (-1.09 to -0.77)
Afghanistan	Thalassemi as trait	32 (28 to 37)	95 (84 to 108)	1.97 (1.84 to 2.12)	280. 25 (248. 44 to 320. 42)	248. 61 (220. 26 to 282. 42)	-0.93 (-1.09 to -0.77)
Afghanistan	Sickle cell disorders	1 (1 to 1)	2 (2 to 3)	1.85 (1.62 to 2.14)	7. 27 (5. 51 to 9. 44)	6. 18 (4. 59 to 8. 01)	-1.12 (-1.29 to -0.94)
Afghanistan	Sickle cell trait	40 (35 to 45)	113 (99 to 129)	1.84 (1.73 to 1.98)	349. 59 (306. 49 to 397. 25)	296. 28 (257. 44 to 336. 68)	-1.09 (-1.25 to -0.93)
Afghanistan	G6PD deficiency	19 (15 to 24)	54 (41 to 67)	1.85 (1.63 to 2.07)	164. 59 (126. 99 to 207. 03)	140. 12 (108. 36 to 175. 13)	-1.41 (-1.7 to -1.12)
Afghanistan	G6PD trait	56 (50 to 62)	161 (144 to 177)	1.86 (1.77 to 1.97)	493. 17 (440. 43 to 542. 65)	421. 49 (376. 94 to 463. 22)	-1.35 (-1.64 to -1.05)
Albania	Inherited anemias	17 (15 to 18)	7 (6 to 8)	-0.57 (-0.57 to -0.56)	499. 45 (450. 37 to 553. 6)	263. 14 (237. 45 to 291. 41)	-2.59 (-2.9 to -2.28)
Albania	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.69 (-0.72 to -0.65)	4. 19 (3. 04 to 5. 96)	1. 58 (1. 2 to 2. 12)	-3.51 (-3.85 to -3.18)
Albania	Thalassemi as trait	4 (4 to 5)	2 (2 to 2)	-0.57 (-0.59 to -0.55)	131.04 (112.02 to 152.1)	68.47 (59.26 to 78.6)	-2.45 (-2.78 to -2.11)
Albania	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.51 (-0.55 to -0.46)	0.53 (0.41 to 0.69)	0. 32 (0. 24 to 0. 4)	-2.16 (-2.49 to -1.82)
Albania	Sickle cell trait	2 (2 to 3)	1 (1 to 1)	-0.55 (-0.57 to -0.52)	72. 68 (63. 4 to 83. 14)	40. 12 (35. 09 to 45. 49)	-2.33 (-2.65 to -2.01)
Albania	G6PD deficiency	3 (2 to 4)	1 (1 to 2)	-0.54 (-0.54 to -0.54)	96. 21 (74. 26 to 120. 53)	53. 99 (41. 68 to 67. 65)	-3. 17 (-3. 52 to -2. 81)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Albania	G6PD trait	6 (6 to 7)	3 (2 to 3)	-0.58 (-0.58 to -0.58)	194. 8 (172. 06 to 218. 68)	98. 66 (87. 15 to 110. 76)	-2.53 (-2.87 to -2.19)
Algeria	Inherited anemias	218 (194 to 245)	247 (220 to 276)	0.13 (0.11 to 0.16)	863.16 (765.86 to 967.67)	590. 38 (524. 71 to 660. 55)	-0.8 (-1.02 to -0.58)
Algeria	Thalassemi as	0 (0 to 0)	0 (0 to 1)	0. 24 (0. 13 to 0. 36)	1.37 (1.06 to 1.77)	1. 02 (0. 8 to 1. 3)	-0.51 (-0.74 to -0.28)
Algeria	Thalassemi as trait	35 (31 to 40)	42 (38 to 48)	0. 22 (0. 16 to 0. 27)	137. 45 (121. 98 to 156. 37)	100. 96 (89. 67 to 113. 65)	-0.56 (-0.78 to -0.33)
Algeria	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.17 (0.1 to 0.23)	0.77 (0.64 to 0.92)	0.54 (0.46 to 0.64)	-0.71 (-0.95 to -0.47)
Algeria	Sickle cell trait	23 (21 to 25)	27 (24 to 29)	0.16 (0.13 to 0.19)	91.41 (83.26 to 100.18)	64.01 (58.43 to 69.75)	-0.71 (-0.95 to -0.48)
Algeria	G6PD deficiency	68 (52 to 84)	75 (57 to 92)	0.1 (0.01 to 0.18)	268. 12 (207. 27 to 333)	178. 12 (137. 22 to 219. 39)	-0.93 (-1.14 to -0.71)
Algeria	G6PD trait	92 (83 to 102)	103 (92 to 114)	0. 12 (0. 1 to 0. 15)	364. 03 (327. 58 to 401. 7)	245. 71 (220. 9 to 271. 52)	-0.82 (-1.04 to -0.59)
American Samoa	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.33 (-0.35 to -0.3)	751. 12 (668. 13 to 839. 8)	442.37 (391.95 to 495.8)	-2.01 (-2.21 to -1.8)
American Samoa	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.46 (-0.53 to -0.38)	3. 45 (1. 87 to 5. 33)	1. 64 (0. 88 to 2. 57)	-1. 62 (-2. 57 to -0. 66)
American Samoa	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.41 (-0.45 to -0.37)	112. 74 (86. 59 to 138. 13)	57. 99 (44. 21 to 71. 29)	-2.04 (-2.41 to -1.65)
American Samoa	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.37 (-0.4 to -0.03)	0 (0 to 0)	0 (0 to 0)	-2. 28 (-2. 38 to -2. 19)
American Samoa	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.38 (-0.4 to -0.16)	4.41 (1.94 to 7.06)	2.38 (1.02 to 3.81)	-2.33 (-2.41 to -2.24)
American Samoa	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.26 (-0.29 to -0.24)	154.65 (119.52 to 192.81)	99.36 (76.79 to 123.49)	-1.79 (-2.05 to -1.52)
American	G6PD trait	0	0	-0.32	475.87	281	-2.09

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Samoa		(0 to 0)	(0 to 0)	(-0.35 to	(428. 14 to	(254.05 to	(-2.29 to
				-0.3)	524. 86)	308. 17)	-1.89)
Andorra	Inherited anemias	0 (0 to 0)	0 (0 to 0)	0 (-0.03 to 0.03)	204. 27 (183. 16 to 226. 19)	132.66 (118.72 to 147.75)	-1.62 (-1.85 to -1.39)
Andorra	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.07 (-0.2 to 0.06)	0. 14 (0. 09 to 0. 19)	0. 08 (0. 06 to 0. 12)	-2. 69 (-3. 55 to -1. 83)
Andorra	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.00) 0.02 (-0.04 to 0.09)	17. 64 (15. 16 to 20. 17)	11. 71 (10. 1 to 13. 43)	-1. 75 (-2. 08 to -1. 42)
Andorra	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.04 (-0.13 to 0.04)	0. 16 (0. 12 to 0. 21)	0. 1 (0. 07 to 0. 13)	-1.79 (-2.09 to -1.49)
Andorra	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.03 (-0.09 to 0.03)	21.48 (17.85 to 25.74)	13. 53 (11. 26 to 16. 07)	-1.73 (-2 to -1.46)
Andorra	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0.05 (0.01 to 0.11)	32.26 (25.06 to 39.91)	22. 02 (16. 94 to 27. 64)	-1.46 (-1.64 to -1.28)
Andorra	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.01 (-0.05 to 0.03)	132. 59 (118. 85 to 146. 78)	85. 22 (76. 27 to 94. 26)	-1.62 (-1.85 to -1.4)
Angola	Inherited anemias	269 (245 to 296)	591 (540 to 646)	1. 2 (1. 12 to 1. 28)	2608. 52 (2372. 45 to 2865. 32)	1961. 97 (1791. 19 to 2143. 92)	-0.93 (-1.1 to -0.76)
Angola	Thalassemi as	0 (0 to 0)	0 (0 to 0)	3. 46 (2. 86 to 4. 3)	0. 12 (0. 07 to 0. 17)	0. 18 (0. 1 to 0. 26)	1.26 (1.03 to 1.49)
Angola	Thalassemi as trait	4 (3 to 5)	11 (9 to 13)	1.74 (1.52 to 1.99)	39. 6 (33. 21 to 46. 77)	37. 18 (30. 51 to 44. 6)	-0.28 (-0.45 to -0.1)
Angola	Sickle cell disorders	6 (5 to 8)	14 (11 to 18)	1.33 (1.03 to 1.66)	59. 52 (46. 53 to 78. 1)	47. 41 (38. 04 to 60. 65)	-0.6 (-0.81 to -0.39)
Angola	Sickle cell trait	99 (89 to 111)	220 (200 to 246)	1. 23 (1. 1 to 1. 37)	956. 55 (857. 78 to 1080. 03)	731. 37 (664. 03 to 816. 78)	-0.82 (-1 to -0.65)
Angola	G6PD deficiency	59 (46 to 74)	129 (99 to 159)	1. 16 (0. 97 to 1. 37)	576. 42 (445. 2 to 719. 71)	426. 64 (328. 08 to 529. 14)	-1.04 (-1.21 to -0.88)
Angola	G6PD trait	101 (93 to 108)	217 (199 to	1.15 (1.09 to	976. 3 (899. 35 to	719. 2 (661. 94 to	-1.01 (-1.18 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
		, ,	232)	1. 22)	1043. 82)	768. 42)	-0.85)
Antigua and Barbuda	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0. 24 (-0. 27 to -0. 22)	557. 97 (491. 56 to 629. 71)	289. 11 (254. 81 to 326. 1)	-2.61 (-2.74 to -2.49)
Antigua and Barbuda	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.2 (-0.26 to 1.5)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	-1. 14 (-1. 44 to -0. 84)
Antigua and Barbuda	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.26 to 0.13)	7.78 (5.89 to 9.93)	4. 64 (3. 62 to 5. 7)	-2.16 (-2.32 to -2)
Antigua and Barbuda	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.15 (-0.24 to -0.05)	4. 46 (3. 26 to 6)	2. 6 (1. 87 to 3. 53)	-2. 29 (-2. 54 to -2. 03)
Antigua and Barbuda	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.22 (-0.27 to -0.17)	162.74 (136.32 to 192.69)	87. 34 (72. 17 to 104. 23)	-2. 49 (-2. 65 to -2. 34)
Antigua and Barbuda	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.26 (-0.32 to -0.2)	173. 97 (134. 12 to 214. 74)	87. 83 (67. 85 to 108. 62)	-2. 69 (-2. 81 to -2. 57)
Antigua and Barbuda	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.26 (-0.28 to -0.23)	209. 01 (186. 51 to 233. 16)	106.68 (95.02 to 118.34)	-2.67 (-2.8 to -2.54)
Argentina	Inherited anemias	69 (60 to 78)	66 (58 to 75)	-0.04 (-0.08 to 0.01)	207. 12 (181. 09 to 234. 73)	146. 26 (128. 69 to 165. 88)	-0.94 (-1.15 to -0.73)
Argentina	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.05 (-0.24 to 0.25)	0. 27 (0. 17 to 0. 42)	0. 19 (0. 13 to 0. 27)	-1.01 (-1.28 to -0.74)
Argentina	Thalassemi as trait	3 (2 to 3)	5 (5 to 6)	0.99 (0.69 to 1.37)	8. 21 (6. 91 to 9. 68)	12 (10.11 to 13.96)	1.95 (1.56 to 2.33)
Argentina	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.03 (0.03 to 0.03)	0 (0 to 0.01)	0 (0 to 0)	-0.71 (-0.85 to -0.57)
Argentina	Sickle cell trait	1 (1 to 2)	1 (1 to 2)	0.03 (0.03 to 0.03)	3. 91 (2. 2 to 5. 95)	2. 96 (1. 69 to 4. 49)	-0.71 (-0.85 to -0.56)
Argentina	G6PD deficiency	11 (8 to 13)	10 (8 to 13)	-0.04 (-0.09 to 0.03)	32. 55 (25 to 40. 43)	22. 91 (17. 7 to 29. 14)	-1.04 (-1.24 to -0.83)
Argentina	G6PD trait	54 (48 to 60)	49 (43 to 55)	-0.09 (-0.13 to -0.04)	162.18 (143.79 to 181.56)	108. 21 (95. 73 to 121. 64)	-1.13 (-1.37 to -0.9)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Armenia	Inherited anemias	11 (10 to 13)	5 (5 to 6)	-0.52 (-0.53 to -0.51)	330.66 (295.8 to 368.12)	178. 23 (159. 35 to 198. 49)	-1.01 (-1.55 to -0.47)
Armenia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.61 (-0.66 to -0.56)	2. 15 (1. 52 to 3. 01)	0. 94 (0. 67 to 1. 31)	-1.76 (-2.27 to -1.25)
Armenia	Thalassemi as trait	4 (3 to 4)	2 (1 to 2)	-0.51 (-0.54 to -0.48)	105. 14 (86. 55 to 130. 86)	58. 08 (48. 06 to 70. 81)	-0.99 (-1.49 to -0.48)
Armenia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.52 (-0.62 to -0.4)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	-0.97 (-1.49 to -0.44)
Armenia	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.52 (-0.57 to -0.45)	10.46 (8.3 to 13.07)	5. 72 (4. 51 to 7. 16)	-0.98 (-1.5 to -0.45)
Armenia	G6PD deficiency	1 (1 to 1)	1 (0 to 1)	-0.5 (-0.54 to -0.46)	32. 46 (24. 99 to 41. 15)	18. 23 (14. 14 to 23. 18)	-0.83 (-1.36 to -0.3)
Armenia	G6PD trait	6 (5 to 7)	3 (3 to 3)	-0.53 (-0.53 to -0.53)	180. 42 (160. 53 to 202. 04)	95. 25 (84. 75 to 106. 66)	-1.06 (-1.62 to -0.5)
Australia	Inherited anemias	18 (16 to 20)	17 (15 to 20)	-0.01 (-0.08 to 0.04)	104. 74 (92. 97 to 117. 38)	70.99 (61.29 to 81.19)	-1.17 (-1.45 to -0.89)
Australia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.14 (-0.01 to 0.31)	0.75 (0.49 to 1.18)	0.59 (0.39 to 0.9)	-0.69 (-0.85 to -0.53)
Australia	Thalassemi as trait	3 (2 to 3)	3 (3 to 4)	0. 26 (0. 17 to 0. 38)	15. 27 (13. 41 to 17. 41)	13. 24 (11. 69 to 14. 92)	-0.44 (-0.55 to -0.32)
Australia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 27 (0. 12 to 0. 6)	0. 02 (0. 01 to 0. 02)	0.01 (0.01 to 0.02)	-0.3 (-0.46 to -0.15)
Australia	Sickle cell trait	2 (1 to 2)	2 (2 to 2)	0. 24 (0. 16 to 0. 41)	9. 28 (7. 8 to 11. 03)	7. 92 (6. 65 to 9. 39)	-0.34 (-0.51 to -0.17)
Australia	G6PD deficiency	1 (1 to 1)	3 (2 to 4)	1.64 (1.38 to 1.99)	6. 8 (5. 16 to 8. 67)	12. 3 (9. 47 to 15. 32)	2. 38 (1. 52 to 3. 24)
Australia	G6PD trait	12 (11 to 14)	9 (7 to 11)	-0.26 (-0.35 to -0.2)	72. 63 (63. 28 to 82. 94)	36. 94 (30. 12 to 43. 6)	-2.11 (-2.65 to -1.57)
Austria	Inherited	16	16	-0.04	207. 21	174.06	-0.71

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	anemias	(14 to 18)	(14 to 17)	(-0.07 to	(185.61 to	(156. 23 to	(-0.96 to
Austria	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0) -0.13 (-0.25 to 0.01)	230. 27) 0. 16 (0. 11 to 0. 21)	193. 79) 0. 12 (0. 08 to 0. 17)	-0. 46) -1. 94 (-2. 65 to -1. 22)
Austria	Thalassemi as trait	2 (1 to 2)	1 (1 to 2)	-0.05 (-0.11 to 0.01)	19. 44 (16. 82 to 22. 27)	16.09 (13.96 to 18.46)	-1 (-1.24 to -0.75)
Austria	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.76 (0.56 to 1)	0.07 (0.05 to 0.08)	0. 1 (0. 08 to 0. 13)	1.99 (1.6 to 2.39)
Austria	Sickle cell trait	1 (1 to 1)	2 (1 to 2)	0.32 (0.24 to 0.41)	16. 25 (14. 31 to 18. 51)	18.72 (16.59 to 21.1)	0.74 (0.45 to 1.03)
Austria	G6PD deficiency	3 (2 to 3)	3 (2 to 3)	-0.02 (-0.07 to 0.03)	33. 33 (25. 68 to 41. 52)	28. 53 (21. 87 to 36. 04)	-0.67 (-0.97 to -0.38)
Austria	G6PD trait	11 (10 to 12)	10 (9 to 11)	-0.08 (-0.12 to -0.04)	137. 97 (123. 66 to 152. 8)	110. 49 (98. 81 to 122. 12)	-0.87 (-1.11 to -0.62)
Azerbaijan	Inherited anemias	31 (28 to 34)	23 (21 to 25)	-0.25 (-0.27 to -0.24)	420. 15 (380. 93 to 460. 11)	223. 74 (202. 92 to 245. 65)	-1.21 (-1.62 to -0.8)
Azerbaijan	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.38 (-0.44 to -0.32)	3. 56 (2. 7 to 4. 68)	1.56 (1.21 to 2.01)	-1.88 (-2.28 to -1.48)
Azerbaijan	Thalassemi as trait	11 (10 to 13)	8 (7 to 10)	-0.23 (-0.27 to -0.19)	150. 16 (130. 64 to 170. 8)	82. 58 (72. 24 to 93. 3)	-1.14 (-1.53 to -0.74)
Azerbaijan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.26 (-0.38 to -0.11)	0.02 (0.01 to 0.03)	0.01 (0.01 to 0.01)	-1.24 (-1.64 to -0.83)
Azerbaijan	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	-0.25 (-0.32 to -0.17)	13. 22 (10. 3 to 16. 54)	7. 04 (5. 51 to 8. 89)	-1.21 (-1.61 to -0.81)
Azerbaijan	G6PD deficiency	3 (2 to 4)	2 (2 to 3)	-0.22 (-0.27 to -0.15)	38. 52 (29. 64 to 48. 01)	21. 48 (16. 65 to 27. 16)	-0.99 (-1.4 to -0.58)
Azerbaijan	G6PD trait	16 (14 to 18)	11 (10 to 13)	-0.27 (-0.27 to -0.27)	214. 67 (191. 53 to 238. 73)	111.07 (99.09 to 123.52)	-1. 3 (-1. 72 to -0. 88)
Bahamas	Inherited anemias	1 (1 to 2)	1 (1 to 1)	-0.17 (-0.2 to	549.95 (486.36 to	308.94 (271.94 to	-2.66 (-2.89 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
				-0.14)	619. 12)	348. 52)	-2.42)
Bahamas	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0. 28 (-0. 23 to 1. 57)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	-1. 19 (-1. 48 to -0. 89)
Bahamas	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.08 (-0.23 to 0.18)	7. 37 (5. 64 to 9. 32)	4. 62 (3. 59 to 5. 62)	-2. 23 (-2. 43 to -2. 04)
Bahamas	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.05 (-0.05 to 0.18)	7. 23 (5. 36 to 9. 36)	5. 18 (3. 77 to 6. 65)	-2.19 (-2.77 to -1.59)
Bahamas	Sickle cell trait	0 (0 to 1)	0 (0 to 1)	-0.09 (-0.14 to -0.04)	187. 1 (159. 25 to 216. 37)	115. 25 (97. 98 to 133. 97)	-2.5 (-2.88 to -2.11)
Bahamas	G6PD deficiency	0 (0 to 1)	0 (0 to 0)	-0. 23 (-0. 28 to -0. 16)	156. 46 (120. 84 to 196. 87)	81.82 (62.79 to 102.5)	-2.81 (-3 to -2.61)
Bahamas	G6PD trait	0 (0 to 1)	0 (0 to 0)	-0. 22 (-0. 25 to -0. 2)	191.77 (170.95 to 214.18)	102.06 (90.8 to 113.89)	-2.75 (-2.94 to -2.55)
Bahrain	Inherited anemias	9 (8 to 10)	8 (7 to 9)	-0.09 (-0.13 to -0.06)	1751. 44 (1612. 79 to 1892. 7)	559. 89 (511. 7 to 613. 55)	-4.3 (-4.79 to -3.81)
Bahrain	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.01 (-0.12 to 0.1)	1. 92 (1. 34 to 2. 75)	0. 67 (0. 46 to 0. 95)	-3.7 (-3.8 to -3.6)
Bahrain	Thalassemi as trait	1 (1 to 1)	1 (1 to 1)	-0.02 (-0.07 to 0.03)	150. 2 (127. 19 to 177. 26)	52.05 (43.96 to 61.77)	-3.71 (-3.81 to -3.6)
Bahrain	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 2 (-0. 28 to -0. 12)	30. 36 (24. 65 to 37. 56)	8. 58 (6. 84 to 10. 85)	-5. 15 (-5. 54 to -4. 77)
Bahrain	Sickle cell trait	3 (2 to 3)	2 (2 to 3)	-0.12 (-0.16 to -0.08)	512.6 (467.9 to 563.44)	158. 3 (143. 23 to 176. 05)	-4.42 (-4.6 to -4.24)
Bahrain	G6PD deficiency	2 (2 to 3)	2 (2 to 3)	-0.12 (-0.22 to -0.03)	454. 78 (360. 81 to 552. 72)	140. 73 (108. 75 to 176. 82)	-4.71 (-5.94 to -3.46)
Bahrain	G6PD trait	3 (3 to 3)	3 (3 to 3)	-0.06 (-0.08 to -0.03)	601. 57 (565. 91 to 630. 99)	199. 57 (187. 41 to 209. 32)	-3.93 (-4.2 to -3.66)
Bangladesh	Inherited anemias	1342 (1200 to 1501)	979 (878 to 1087)	-0. 27 (-0. 29 to -0. 25)	1230. 71 (1100. 11 to 1376. 68)	614.81 (551.38 to 682.46)	-2.34 (-2.37 to -2.32)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Bangladesh	Thalassemi as	7 (6 to 9)	8 (7 to 11)	0. 15 (0. 06 to 0. 24)	6. 73 (5. 49 to 8. 55)	5. 31 (4. 26 to 6. 69)	-0.78 (-0.82 to -0.75)
Bangladesh	Thalassemi as trait	277 (253 to 304)	227 (208 to 246)	-0.18 (-0.21 to -0.16)	253. 94 (232. 42 to 278. 51)	142. 24 (130. 52 to 154. 54)	-1.98 (-2.01 to -1.95)
Bangladesh	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.32 (-0.43 to -0.23)	0.06 (0.04 to 0.09)	0.03 (0.02 to 0.04)	-2. 69 (-2. 76 to -2. 62)
Bangladesh	Sickle cell trait	29 (24 to 36)	20 (16 to 25)	-0.31 (-0.38 to -0.27)	26. 73 (21. 59 to 33. 43)	12. 6 (10. 11 to 15. 82)	-2.61 (-2.66 to -2.56)
Bangladesh	G6PD deficiency	387 (300 to 485)	268 (209 to 332)	-0.31 (-0.35 to -0.25)	354. 84 (274. 98 to 445. 02)	168. 05 (131. 15 to 208. 49)	-2. 48 (-2. 51 to -2. 46)
Bangladesh	G6PD trait	642 (585 to 695)	456 (417 to 492)	-0. 29 (-0. 3 to -0. 28)	588. 4 (536. 42 to 637. 02)	286. 58 (262. 08 to 309. 16)	-2. 44 (-2. 46 to -2. 42)
Barbados	Inherited anemias	1 (1 to 1)	1 (1 to 1)	-0.3 (-0.33 to -0.28)	423. 36 (374. 89 to 479. 25)	251. 51 (222. 79 to 285. 5)	-1.83 (-1.97 to -1.69)
Barbados	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.11 (-0.32 to 1.25)	0.01 (0 to 0.01)	0.01 (0 to 0.01)	-0.36 (-0.76 to 0.04)
Barbados	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0. 2 (-0. 32 to 0. 03)	5. 75 (4. 38 to 7. 33)	3. 93 (3. 07 to 4. 85)	-1.38 (-1.61 to -1.14)
Barbados	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 2 (-0. 29 to -0. 09)	3. 67 (2. 7 to 4. 84)	2. 5 (1. 77 to 3. 31)	-1.49 (-1.65 to -1.33)
Barbados	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.27 (-0.32 to -0.22)	125. 34 (105. 26 to 146. 52)	77.69 (64.86 to 92.1)	-1.71 (-1.82 to -1.61)
Barbados	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.32 (-0.37 to -0.27)	132. 11 (102 to 163. 94)	76. 41 (58. 89 to 94. 81)	-1. 9 (-2. 07 to -1. 73)
Barbados	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.32 (-0.35 to -0.29)	156. 48 (139. 25 to 174. 57)	90. 97 (81. 13 to 100. 06)	-1.89 (-2.05 to -1.73)
Belarus	Inherited anemias	17 (15 to 19)	13 (12 to 15)	-0.25 (-0.26 to -0.23)	166. 42 (147. 84 to 186. 05)	137. 95 (122. 47 to 154. 84)	0.54 (0.01 to 1.06)
Belarus	Thalassemi	0	0	-0.49	0.71	0.4	-0.76

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	as	(0 to 0)	(0 to 0)	(-0.55 to -0.42)	(0.5 to 1.05)	(0. 29 to 0. 56)	(-1. 3 to -0. 22)
Belarus	Thalassemi as trait	3 (3 to 4)	3 (2 to 3)	-0.24 (-0.28 to -0.18)	32.88 (27.16 to 40.03)	27. 72 (23 to 33. 81)	0.59 (0.06 to 1.13)
Belarus	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.23 (-0.38 to -0.07)	0.01 (0.01 to 0.01)	0.01 (0 to 0.01)	0.62 (0.13 to 1.12)
Belarus	Sickle cell trait	1 (1 to 1)	0 (0 to 1)	-0. 24 (-0. 33 to -0. 17)	6. 28 (5. 03 to 7. 72)	5. 24 (4. 22 to 6. 45)	0.59 (0.08 to 1.1)
Belarus	G6PD deficiency	3 (2 to 3)	2 (2 to 3)	-0.21 (-0.23 to -0.19)	26. 14 (20. 2 to 33. 16)	22. 8 (17. 61 to 28. 41)	0.41 (-0.09 to 0.91)
Belarus	G6PD trait	11 (9 to 12)	8 (7 to 9)	-0.26 (-0.26 to -0.26)	100. 4 (89. 17 to 112. 22)	81. 79 (72. 64 to 91. 42)	0.55 (0.02 to 1.09)
Belgium	Inherited anemias	23 (21 to 26)	21 (19 to 23)	-0.11 (-0.14 to -0.08)	235. 05 (211. 85 to 259. 22)	182. 56 (162. 58 to 203. 15)	-0.51 (-0.66 to -0.35)
Belgium	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0. 2 (-0. 3 to -0. 1)	0. 2 (0. 14 to 0. 27)	0. 14 (0. 09 to 0. 2)	-1.75 (-2.41 to -1.08)
Belgium	Thalassemi as trait	1 (1 to 2)	1 (1 to 2)	-0.08 (-0.18 to 0.02)	14. 11 (11. 96 to 16. 26)	11. 39 (9. 57 to 13. 42)	-0.71 (-0.96 to -0.45)
Belgium	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 64 (-0. 7 to -0. 58)	0.4 (0.3 to 0.53)	0. 13 (0. 09 to 0. 17)	-1.65 (-2.23 to -1.07)
Belgium	Sickle cell trait	4 (3 to 5)	2 (2 to 3)	-0.43 (-0.49 to -0.37)	40.93 (34.76 to 47.89)	20. 5 (16. 76 to 24. 52)	-1.05 (-1.41 to -0.69)
Belgium	G6PD deficiency	3 (3 to 4)	3 (3 to 4)	0.01 (-0.06 to 0.05)	34. 7 (26. 68 to 43. 34)	30. 51 (23. 66 to 37. 91)	-0. 25 (-0. 38 to -0. 11)
Belgium	G6PD trait	14 (13 to 16)	14 (12 to 15)	-0.05 (-0.09 to -0.01)	144.71 (129.78 to 158.76)	119.89 (107.32 to 131.64)	-0. 42 (-0. 57 to -0. 26)
Belize	Inherited anemias	2 (1 to 2)	2 (2 to 2)	0. 32 (0. 28 to 0. 36)	877. 93 (775. 17 to 994. 28)	525. 08 (464. 06 to 592. 68)	-1.8 (-1.87 to -1.72)
Belize	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1. 1 (0. 28 to	0.02 (0.01 to	0.02 (0.01 to	-0.22 (-0.52 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
		, ,	, ,	3. 1)	0.03)	0.02)	0.09)
Belize	Thalassemi	0	0	0.51 (0.29 to	11.98 (9.27 to	8. 23 (6. 38 to	-1.32 (-1.46 to
Delize	as trait	(0 to 0)	(0 to 0)	0. 29 10	15. 06)	9. 92)	-1. 17)
Belize	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 48 (0. 32 to 0. 65)	12. 9 (9. 29 to 17. 29)	8. 64 (6. 16 to 11. 54)	-1.51 (-1.72 to -1.3)
Belize	Sickle cell trait	1 (0 to 1)	1 (1 to 1)	0.36 (0.28 to 0.43)	304. 32 (255. 63 to 360. 23)	187. 16 (155. 23 to 222)	-1.71 (-1.83 to -1.6)
Belize	G6PD deficiency	0 (0 to 1)	1 (0 to 1)	0. 28 (0. 24 to 0. 3)	249. 41 (191. 91 to 312. 55)	145. 23 (111. 48 to 182. 28)	-1.86 (-1.95 to -1.78)
Belize	G6PD trait	1 (0 to 1)	1 (1 to 1)	0.3 (0.25 to 0.35)	299. 31 (266. 36 to 334. 43)	175. 81 (156. 61 to 195. 83)	-1.86 (-1.94 to -1.78)
Benin	Inherited anemias	117 (107 to 127)	230 (210 to 251)	0.97 (0.89 to 1.04)	2408. 92 (2207. 43 to 2607. 35)	1816. 53 (1657. 21 to 1983. 97)	-0.94 (-1.05 to -0.83)
Benin	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.77 (1.36 to 2.28)	0.38 (0.26 to 0.57)	0.41 (0.28 to 0.56)	0.33 (0.25 to 0.4)
Benin	Thalassemi as trait	5 (4 to 6)	11 (9 to 13)	1. 37 (1. 23 to 1. 52)	94. 58 (78. 33 to 115. 6)	85. 87 (71. 78 to 101. 94)	-0.22 (-0.29 to -0.15)
Benin	Sickle cell disorders	8 (7 to 10)	12 (10 to 15)	0. 47 (0. 32 to 0. 62)	169. 46 (142. 11 to 201. 32)	95. 64 (76. 88 to 115. 74)	-2.29 (-2.63 to -1.95)
Benin	Sickle cell trait	51 (46 to 56)	91 (80 to 104)	0.81 (0.67 to 0.94)	1043. 27 (943. 22 to 1156. 97)	722. 36 (634. 24 to 817. 69)	-1.29 (-1.46 to -1.11)
Benin	G6PD deficiency	16 (12 to 20)	35 (27 to 44)	1. 2 (1. 04 to 1. 35)	330. 22 (254. 3 to 417. 92)	278. 4 (215. 58 to 346. 03)	-0.43 (-0.47 to -0.39)
Benin	G6PD trait	37 (34 to 41)	80 (73 to 87)	1.15 (1.07 to 1.19)	771. 01 (697. 99 to 836. 18)	633. 86 (575. 28 to 686. 66)	-0.56 (-0.63 to -0.5)
Bermuda	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.41 (-0.43 to -0.4)	353. 29 (310. 06 to 400. 11)	192. 19 (169. 68 to 217. 93)	-2.08 (-2.27 to -1.89)
Bermuda	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.06 (-0.43 to 0.92)	0.01 (0 to 0.01)	0.01 (0 to 0.01)	-0.59 (-1 to -0.17)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Bermuda	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.32 (-0.43 to -0.13)	4.89 (3.83 to 6.1)	3. 08 (2. 45 to 3. 73)	-1.62 (-1.9 to -1.34)
Bermuda	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.35 (-0.42 to -0.27)	2.05 (1.5 to 2.76)	1. 23 (0. 88 to 1. 66)	-1.81 (-1.94 to -1.69)
Bermuda	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.39 (-0.43 to -0.36)	98. 19 (82. 41 to 115. 4)	55. 29 (46. 12 to 65. 03)	-1.99 (-2.14 to -1.84)
Bermuda	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.43 (-0.43 to -0.43)	110. 41 (85. 44 to 137. 98)	58. 55 (45. 39 to 73. 16)	-2.15 (-2.37 to -1.93)
Bermuda	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.42 to -0.42)	137. 74 (122. 56 to 153. 63)	74. 03 (65. 89 to 82. 58)	-2.11 (-2.32 to -1.91)
Bhutan	Inherited anemias	5 (4 to 5)	3 (3 to 3)	-0.37 (-0.38 to -0.36)	807. 07 (718. 88 to 896. 99)	412. 5 (365. 79 to 459. 79)	-2. 22 (-2. 26 to -2. 18)
Bhutan	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.31 (-0.38 to -0.25)	1.61 (1.16 to 2.16)	0.9 (0.62 to 1.23)	-1.89 (-1.92 to -1.86)
Bhutan	Thalassemi as trait	1 (1 to 1)	1 (1 to 1)	-0.37 (-0.4 to -0.34)	162. 44 (138. 08 to 189. 62)	83 (70.07 to 97.61)	-2. 2 (-2. 24 to -2. 17)
Bhutan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 4 (-0. 46 to -0. 29)	0.06 (0.04 to 0.09)	0. 03 (0. 02 to 0. 04)	-2.44 (-2.5 to -2.39)
Bhutan	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0. 4 (-0. 43 to -0. 34)	28. 23 (22. 76 to 35. 02)	13.79 (11.12 to 17)	-2. 4 (-2. 45 to -2. 35)
Bhutan	G6PD deficiency	1 (1 to 1)	1 (1 to 1)	-0.34 (-0.38 to -0.3)	169. 58 (130. 91 to 211. 22)	91.36 (70.82 to 113.64)	-2. 21 (-2. 27 to -2. 15)
Bhutan	G6PD trait	3 (2 to 3)	2 (2 to 2)	-0.38 (-0.4 to -0.37)	445. 15 (398. 87 to 487. 08)	223. 42 (200. 16 to 244. 62)	-2. 23 (-2. 27 to -2. 18)
Bolivia (Plurinatio nal State of)	Inherited anemias	38 (34 to 42)	57 (50 to 64)	0.51 (0.46 to 0.56)	586. 8 (527. 72 to 647. 5)	473. 68 (418. 07 to 531. 53)	-0.93 (-1.12 to -0.75)
Bolivia (Plurinatio nal State	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.61 (0.27 to 1.11)	0.07 (0.05 to 0.09)	0.06 (0.04 to 0.07)	-0.33 (-0.43 to -0.22)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
of)		,					
Bolivia (Plurinatio nal State of)	Thalassemi as trait	2 (2 to 3)	3 (3 to 4)	0.43 (0.29 to 0.61)	33. 87 (29. 47 to 38. 94)	25. 95 (22. 51 to 29. 74)	-0.74 (-0.88 to -0.6)
Bolivia (Plurinatio nal State of)	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.35 (0.21 to 0.5)	0. 24 (0. 16 to 0. 33)	0. 17 (0. 12 to 0. 24)	-0.98 (-1.11 to -0.86)
Bolivia (Plurinatio nal State of)	Sickle cell trait	4 (3 to 4)	5 (4 to 6)	0. 34 (0. 27 to 0. 42)	57. 29 (46. 6 to 69. 04)	41. 14 (33. 8 to 49. 6)	-0.99 (-1.13 to -0.85)
Bolivia (Plurinatio nal State of)	G6PD deficiency	4 (3 to 5)	12 (9 to 15)	2. 33 (2. 1 to 2. 52)	56. 92 (44. 28 to 72. 43)	101. 21 (78. 52 to 126. 22)	-0.24 (-0.96 to 0.49)
Bolivia (Plurinatio nal State of)	G6PD trait	28 (25 to 31)	37 (33 to 41)	0.3 (0.24 to 0.36)	438. 42 (394. 02 to 484. 65)	305. 15 (273. 41 to 338. 4)	-1.08 (-1.23 to -0.93)
Bosnia and Herzegovina	Inherited anemias	9 (8 to 11)	4 (3 to 4)	-0.59 (-0.6 to -0.58)	208. 26 (184. 33 to 234. 32)	117. 11 (103. 79 to 131. 62)	-1.85 (-2.05 to -1.65)
Bosnia and Herzegovina	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.76 (-0.78 to -0.72)	1.08 (0.71 to 1.7)	0.36 (0.25 to 0.54)	-3.37 (-3.59 to -3.14)
Bosnia and Herzegovina	Thalassemi as trait	1 (1 to 2)	0 (0 to 1)	-0.6 (-0.63 to -0.56)	27. 29 (22. 88 to 33. 44)	15. 13 (12. 73 to 18. 39)	-1.74 (-1.97 to -1.51)
Bosnia and Herzegovina	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.56 (-0.6 to -0.5)	0.11 (0.08 to 0.15)	0.07 (0.05 to 0.09)	-1.46 (-1.6 to -1.31)
Bosnia and Herzegovina	Sickle cell trait	1 (1 to 1)	0 (0 to 1)	-0.58 (-0.6 to -0.56)	24. 12 (20. 74 to 27. 79)	13. 91 (11. 91 to 15. 98)	-1.58 (-1.76 to -1.4)
Bosnia and Herzegovina	G6PD deficiency	2 (2 to 3)	1 (1 to 1)	-0.57 (-0.6 to -0.53)	50.89 (39.45 to 63.51)	30. 32 (23. 47 to 37. 67)	-2.39 (-2.73 to -2.04)
Bosnia and Herzegovina	G6PD trait	5 (4 to 5)	2 (2 to 2)	-0.6 (-0.6 to -0.6)	104.78 (92.95 to 117.92)	57. 32 (50. 85 to 64. 51)	-1.7 (-1.92 to -1.49)
Botswana	Inherited	12	13	0.15	888.63	569.67	-1.36

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	anemias	(10 to 13)	(12 to 15)	(0.12 to	(775.93 to	(498. 42 to	(-1.46 to
Botswana	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0. 18) 1. 5 (1. 03 to 2. 08)	1008. 11) 0. 06 (0. 04 to 0. 09)	646.06) 0.08 (0.05 to 0.13)	-1. 27) 1 (0. 84 to 1. 15)
Botswana	Thalassemi as trait	0 (0 to 0)	0 (0 to 1)	0. 53 (0. 38 to 0. 68)	22. 41 (19. 03 to 26. 31)	19. 05 (15. 52 to 22. 53)	-0.52 (-0.59 to -0.45)
Botswana	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 18 (0. 07 to 0. 29)	0.09 (0.06 to 0.14)	0.06 (0.04 to 0.09)	-1.3 (-1.37 to -1.24)
Botswana	Sickle cell trait	0 (0 to 0)	0 (0 to 1)	0. 19 (0. 12 to 0. 25)	28. 61 (22. 16 to 37. 16)	18. 91 (14. 55 to 24. 67)	-1. 29 (-1. 35 to -1. 22)
Botswana	G6PD deficiency	4 (3 to 5)	4 (3 to 5)	0.11 (0.03 to 0.16)	287. 06 (221. 96 to 362. 37)	176. 59 (135. 68 to 220. 41)	-1.51 (-1.64 to -1.38)
Botswana	G6PD trait	7 (7 to 8)	8 (8 to 9)	0. 16 (0. 12 to 0. 2)	550. 39 (501. 94 to 594. 72)	354. 97 (323. 51 to 385. 17)	-1.33 (-1.42 to -1.25)
Brazil	Inherited anemias	589 (576 to 603)	573 (560 to 587)	-0.03 (-0.03 to -0.02)	396. 02 (386. 75 to 405. 37)	264. 62 (258. 45 to 270. 84)	-0.92 (-1.17 to -0.66)
Brazil	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.11 (-0.25 to 0.09)	0.06 (0.04 to 0.08)	0.03 (0.03 to 0.05)	-1.49 (-1.6 to -1.39)
Brazi1	Thalassemi as trait	28 (24 to 33)	25 (22 to 29)	-0.1 (-0.17 to 0)	18.83 (15.93 to 21.99)	11. 7 (9. 99 to 13. 48)	-1.45 (-1.53 to -1.37)
Brazi1	Sickle cell disorders	1 (1 to 1)	1 (1 to 1)	-0.1 (-0.16 to -0.03)	0.6 (0.49 to 0.73)	0. 37 (0. 31 to 0. 45)	-2.04 (-2.2 to -1.89)
Brazil	Sickle cell trait	77 (69 to 85)	78 (70 to 86)	0.02 (-0.02 to 0.05)	51. 43 (46. 03 to 57. 27)	35. 9 (32. 38 to 39. 69)	-1.07 (-1.16 to -0.98)
Brazi1	G6PD deficiency	91 (87 to 94)	106 (102 to 110)	0. 17 (0. 15 to 0. 19)	61. 07 (58. 75 to 63. 2)	49. 05 (47. 16 to 50. 93)	0.15 (-0.39 to 0.68)
Brazi1	G6PD trait	393 (386 to 400)	363 (356 to 369)	-0.08 (-0.08 to -0.07)	264. 02 (259. 14 to 268. 62)	167. 56 (164. 39 to 170. 45)	-1.14 (-1.37 to -0.91)
Brunei Darussalam	Inherited anemias	1 (0 to 1)	0 (0 to 0)	-0.3 (-0.33 to	205. 43 (175. 33 to	85. 19 (74. 65 to	-3.26 (-3.49 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
				-0.26)	237. 26)	96. 88)	-3.04)
Brunei Darussalam	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0. 25 (-0. 34 to -0. 14)	1. 25 (0. 81 to 1. 97)	0.56 (0.36 to 0.88)	-3.01 (-3.17 to -2.85)
Brunei Darussalam	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.57 (0.3 to 0.89)	7.77 (6 to 9.91)	7. 22 (5. 93 to 8. 72)	-0.7 (-1 to -0.39)
Brunei Darussalam	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.08 (-0.27 to 0.04)	0.03 (0.02 to 0.04)	0. 01 (0. 01 to 0. 02)	-2.21 (-2.38 to -2.05)
Brunei Darussalam	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.07 (-0.18 to 0.05)	12.74 (10.09 to 15.71)	7. 03 (5. 55 to 8. 7)	-2.21 (-2.36 to -2.06)
Brunei Darussalam	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.76 (-0.78 to -0.73)	58. 85 (44. 99 to 73. 59)	8.51 (6.51 to 10.76)	-6.6 (-7.85 to -5.35)
Brunei Darussalam	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.16 (-0.2 to -0.11)	124. 79 (108. 43 to 143. 64)	61. 86 (53. 28 to 70. 97)	-2.65 (-2.74 to -2.56)
Bulgaria	Inherited anemias	19 (17 to 21)	11 (10 to 12)	-0.41 (-0.42 to -0.4)	215. 94 (192. 58 to 242. 37)	159. 29 (142. 67 to 177. 49)	-0. 2 (-0. 54 to 0. 16)
Bulgaria	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.72 (-0.77 to -0.66)	1. 57 (1. 15 to 2. 12)	0.55 (0.39 to 0.8)	-2.87 (-3.39 to -2.34)
Bulgaria	Thalassemi as trait	3 (2 to 3)	2 (1 to 2)	-0.38 (-0.41 to -0.34)	30. 28 (25. 89 to 35. 49)	23. 69 (20. 18 to 27. 52)	0.02 (-0.33 to 0.36)
Bulgaria	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.23 (-0.32 to -0.13)	0. 1 (0. 08 to 0. 13)	0. 1 (0. 07 to 0. 13)	0.46 (0.16 to 0.76)
Bulgaria	Sickle cell trait	2 (2 to 2)	1 (1 to 1)	-0.32 (-0.36 to -0.28)	20. 26 (17. 39 to 23. 44)	17. 2 (14. 63 to 19. 92)	0.18 (-0.13 to 0.49)
Bulgaria	G6PD deficiency	4 (3 to 5)	2 (2 to 3)	-0.5 (-0.5 to -0.49)	48. 28 (37. 23 to 60. 41)	30. 44 (23. 54 to 38)	-0.79 (-1.21 to -0.36)
Bulgaria	G6PD trait	10 (9 to 11)	6 (5 to 7)	-0. 4 (-0. 4 to -0. 4)	115. 44 (103 to 128. 44)	87. 32 (77. 91 to 97. 15)	-0.07 (-0.42 to 0.28)
Burkina Faso	Inherited anemias	305 (295 to 317)	588 (530 to 647)	0.92 (0.75 to 1.11)	3195.97 (3081.68 to 3312.35)	2590. 21 (2337. 45 to 2852. 36)	-0.75 (-0.83 to -0.67)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Burkina Faso	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.65 (1.33 to 2.05)	0.4 (0.3 to 0.53)	0. 45 (0. 33 to 0. 59)	0.36 (0.31 to 0.42)
Burkina Faso	Thalassemi as trait	9 (8 to 11)	21 (18 to 24)	1. 28 (1. 17 to 1. 39)	95. 91 (82. 81 to 111. 05)	91. 91 (79. 52 to 105. 6)	-0.17 (-0.21 to -0.13)
Burkina Faso	Sickle cell disorders	15 (14 to 17)	22 (18 to 27)	0. 45 (0. 2 to 0. 7)	161. 95 (144. 14 to 182. 27)	98. 79 (80. 25 to 120. 79)	-1.72 (-1.96 to -1.49)
Burkina Faso	Sickle cell trait	103 (96 to 110)	185 (164 to 209)	0.8 (0.61 to 0.99)	1074. 27 (1000. 12 to 1149. 04)	814. 2 (722. 19 to 921. 26)	-1.04 (-1.3 to -0.78)
Burkina Faso	G6PD deficiency	84 (79 to 89)	167 (129 to 207)	0. 98 (0. 54 to 1. 46)	882. 04 (829. 8 to 936. 05)	734.66 (568.79 to 912.74)	-0.6 (-0.78 to -0.41)
Burkina Faso	G6PD trait	94 (92 to 95)	193 (179 to 205)	1.06 (0.91 to 1.19)	981. 4 (963. 85 to 997. 85)	850. 22 (787. 48 to 905. 22)	-0.51 (-0.54 to -0.47)
Burundi	Inherited anemias	94 (84 to 105)	151 (135 to 168)	0.61 (0.57 to 0.65)	1687.06 (1500.45 to 1880.72)	1268.05 (1133.67 to 1411.39)	-0.77 (-0.91 to -0.63)
Burundi	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 95 (2. 37 to 3. 75)	0. 1 (0. 06 to 0. 15)	0. 18 (0. 1 to 0. 28)	2.02 (1.86 to 2.18)
Burundi	Thalassemi as trait	2 (1 to 2)	4 (3 to 5)	1.44 (1.24 to 1.7)	27. 95 (22. 01 to 34. 06)	31.84 (24.84 to 39.11)	0.51 (0.43 to 0.59)
Burundi	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.6 (0.39 to 0.76)	4. 07 (3. 15 to 5. 28)	3. 04 (2. 39 to 3. 98)	-0.9 (-1 to -0.8)
Burundi	Sickle cell trait	15 (13 to 17)	25 (22 to 28)	0.68 (0.56 to 0.76)	265. 11 (234. 4 to 302. 41)	207. 56 (184. 15 to 237. 8)	-0.7 (-0.78 to -0.62)
Burundi	G6PD deficiency	28 (22 to 35)	40 (31 to 49)	0.43 (0.35 to 0.5)	499. 83 (386. 99 to 623. 44)	333. 9 (258. 95 to 414. 23)	-1.17 (-1.42 to -0.91)
Burundi	G6PD trait	50 (46 to 53)	83 (75 to 89)	0.66 (0.63 to 0.71)	890. 01 (818. 65 to 955. 83)	691.52 (631.85 to 746.91)	-0.63 (-0.75 to -0.52)
Cabo Verde	Inherited anemias	3 (3 to 3)	3 (2 to 3)	-0.04 (-0.06 to -0.02)	802. 56 (729. 45 to 879. 12)	480. 2 (433. 64 to 528. 84)	-1.61 (-1.7 to -1.52)
Cabo Verde	Thalassemi	0	0	0.18	0.18	0.13	-0.95

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	as	(0 to 0)	(0 to 0)	(0 to 0.42)	(0.13 to 0.27)	(0.09 to 0.19)	(-1.02 to -0.89)
Cabo Verde	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.01 (-0.06 to 0.08)	53.75 (44.78 to 66.23)	33. 84 (28. 36 to 40. 67)	-1.48 (-1.56 to -1.41)
Cabo Verde	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.09 (-0.15 to -0.03)	2.6 (1.97 to 3.33)	1.47 (1.14 to 1.9)	-1.79 (-1.9 to -1.68)
Cabo Verde	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.08 (-0.12 to -0.05)	116.88 (101.92 to 134.03)	67. 15 (58. 06 to 77. 26)	-1.73 (-1.84 to -1.62)
Cabo Verde	G6PD deficiency	0 (0 to 0)	0 (0 to 1)	0.09 (0.01 to 0.17)	111. 32 (88. 24 to 137. 44)	75. 64 (58. 16 to 94. 95)	-0.96 (-1.14 to -0.78)
Cabo Verde	G6PD trait	2 (2 to 2)	2 (2 to 2)	-0.07 (-0.08 to -0.04)	517. 83 (469. 27 to 563. 32)	301. 97 (273. 75 to 329. 53)	-1.75 (-1.84 to -1.66)
Cambodia	Inherited anemias	171 (153 to 191)	150 (135 to 166)	-0.12 (-0.14 to -0.1)	1648. 13 (1474. 12 to 1840. 62)	905. 67 (813. 56 to 1002. 68)	-1.61 (-1.93 to -1.29)
Cambodia	Thalassemi as	3 (2 to 4)	3 (3 to 4)	0. 2 (0. 08 to 0. 3)	27. 4 (22. 43 to 33. 75)	20. 63 (16. 33 to 26. 32)	-0.87 (-1.09 to -0.64)
Cambodia	Thalassemi as trait	44 (40 to 49)	44 (40 to 48)	-0.01 (-0.05 to 0.02)	426. 3 (387. 57 to 473. 2)	262. 81 (239. 85 to 289. 34)	-1.56 (-1.76 to -1.36)
Cambodia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.16 (-0.25 to 0)	0.04 (0.03 to 0.06)	0.02 (0.01 to 0.03)	-2. 1 (-2. 32 to -1. 87)
Cambodia	Sickle cell trait	2 (2 to 3)	2 (2 to 2)	-0.17 (-0.21 to -0.09)	23. 78 (19. 46 to 28. 49)	12. 41 (10. 17 to 14. 73)	-2.12 (-2.33 to -1.9)
Cambodia	G6PD deficiency	50 (38 to 62)	41 (32 to 51)	-0.16 (-0.23 to -0.1)	477. 44 (369. 01 to 593. 06)	249. 9 (192. 77 to 309. 91)	-1.65 (-2.02 to -1.28)
Cambodia	G6PD trait	72 (65 to 78)	60 (54 to 65)	-0.17 (-0.17 to -0.17)	693. 18 (629. 95 to 755. 45)	359. 9 (327. 06 to 392. 28)	-1.63 (-2.01 to -1.25)
Cameroon	Inherited anemias	186 (173 to 200)	372 (343 to 403)	1 (0.93 to 1.09)	1789. 38 (1664. 05 to 1921. 73)	1279. 35 (1178. 35 to 1384)	-1.01 (-1.23 to -0.8)
Cameroon	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.6 (1.24 to	0.34 (0.23 to	0.31 (0.22 to	-0.12 (-0.32 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
		,	,	2.06)	0.49)	0.44)	0.08)
Cameroon	Thalassemi as trait	9 (7 to 11)	19 (16 to 23)	1. 19 (1. 07 to 1. 33)	84.92 (70.02 to 103.28)	66. 45 (55. 69 to 79. 48)	-0.69 (-0.9 to -0.49)
Cameroon	Sickle cell disorders	4 (3 to 4)	8 (7 to 10)	1. 14 (0. 79 to 1. 58)	36. 27 (32. 79 to 40. 06)	27. 71 (22. 61 to 35. 32)	-0.89 (-1.12 to -0.65)
Cameroon	Sickle cell trait	75 (72 to 79)	152 (139 to 171)	1.03 (0.87 to 1.21)	722. 87 (689. 72 to 757. 38)	523. 58 (477. 08 to 586. 05)	-0.99 (-1.22 to -0.77)
Cameroon	G6PD deficiency	24 (19 to 30)	48 (37 to 60)	0.96 (0.89 to 1.08)	234. 22 (180. 98 to 291. 23)	164. 1 (126. 61 to 206. 75)	-1.06 (-1.26 to -0.86)
Cameroon	G6PD trait	74 (67 to 80)	145 (131 to 157)	0.96 (0.96 to 0.97)	710.77 (644.3 to 771.92)	497. 19 (451. 29 to 539. 69)	-1.06 (-1.27 to -0.86)
Canada	Inherited anemias	72 (63 to 82)	57 (49 to 65)	-0.21 (-0.25 to -0.18)	264. 48 (229. 92 to 302. 41)	155. 59 (134. 65 to 178. 23)	-1.57 (-1.81 to -1.32)
Canada	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.21 (-0.34 to -0.07)	0.07 (0.05 to 0.09)	0.04 (0.03 to 0.06)	-2.18 (-2.38 to -1.97)
Canada	Thalassemi as trait	2 (1 to 2)	1 (1 to 2)	-0.14 (-0.32 to 0.04)	5. 56 (4. 7 to 6. 51)	3. 59 (2. 96 to 4. 26)	-0.99 (-1.3 to -0.68)
Canada	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.85 (-0.9 to -0.77)	0.08 (0.05 to 0.12)	0.01 (0.01 to 0.01)	-6.76 (-8.48 to -5.01)
Canada	Sickle cell trait	2 (1 to 2)	1 (1 to 2)	-0.16 (-0.35 to -0.07)	5. 81 (4. 85 to 6. 86)	3. 63 (2. 9 to 4. 43)	-1.31 (-1.6 to -1.03)
Canada	G6PD deficiency	19 (15 to 24)	15 (12 to 19)	-0. 2 (-0. 25 to -0. 14)	70.03 (54.12 to 87.07)	41. 65 (32. 13 to 52. 51)	-1.62 (-1.87 to -1.37)
Canada	G6PD trait	50 (45 to 55)	39 (35 to 43)	-0.22 (-0.26 to -0.19)	182. 93 (164. 38 to 202. 04)	106. 67 (95. 49 to 118. 3)	-1.57 (-1.82 to -1.33)
Central African Republic	Inherited anemias	65 (59 to 71)	101 (92 to 111)	0.55 (0.51 to 0.59)	2376. 47 (2161. 09 to 2599. 21)	1908. 83 (1732. 81 to 2103. 6)	-0.71 (-0.78 to -0.64)
Central African Republic	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 2 (1. 76 to 2. 72)	0. 11 (0. 07 to 0. 16)	0. 18 (0. 1 to 0. 28)	1.56 (1.4 to 1.73)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Central African Republic	Thalassemi as trait	1 (1 to 1)	2 (2 to 2)	0. 98 (0. 84 to 1. 13)	37. 55 (31. 26 to 44. 42)	38. 48 (31. 44 to 46. 36)	0.05 (-0.03 to 0.13)
Central African Republic	Sickle cell disorders	1 (1 to 2)	2 (1 to 2)	0. 52 (0. 38 to 0. 68)	45. 34 (35. 59 to 58. 72)	35. 74 (27. 86 to 47. 03)	-0.76 (-0.82 to -0.7)
Central African Republic	Sickle cell trait	23 (20 to 25)	35 (31 to 39)	0.54 (0.47 to 0.61)	822. 03 (738. 55 to 924. 95)	653. 99 (585. 57 to 741. 41)	-0.73 (-0.8 to -0.67)
Central African Republic	G6PD deficiency	15 (12 to 19)	23 (18 to 29)	0.56 (0.46 to 0.66)	546. 31 (422. 22 to 677. 9)	440.79 (341.49 to 552.03)	-0.73 (-0.81 to -0.65)
Central African Republic	G6PD trait	25 (23 to 27)	39 (36 to 42)	0.54 (0.5 to 0.58)	925. 13 (853. 3 to 988. 9)	739.64 (683.05 to 792.93)	-0.71 (-0.78 to -0.64)
Chad	Inherited anemias	108 (98 to 119)	265 (240 to 292)	1.46 (1.39 to 1.52)	1791. 43 (1619. 68 to 1968. 92)	1617.72 (1461.37 to 1782.15)	-0.37 (-0.42 to -0.32)
Chad	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 36 (1. 92 to 2. 89)	0.36 (0.27 to 0.48)	0.45 (0.32 to 0.6)	0.66 (0.6 to 0.72)
Chad	Thalassemi as trait	6 (5 to 7)	16 (14 to 18)	1.76 (1.64 to 1.92)	95.78 (82.04 to 111.77)	97. 21 (83. 72 to 112. 3)	0 (-0.04 to 0.05)
Chad	Sickle cell disorders	1 (1 to 1)	2 (1 to 2)	1.41 (1.21 to 1.6)	11. 35 (9. 21 to 13. 71)	10.04 (8.27 to 12.21)	-0.43 (-0.48 to -0.38)
Chad	Sickle cell trait	27 (25 to 30)	67 (61 to 74)	1.44 (1.33 to 1.53)	455.8 (410.9 to 501)	407. 73 (369. 81 to 449. 62)	-0.4 (-0.45 to -0.36)
Chad	G6PD deficiency	24 (19 to 30)	57 (44 to 71)	1.37 (1.18 to 1.58)	396. 94 (307. 63 to 492. 97)	346. 15 (267. 56 to 432. 04)	-0.45 (-0.52 to -0.38)
Chad	G6PD trait	50 (45 to 54)	124 (112 to 135)	1.48 (1.39 to 1.55)	831. 19 (753. 63 to 904. 27)	756. 14 (684. 57 to 820. 83)	-0.36 (-0.41 to -0.32)
Chile	Inherited anemias	30 (26 to 34)	22 (20 to 25)	-0. 25 (-0. 28 to -0. 22)	225. 26 (198. 52 to 254. 58)	122. 87 (108. 79 to 138. 74)	-1.85 (-2.03 to -1.67)
Chile	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.22 (-0.36 to 0.02)	0. 28 (0. 18 to 0. 41)	0. 16 (0. 12 to 0. 22)	-1.64 (-1.99 to -1.3)
Chile	Thalassemi	2	3	0.36	15. 55	15. 47	0.47

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	as trait	(2 to 2)	(2 to 3)	(0. 21 to 0. 53)	(13.31 to 18.21)	(13.63 to 17.39)	(0. 21 to 0. 73)
Chile	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 25 (-0. 5 to -0. 12)	0 (0 to 0.01)	0 (0 to 0)	-1. 53 (-1. 82 to -1. 24)
Chile	Sickle cell trait	1 (0 to 1)	0 (0 to 1)	-0.25 (-0.47 to -0.21)	4. 17 (2. 4 to 6. 35)	2. 28 (1. 29 to 3. 44)	-1.6 (-1.84 to -1.35)
Chile	G6PD deficiency	5 (4 to 6)	3 (3 to 4)	-0.27 (-0.31 to -0.23)	34. 21 (26. 52 to 43. 62)	18.3 (14.15 to 22.91)	-2.02 (-2.19 to -1.84)
Chile	G6PD trait	23 (20 to 25)	16 (14 to 18)	-0.31 (-0.33 to -0.27)	171.04 (152.05 to 191.27)	86. 66 (76. 7 to 97. 49)	-2.11 (-2.3 to -1.93)
China	Inherited anemias	6133 (5719 to 6696)	4025 (3790 to 4339)	-0.34 (-0.36 to -0.33)	518. 17 (483. 18 to 565. 73)	282. 95 (266. 48 to 305. 08)	-2.05 (-2.37 to -1.74)
China	Thalassemi as	101 (72 to 143)	60 (43 to 86)	-0.4 (-0.44 to -0.36)	8. 51 (6. 06 to 12. 08)	4. 23 (3. 04 to 6. 04)	-2.34 (-2.85 to -1.84)
China	Thalassemi as trait	2543 (2164 to 3051)	1475 (1261 to 1748)	-0.42 (-0.44 to -0.4)	214. 83 (182. 84 to 257. 76)	103.73 (88.68 to 122.9)	-2. 27 (-2. 82 to -1. 71)
China	Sickle cell disorders	1 (1 to 2)	0 (0 to 1)	-0.56 (-0.57 to -0.53)	0.09 (0.06 to 0.13)	0.03 (0.02 to 0.05)	-3. 53 (-4. 22 to -2. 84)
China	Sickle cell trait	303 (249 to 365)	158 (132 to 190)	-0.48 (-0.49 to -0.46)	25.58 (20.99 to 30.8)	11. 13 (9. 31 to 13. 33)	-2. 8 (-3. 41 to -2. 19)
China	G6PD deficiency	841 (808 to 872)	724 (691 to 753)	-0.14 (-0.17 to -0.12)	71.04 (68.26 to 73.65)	50. 89 (48. 6 to 52. 97)	-0.89 (-1.08 to -0.7)
China	G6PD trait	2345 (2303 to 2382)	1606 (1576 to 1635)	-0.32 (-0.32 to -0.31)	198. 12 (194. 6 to 201. 24)	112. 94 (110. 79 to 114. 96)	-2. 23 (-2. 43 to -2. 03)
Colombia	Inherited anemias	210 (186 to 235)	180 (159 to 202)	-0.15 (-0.16 to -0.11)	646. 5 (572. 18 to 722. 57)	376. 47 (333. 1 to 423. 5)	-2.23 (-2.5 to -1.96)
Colombia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.36 (-0.15 to 1.49)	0.02 (0.01 to 0.03)	0.01 (0.01 to 0.02)	-0.46 (-0.7 to -0.22)
Colombia	Thalassemi as trait	4 (3 to 5)	4 (3 to 4)	-0.01 (-0.15 to	11.78 (9.73 to	7. 97 (6. 62 to	-1.49 (-1.57 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
				0.21)	14. 42)	9. 36)	-1.41)
Colombia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.16 (-0.24 to -0.05)	0.46 (0.31 to 0.66)	0. 26 (0. 18 to 0. 37)	-1.98 (-2.02 to -1.94)
Colombia	Sickle cell trait	9 (8 to 10)	7 (6 to 8)	-0.18 (-0.25 to -0.14)	26. 52 (23. 49 to 29. 96)	14.74 (13.15 to 16.58)	-1.95 (-2.02 to -1.88)
Colombia	G6PD deficiency	48 (37 to 60)	41 (32 to 51)	-0.15 (-0.2 to -0.1)	147. 51 (113. 84 to 183. 72)	85. 5 (66. 18 to 106. 81)	-2. 54 (-3. 05 to -2. 02)
Colombia	G6PD trait	150 (136 to 162)	128 (116 to 140)	-0.15 (-0.16 to -0.12)	460. 21 (417. 91 to 497. 27)	267. 98 (243. 46 to 292. 21)	-2.18 (-2.4 to -1.96)
Comoros	Inherited anemias	6 (6 to 7)	5 (4 to 5)	-0. 24 (-0. 26 to -0. 22)	1361.57 (1187.7 to 1535.19)	670.83 (590.62 to 755.67)	-2. 5 (-2. 67 to -2. 32)
Comoros	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.83 (0.57 to 1.2)	0.08 (0.05 to 0.12)	0.1 (0.05 to 0.15)	0. 2 (-0. 02 to 0. 41)
Comoros	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0. 14 (0. 05 to 0. 26)	24.78 (19.46 to 30.4)	18. 43 (14. 56 to 22. 44)	-1.26 (-1.39 to -1.13)
Comoros	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.18 (-0.25 to -0.08)	0.54 (0.34 to 0.83)	0. 29 (0. 18 to 0. 45)	-2. 19 (-2. 28 to -2. 1)
Comoros	Sickle cell trait	0 (0 to 1)	0 (0 to 0)	-0.17 (-0.22 to -0.12)	88. 56 (68. 49 to 113. 2)	47.67 (36.96 to 61.11)	-2. 21 (-2. 29 to -2. 12)
Comoros	G6PD deficiency	2 (2 to 3)	1 (1 to 2)	-0.32 (-0.36 to -0.28)	444. 16 (341. 86 to 552. 39)	195. 47 (151. 58 to 246. 5)	-2.89 (-3.18 to -2.59)
Comoros	G6PD trait	4 (3 to 4)	3 (3 to 3)	-0. 22 (-0. 24 to -0. 19)	803. 46 (735. 48 to 866. 53)	408. 87 (373. 08 to 441. 93)	-2. 37 (-2. 51 to -2. 24)
Congo	Inherited anemias	50 (45 to 55)	71 (63 to 78)	0.41 (0.37 to 0.46)	2049. 99 (1847. 05 to 2258. 65)	1342.47 (1203.96 to 1489.15)	-1. 18 (-1. 43 to -0. 93)
Congo	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.88 (1.44 to 2.39)	0.09 (0.06 to 0.14)	0. 12 (0. 07 to 0. 18)	1.13 (0.87 to 1.4)
Congo	Thalassemi as trait	1 (1 to 1)	1 (1 to 2)	0.81 (0.67 to 0.97)	32. 22 (26. 8 to 38. 23)	27. 01 (22. 04 to 31. 98)	-0.36 (-0.6 to -0.13)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Congo	Sickle cell disorders	1 (1 to 1)	1 (1 to 1)	0. 23 (0. 1 to 0. 36)	27. 04 (21. 72 to 32. 92)	15. 49 (12. 09 to 19. 48)	-1.67 (-1.96 to -1.37)
Congo	Sickle cell trait	14 (12 to 15)	18 (16 to 20)	0.33 (0.24 to 0.4)	563. 74 (501. 76 to 622. 74)	347. 42 (305. 17 to 388. 39)	-1.4 (-1.66 to -1.14)
Congo	G6PD deficiency	14 (11 to 18)	21 (16 to 26)	0.46 (0.35 to 0.59)	587. 04 (463. 2 to 725. 33)	397. 26 (306. 38 to 493. 65)	-1.1 (-1.37 to -0.83)
Congo	G6PD trait	21 (19 to 22)	29 (27 to 31)	0. 42 (0. 42 to 0. 44)	839. 87 (775. 05 to 897. 59)	555. 16 (511. 91 to 593. 41)	-1.11 (-1.35 to -0.86)
Cook Islands	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.36 (-0.37 to -0.35)	514. 26 (457. 02 to 577. 72)	347. 86 (307. 13 to 390. 03)	-1.37 (-1.51 to -1.23)
Cook Islands	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0. 5 (-0. 57 to -0. 41)	1.99 (1.1 to 3.21)	1.06 (0.58 to 1.77)	-0.87 (-1.99 to 0.27)
Cook Islands	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.45 (-0.49 to -0.41)	71. 72 (54. 98 to 89. 64)	41. 8 (31. 97 to 53. 19)	-1.36 (-1.82 to -0.9)
Cook Islands	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.43 to -0.29)	0 (0 to 0)	0 (0 to 0)	-1.78 (-1.84 to -1.71)
Cook Islands	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.43 to -0.34)	3. 02 (1. 33 to 4. 87)	1.85 (0.8 to 2.99)	-1.8 (-1.87 to -1.74)
Cook Islands	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.31 (-0.34 to -0.26)	107. 18 (83. 24 to 134. 41)	78. 7 (60. 51 to 98. 29)	-1.18 (-1.35 to -1.01)
Cook Islands	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.36 (-0.37 to -0.35)	330. 34 (297. 17 to 363. 11)	224. 45 (202. 56 to 244. 39)	-1.46 (-1.56 to -1.35)
Costa Rica	Inherited anemias	14 (13 to 16)	11 (10 to 12)	-0. 24 (-0. 29 to -0. 19)	472. 53 (419. 23 to 528. 98)	230. 93 (202. 18 to 258. 39)	-2. 2 (-2. 36 to -2. 05)
Costa Rica	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.38 (-0.18 to 2.02)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	-0.26 (-0.4 to -0.12)
Costa Rica	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.01 (-0.18 to 0.41)	6. 55 (4. 79 to 8. 91)	4. 28 (3. 16 to 5. 4)	-1. 29 (-1. 38 to -1. 2)
Costa Rica	Sickle	0	0	-0.18	0.01	0	-2.24

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	cell disorders	(0 to 0)	(0 to 0)	(-0.34 to 0.08)	(0 to 0.01)	(0 to 0.01)	(-2.72 to -1.76)
Costa Rica	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0. 2 (-0. 46 to -0. 18)	2. 62 (1. 18 to 4. 12)	1. 35 (0. 63 to 2. 15)	-2.38 (-3.03 to -1.73)
Costa Rica	G6PD deficiency	4 (3 to 5)	2 (2 to 3)	-0.46 (-0.53 to -0.38)	138. 66 (112. 31 to 167. 23)	48. 14 (37. 32 to 59. 7)	-3. 19 (-3. 5 to -2. 89)
Costa Rica	G6PD trait	10 (9 to 11)	8 (8 to 9)	-0.15 (-0.21 to -0.11)	324.68 (296.36 to 353.9)	177. 14 (159. 11 to 193. 39)	-1.88 (-2.08 to -1.67)
Côte d'Ivoire	Inherited anemias	241 (222 to 263)	384 (354 to 418)	0.59 (0.56 to 0.62)	1975. 02 (1819. 25 to 2148. 72)	1467. 09 (1353. 87 to 1595. 35)	-0.97 (-1.05 to -0.89)
Côte d'Ivoire	Thalassemi as	0 (0 to 0)	1 (0 to 1)	0.64 (0.48 to 0.8)	2. 84 (2. 17 to 3. 63)	2. 17 (1. 68 to 2. 79)	-0.85 (-0.94 to -0.76)
Côte d'Ivoire	Thalassemi as trait	29 (26 to 33)	48 (42 to 54)	0.63 (0.55 to 0.71)	240. 87 (212. 56 to 270. 17)	183. 15 (162. 01 to 205. 76)	-0.89 (-0.98 to -0.81)
Côte d'Ivoire	Sickle cell disorders	4 (3 to 4)	6 (5 to 7)	0.53 (0.46 to 0.61)	31. 93 (27. 9 to 36. 18)	22. 88 (19. 88 to 25. 96)	-1. 1 (-1. 18 to -1. 01)
Côte d'Ivoire	Sickle cell trait	73 (68 to 79)	113 (104 to 122)	0.54 (0.49 to 0.59)	599. 88 (555. 56 to 646. 89)	431. 83 (398. 12 to 467. 91)	-1.08 (-1.16 to -0.99)
Côte d'Ivoire	G6PD deficiency	43 (33 to 54)	69 (53 to 87)	0.59 (0.56 to 0.63)	352. 29 (272. 18 to 437. 69)	262. 43 (202. 87 to 331. 01)	-0.89 (-0.99 to -0.78)
Côte d'Ivoire	G6PD trait	91 (83 to 99)	148 (134 to 161)	0. 62 (0. 58 to 0. 65)	747. 21 (676. 98 to 813. 74)	564. 62 (513. 68 to 614. 69)	-0.95 (-1.02 to -0.88)
Croatia	Inherited anemias	8 (7 to 9)	5 (4 to 5)	-0.39 (-0.41 to -0.37)	156. 61 (135. 32 to 179. 65)	110. 46 (96. 23 to 126. 05)	-0.57 (-0.86 to -0.27)
Croatia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.6 (-0.64 to -0.54)	0.8 (0.53 to 1.26)	0. 37 (0. 25 to 0. 57)	-2. 23 (-2. 44 to -2. 02)
Croatia	Thalassemi as trait	1 (1 to 1)	1 (1 to 1)	-0.32 (-0.36 to -0.27)	19.62 (16.26 to 23.7)	15. 46 (12. 98 to 18. 64)	-0.5 (-0.71 to -0.29)
Croatia	Sickle cell	0 (0 to 0)	0 (0 to 0)	-0.32 (-0.38 to	0.1 (0.08 to	0.08 (0.06 to	-0.59 (-0.85 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	disorders	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(227222)	-0. 26)	0.13)	0.1)	-0.33)
Croatia	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	-0.31 (-0.34 to -0.28)	17. 79 (15. 23 to 20. 49)	14. 2 (12. 22 to 16. 36)	-0.49 (-0.72 to -0.26)
Croatia	G6PD deficiency	3 (2 to 4)	2 (1 to 2)	-0. 47 (-0. 52 to -0. 42)	61. 5 (47. 54 to 77. 49)	37. 49 (28. 86 to 46. 57)	-0.63 (-1.09 to -0.17)
Croatia	G6PD trait	3 (2 to 3)	2 (2 to 2)	-0.35 (-0.35 to -0.35)	56. 8 (49. 68 to 64. 89)	42. 87 (37. 49 to 48. 97)	-0.53 (-0.76 to -0.3)
Cuba	Inherited anemias	32 (29 to 36)	20 (18 to 23)	-0.37 (-0.39 to -0.34)	297. 17 (264. 47 to 333. 34)	179. 56 (160. 46 to 200. 62)	-1.27 (-1.56 to -0.98)
Cuba	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.01 (-0.42 to 1.19)	0.01 (0 to 0.01)	0.01 (0 to 0.01)	0. 14 (-0. 18 to 0. 45)
Cuba	Thalassemi as trait	0 (0 to 1)	0 (0 to 0)	-0.28 (-0.42 to 0)	4. 02 (2. 95 to 5. 41)	2. 77 (2. 07 to 3. 44)	-0.86 (-1.11 to -0.6)
Cuba	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.11 (-0.05 to 0.3)	1. 14 (0. 96 to 1. 35)	1. 21 (0. 92 to 1. 55)	0.62 (-0.04 to 1.29)
Cuba	Sickle cell trait	8 (7 to 9)	6 (5 to 7)	-0.25 (-0.31 to -0.18)	72. 28 (65. 41 to 80. 61)	52. 03 (45 to 60. 58)	-0.68 (-1.07 to -0.3)
Cuba	G6PD deficiency	7 (5 to 9)	4 (3 to 5)	-0.41 (-0.44 to -0.37)	64.96 (50.18 to 81.39)	36. 71 (28. 46 to 45. 84)	-1.51 (-1.77 to -1.25)
Cuba	G6PD trait	17 (15 to 19)	10 (9 to 11)	-0.41 (-0.44 to -0.38)	154. 77 (137. 83 to 172. 56)	86. 85 (77. 42 to 96. 24)	-1.5 (-1.77 to -1.24)
Cyprus	Inherited anemias	5 (5 to 6)	5 (5 to 6)	0.05 (0.02 to 0.08)	658. 64 (596. 74 to 727. 39)	408. 55 (368. 44 to 451. 63)	-1.23 (-1.9 to -0.55)
Cyprus	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.04 (-0.09 to 0.17)	4. 42 (3. 22 to 5. 83)	2. 72 (1. 96 to 3. 64)	-1.43 (-1.77 to -1.08)
Cyprus	Thalassemi as trait	1 (1 to 2)	1 (1 to 2)	0.04 (-0.02 to 0.1)	182. 59 (157. 94 to 208. 12)	112. 81 (97. 31 to 129. 33)	-1.43 (-1.78 to -1.07)
Cyprus	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0 (-0.1 to 0.12)	0.73 (0.52 to 0.99)	0. 43 (0. 31 to 0. 58)	-1.46 (-1.77 to -1.15)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Cyprus	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.01 (-0.08 to 0.06)	41. 73 (33. 9 to 50. 44)	24. 37 (20. 11 to 28. 9)	-1.49 (-1.83 to -1.13)
Cyprus	G6PD deficiency	1 (1 to 1)	1 (1 to 1)	0.08 (0.01 to 0.15)	132. 75 (102. 77 to 164. 65)	84.66 (65.54 to 106.09)	-0.89 (-2.1 to 0.33)
Cyprus	G6PD trait	2 (2 to 3)	2 (2 to 3)	0.05 (0.02 to 0.08)	296. 41 (269. 04 to 321. 76)	183. 56 (166. 65 to 199. 63)	-1. 2 (-1. 96 to -0. 43)
Czechia	Inherited anemias	18 (16 to 20)	16 (14 to 18)	-0.12 (-0.14 to -0.1)	175. 82 (155. 23 to 197. 76)	149. 09 (131. 13 to 168. 97)	0.08 (-0.34 to 0.51)
Czechia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.48 (-0.54 to -0.41)	0.9 (0.59 to 1.42)	0.45 (0.31 to 0.68)	-1.45 (-1.89 to -1.01)
Czechia	Thalassemi as trait	2 (2 to 3)	2 (2 to 2)	-0.11 (-0.17 to -0.04)	21.87 (18.08 to 26.54)	18.89 (15.8 to 22.72)	0.33 (-0.1 to 0.76)
Czechia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.04 (-0.14 to 0.06)	0.09 (0.06 to 0.11)	0.08 (0.06 to 0.11)	0.49 (0.1 to 0.88)
Czechia	Sickle cell trait	2 (2 to 2)	2 (2 to 2)	-0. 1 (-0. 14 to -0. 06)	19. 96 (17. 2 to 22. 87)	17. 39 (14. 89 to 20. 09)	0.35 (-0.07 to 0.76)
Czechia	G6PD deficiency	4 (3 to 6)	4 (3 to 5)	-0.08 (-0.15 to 0)	43. 12 (33. 36 to 53. 47)	38. 39 (29. 67 to 48. 65)	-0.52 (-1.04 to 0)
Czechia	G6PD trait	9 (8 to 10)	8 (7 to 9)	-0.15 (-0.15 to -0.15)	89. 88 (79. 3 to 100. 74)	73.89 (65.19 to 82.81)	0. 22 (-0. 21 to 0. 66)
Democratic People's Republic of Korea	Inherited anemias	164 (147 to 182)	76 (68 to 85)	-0. 54 (-0. 55 to -0. 52)	779. 55 (700. 43 to 864. 63)	290. 11 (260. 77 to 323. 05)	-3.78 (-3.94 to -3.61)
Democratic People's Republic of Korea	Thalassemi as	1 (1 to 1)	0 (0 to 1)	-0.54 (-0.6 to -0.47)	3. 92 (2. 87 to 5. 27)	1.45 (1.03 to 2.01)	-3.77 (-3.94 to -3.6)
Democratic People's Republic of Korea	Thalassemi as trait	42 (35 to 50)	21 (18 to 26)	-0.49 (-0.52 to -0.45)	198. 87 (165. 48 to 237. 62)	81.63 (68.26 to 97.9)	-3. 43 (-3. 6 to -3. 26)
Democratic	Sickle	0	0	-0.5	0.11	0.05	-3. 21

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
People's Republic of Korea	cell disorders	(0 to 0)	(0 to 0)	(-0.57 to -0.43)	(0.08 to 0.16)	(0.03 to 0.06)	(-3. 38 to -3. 03)
Democratic People's Republic of Korea	Sickle cell trait	8 (7 to 10)	4 (3 to 5)	-0.53 (-0.56 to -0.49)	38. 73 (32. 54 to 46. 24)	14. 72 (12. 09 to 17. 49)	-3.53 (-3.67 to -3.39)
Democratic People's Republic of Korea	G6PD deficiency	28 (22 to 35)	13 (10 to 16)	-0.53 (-0.56 to -0.5)	132.79 (102.64 to 165.4)	49. 62 (38. 42 to 61. 47)	-3.84 (-4.04 to -3.63)
Democratic People's Republic of Korea	G6PD trait	85 (77 to 94)	37 (33 to 41)	-0.56 (-0.58 to -0.55)	405. 13 (363. 97 to 444. 56)	142.65 (127.39 to 156.98)	-3. 97 (-4. 13 to -3. 8)
Democratic Republic of the Congo	Inherited anemias	1086 (986 to 1188)	1754 (1599 to 1923)	0.61 (0.56 to 0.68)	2815. 29 (2555. 37 to 3077. 74)	2001. 1 (1823. 95 to 2193. 21)	-1.1 (-1.25 to -0.94)
Democratic Republic of the Congo	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 15 (1. 75 to 2. 74)	0.11 (0.07 to 0.17)	0.16 (0.09 to 0.24)	1.03 (0.82 to 1.24)
Democratic Republic of the Congo	Thalassemi as trait	15 (13 to 18)	30 (24 to 35)	0.97 (0.84 to 1.13)	39. 11 (32. 58 to 46. 51)	33. 95 (27. 94 to 40. 43)	-0.46 (-0.61 to -0.3)
Democratic Republic of the Congo	Sickle cell disorders	30 (24 to 38)	55 (44 to 69)	0.8 (0.57 to 1.1)	78. 92 (61. 65 to 97. 92)	62. 68 (50. 21 to 78. 77)	-0.74 (-0.96 to -0.52)
Democratic Republic of the Congo	Sickle cell trait	405 (362 to 447)	673 (610 to 744)	0.66 (0.56 to 0.78)	1049. 97 (937. 47 to 1159. 48)	767. 53 (696. 35 to 848. 88)	-1 (-1.17 to -0.82)
Democratic Republic of the Congo	G6PD deficiency	260 (200 to 322)	411 (318 to 514)	0. 58 (0. 48 to 0. 72)	672. 49 (519. 31 to 835. 4)	468. 64 (362. 36 to 586. 07)	-1.22 (-1.36 to -1.08)
Democratic Republic of the Congo	G6PD trait	376 (347 to 402)	586 (540 to 626)	0. 56 (0. 52 to 0. 6)	974. 69 (899. 69 to 1041. 09)	668. 14 (615. 43 to 714. 13)	-1.18 (-1.34 to -1.03)
Denmark	Inherited anemias	12 (10 to 13)	11 (10 to 12)	-0.04 (-0.07 to -0.02)	224. 44 (200. 96 to 248. 67)	190. 6 (170. 94 to 212. 31)	-1.03 (-1.21 to -0.85)
Denmark	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.08 (-0.2 to 0.05)	0. 16 (0. 11 to 0. 21)	0.13 (0.09 to 0.17)	-2 (-2.89 to -1.1)
Denmark	Thalassemi	1	1	0	19.85	17. 51	-1.12

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	as trait	(1 to 1)	(1 to 1)	(-0.07 to 0.06)	(17. 16 to 22. 55)	(15. 28 to	(-1.44 to
Denmark	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 22 (-0. 31 to -0. 12)	0. 2 (0. 14 to 0. 29)	20. 11) 0. 14 (0. 1 to 0. 19)	-0.8) -1.6 (-2.05 to -1.14)
Denmark	Sickle cell trait	1 (1 to 2)	1 (1 to 2)	-0.15 (-0.2 to -0.09)	28. 67 (23. 14 to 34. 98)	21.69 (17.91 to 26.11)	-1.35 (-1.66 to -1.05)
Denmark	G6PD deficiency	2 (1 to 2)	2 (1 to 2)	0.02 (-0.04 to 0.08)	33.75 (25.94 to 42)	30. 52 (23. 55 to 38. 79)	-0.83 (-0.98 to -0.68)
Denmark	G6PD trait	7 (7 to 8)	7 (6 to 8)	-0.04 (-0.07 to 0)	141.8 (127.01 to 156.2)	120. 62 (108. 25 to 133. 2)	-1 (-1.15 to -0.84)
Djibouti	Inherited anemias	7 (6 to 8)	10 (9 to 12)	0.46 (0.43 to 0.48)	1473. 52 (1294. 67 to 1650. 57)	869. 24 (768. 56 to 971. 13)	-1.64 (-1.98 to -1.29)
Djibouti	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 55 (2. 01 to 3. 4)	0.09 (0.05 to 0.13)	0. 13 (0. 07 to 0. 19)	1.17 (0.86 to 1.48)
Djibouti	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	1. 21 (1. 02 to 1. 48)	26. 1 (20. 58 to 32. 09)	23. 26 (18. 43 to 28. 43)	-0.31 (-0.57 to -0.05)
Djibouti	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.55 (0.4 to 0.69)	1. 2 (0. 88 to 1. 64)	0.75 (0.54 to 1.03)	-2.75 (-3.31 to -2.19)
Djibouti	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	0.57 (0.5 to 0.64)	142.39 (121.97 to 167.7)	90.44 (76.93 to 106.47)	-2.03 (-2.38 to -1.68)
Djibouti	G6PD deficiency	2 (2 to 3)	3 (2 to 4)	0. 3 (0. 23 to 0. 37)	465. 8 (358. 94 to 577. 42)	245. 09 (188. 28 to 307. 7)	-1.96 (-2.43 to -1.49)
Djibouti	G6PD trait	4 (4 to 4)	6 (6 to 7)	0.51 (0.5 to 0.51)	837. 94 (767. 87 to 899. 87)	509. 57 (465. 66 to 549. 41)	-1.45 (-1.76 to -1.15)
Dominica	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.48 (-0.5 to -0.45)	583. 68 (515. 83 to 660. 33)	328. 73 (289. 57 to 372. 25)	-2. 29 (-2. 39 to -2. 18)
Dominica	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0. 2 (-0. 52 to 0. 55)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.01)	-0.9 (-1.13 to -0.67)
Dominica	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.43 (-0.52 to	8.62 (6.69 to	5. 3 (4. 15 to	-1.97 (-2.07 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
				-0.29)	10.96)	6. 43)	-1.87)
Dominica	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.28 (-0.38 to -0.16)	5. 03 (3. 74 to 6. 6)	3. 88 (2. 74 to 5. 22)	-1.49 (-1.77 to -1.21)
Dominica	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.39 (-0.43 to -0.33)	165. 52 (140. 09 to 192. 5)	109.35 (90.64 to 130.15)	-1.89 (-2.07 to -1.7)
Dominica	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.52 (-0.57 to -0.47)	184. 68 (142. 66 to 229. 12)	95. 4 (73. 42 to 117. 54)	-2. 51 (-2. 62 to -2. 41)
Dominica	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.52 (-0.53 to -0.49)	219. 83 (196. 42 to 242. 27)	114.8 (102.38 to 128.14)	-2. 48 (-2. 59 to -2. 36)
Dominican Republic	Inherited anemias	72 (64 to 80)	68 (61 to 76)	-0.05 (-0.07 to -0.02)	994. 2 (888. 68 to 1109. 16)	627. 57 (563. 7 to 697. 91)	-1.72 (-1.9 to -1.53)
Dominican Republic	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.15 (-0.14 to 0.56)	0.05 (0.04 to 0.07)	0.04 (0.03 to 0.05)	-1.09 (-1.19 to -0.99)
Dominican Republic	Thalassemi as trait	2 (2 to 2)	2 (2 to 2)	0.01 (-0.11 to 0.13)	28. 87 (24. 28 to 34. 04)	19. 25 (16. 32 to 22. 65)	-1.53 (-1.66 to -1.39)
Dominican Republic	Sickle cell disorders	1 (1 to 1)	1 (1 to 1)	-0.01 (-0.08 to 0.08)	15. 98 (13. 25 to 18. 95)	10. 51 (8. 84 to 12. 44)	-1.61 (-1.85 to -1.37)
Dominican Republic	Sickle cell trait	26 (23 to 29)	25 (23 to 28)	-0.03 (-0.07 to 0.03)	360. 94 (322. 16 to 399. 98)	232. 42 (209. 57 to 256. 52)	-1.66 (-1.86 to -1.45)
Dominican Republic	G6PD deficiency	19 (15 to 24)	18 (14 to 22)	-0.07 (-0.07 to -0.06)	267. 4 (205. 74 to 332. 26)	165. 46 (127. 32 to 205. 65)	-1.77 (-1.93 to -1.61)
Dominican Republic	G6PD trait	23 (21 to 26)	22 (19 to 24)	-0.06 (-0.1 to -0.02)	320. 97 (284. 97 to 356. 46)	199. 89 (178. 05 to 221. 77)	-1.76 (-1.93 to -1.59)
Ecuador	Inherited anemias	46 (42 to 51)	63 (56 to 71)	0.35 (0.31 to 0.41)	462. 39 (416. 65 to 510. 78)	356. 85 (316. 75 to 401. 21)	-1.35 (-1.48 to -1.23)
Ecuador	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.64 (0.26 to 1.13)	0.05 (0.03 to 0.06)	0.04 (0.03 to 0.06)	-0.19 (-0.34 to -0.05)
Ecuador	Thalassemi as trait	2 (2 to 3)	3 (3 to 4)	0.34 (0.2 to 0.51)	24.06 (20.83 to 27.76)	18. 42 (15. 92 to 21. 13)	-0.96 (-1.02 to -0.9)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Ecuador	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 91 (0. 71 to 1. 12)	0. 13 (0. 11 to 0. 16)	0. 14 (0. 11 to 0. 17)	0. 19 (0. 1 to 0. 28)
Ecuador	Sickle cell trait	4 (3 to 4)	6 (5 to 6)	0.52 (0.44 to 0.59)	37. 27 (33. 32 to 41. 82)	32. 27 (28. 89 to 36. 11)	-0.58 (-0.63 to -0.54)
Ecuador	G6PD deficiency	5 (4 to 6)	14 (11 to 17)	1.9 (1.7 to 2.13)	47. 46 (36. 64 to 60. 35)	78.54 (61.71 to 98.21)	-0.75 (-1.46 to -0.04)
Ecuador	G6PD trait	35 (32 to 39)	40 (36 to 44)	0.13 (0.09 to 0.18)	353. 44 (317. 29 to 391. 23)	227. 43 (204. 37 to 251. 44)	-1.6 (-1.65 to -1.55)
Egypt	Inherited anemias	648 (605 to 698)	686 (633 to 742)	0.06 (0.03 to 0.09)	1164.09 (1086.77 to 1253.66)	692. 15 (639. 2 to 749. 44)	-1.22 (-1.42 to -1.02)
Egypt	Thalassemi as	1 (1 to 1)	1 (1 to 1)	0. 16 (0. 05 to 0. 28)	1. 48 (1. 17 to 1. 93)	0.97 (0.76 to 1.21)	-1.07 (-1.23 to -0.91)
Egypt	Thalassemi as trait	86 (77 to 97)	98 (87 to 110)	0.14 (0.09 to 0.19)	154. 22 (138. 31 to 174. 66)	98.66 (88.17 to 110.7)	-1.13 (-1.28 to -0.97)
Egypt	Sickle cell disorders	3 (3 to 4)	3 (3 to 4)	0.07 (-0.01 to 0.15)	5. 7 (4. 74 to 6. 9)	3. 42 (2. 88 to 4. 13)	-1.31 (-1.46 to -1.16)
Egypt	Sickle cell trait	150 (138 to 165)	161 (148 to 177)	0.07 (0.04 to 0.11)	269. 75 (247. 13 to 296. 28)	162. 93 (149. 59 to 178. 58)	-1.3 (-1.45 to -1.15)
Egypt	G6PD deficiency	96 (81 to 113)	81 (62 to 100)	-0.16 (-0.27 to -0.07)	173. 03 (145. 38 to 202. 31)	81.59 (62.65 to 101.21)	-1.13 (-1.68 to -0.58)
Egypt	G6PD trait	312 (284 to 339)	341 (310 to 370)	0.09 (0.07 to 0.13)	559. 92 (509. 67 to 608. 07)	344. 59 (312. 8 to 373. 19)	-1.23 (-1.38 to -1.08)
El Salvador	Inherited anemias	29 (26 to 33)	17 (15 to 19)	-0.41 (-0.43 to -0.39)	558. 82 (491. 77 to 624. 1)	277. 4 (244. 06 to 310. 55)	-2.65 (-2.85 to -2.46)
El Salvador	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.16 (-0.32 to 1.39)	0. 01 (0. 01 to 0. 02)	0.01 (0.01 to 0.02)	-0.36 (-0.56 to -0.15)
El Salvador	Thalassemi as trait	0 (0 to 1)	0 (0 to 0)	-0.15 (-0.32 to 0.17)	8.46 (6.09 to 11.46)	6.04 (4.49 to 7.74)	-1.41 (-1.62 to -1.21)
El Salvador	Sickle	0	0	-0.33	0.07	0.04	-2.19

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	cell disorders	(0 to 0)	(0 to 0)	(-0.41 to -0.24)	(0.03 to 0.11)	(0. 02 to 0. 06)	(-2.48 to -1.91)
El Salvador	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.34 (-0.45 to -0.32)	3. 48 (1. 41 to 6. 08)	1.93 (0.8 to 3.07)	-2. 12 (-2. 37 to -1. 87)
El Salvador	G6PD deficiency	6 (5 to 7)	3 (2 to 4)	-0.49 (-0.51 to -0.45)	111. 49 (85. 92 to 137. 92)	47.87 (36.91 to 60.33)	-3. 1 (-3. 27 to -2. 92)
El Salvador	G6PD trait	23 (21 to 25)	14 (12 to 15)	-0. 4 (-0. 42 to -0. 37)	435. 31 (392. 4 to 475. 44)	221. 51 (198. 94 to 242. 49)	-2. 58 (-2. 8 to -2. 36)
Equatorial Guinea	Inherited anemias	11 (10 to 12)	19 (18 to 20)	0.65 (0.55 to 0.76)	2640. 52 (2426. 37 to 2869. 86)	1322. 2 (1247. 2 to 1406. 4)	-2. 47 (-2. 63 to -2. 31)
Equatorial Guinea	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 4 (1. 88 to 3)	0.13 (0.08 to 0.18)	0.13 (0.07 to 0.2)	-0.34 (-0.58 to -0.09)
Equatorial Guinea	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	1. 08 (0. 85 to 1. 25)	42. 94 (35. 86 to 50. 85)	27. 06 (22. 03 to 31. 98)	-1.87 (-2.04 to -1.69)
Equatorial Guinea	Sickle cell disorders	1 (0 to 1)	1 (1 to 1)	0.65 (0.53 to 0.79)	126. 34 (100. 42 to 156. 53)	63. 25 (50. 87 to 78. 56)	-2. 26 (-2. 45 to -2. 07)
Equatorial Guinea	Sickle cell trait	5 (4 to 5)	8 (7 to 9)	0. 64 (0. 58 to 0. 72)	1099. 69 (987. 53 to 1237. 01)	547. 22 (488. 85 to 612. 39)	-2. 38 (-2. 55 to -2. 22)
Equatorial Guinea	G6PD deficiency	2 (1 to 2)	3 (2 to 3)	0. 62 (0. 31 to 1. 08)	375. 44 (289. 39 to 472. 07)	184. 3 (170. 53 to 198. 59)	-2. 66 (-2. 84 to -2. 47)
Equatorial Guinea	G6PD trait	4 (4 to 5)	7 (7 to 7)	0.66 (0.55 to 0.79)	995. 98 (913. 7 to 1076. 37)	500. 25 (485. 34 to 515. 57)	-2. 55 (-2. 72 to -2. 38)
Eritrea	Inherited anemias	44 (39 to 50)	60 (53 to 66)	0. 34 (0. 31 to 0. 38)	1480.77 (1305.66 to 1658.81)	889. 52 (792. 39 to 989. 47)	-1.77 (-1.93 to -1.61)
Eritrea	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 29 (1. 81 to 3. 03)	0.09 (0.05 to 0.13)	0. 13 (0. 07 to 0. 2)	0.96 (0.74 to 1.19)
Eritrea	Thalassemi as trait	1 (1 to 1)	2 (1 to 2)	1.03 (0.87 to 1.28)	26. 11 (20. 72 to 31. 93)	23. 72 (18. 8 to 28. 97)	-0.52 (-0.64 to -0.4)
Eritrea	Sickle cell	0 (0 to 0)	0 (0 to 0)	0.47 (0.33 to	1.59 (1.13 to	1.04 (0.74 to	-1.5 (-1.57 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	disorders	(* - * * - *)	(**************************************	0. 62)	2. 24)	1.44)	-1.43)
Eritrea	Sickle cell trait	5 (4 to 6)	7 (6 to 8)	0. 47 (0. 39 to 0. 54)	163. 04 (136. 92 to 194. 52)	106. 86 (89. 52 to 126. 45)	-1.5 (-1.57 to -1.43)
Eritrea	G6PD deficiency	14 (11 to 17)	16 (13 to 21)	0. 19 (0. 12 to 0. 26)	456. 52 (351. 39 to 567. 72)	242. 97 (188. 06 to 305. 85)	-2.19 (-2.48 to -1.9)
Eritrea	G6PD trait	25 (23 to 27)	35 (32 to 37)	0. 38 (0. 34 to 0. 42)	833. 42 (762. 18 to 897. 05)	514.8 (470.86 to 555.58)	-1.66 (-1.79 to -1.54)
Estonia	Inherited anemias	3 (2 to 3)	2 (1 to 2)	-0.36 (-0.37 to -0.35)	165.66 (147.15 to 185.66)	126. 82 (112. 47 to 142. 34)	0. 21 (-0. 22 to 0. 65)
Estonia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.57 (-0.62 to -0.5)	0.66 (0.45 to 1)	0. 34 (0. 24 to 0. 48)	-1.08 (-1.52 to -0.64)
Estonia	Thalassemi as trait	0 (0 to 1)	0 (0 to 0)	-0.35 (-0.39 to -0.3)	31. 52 (26. 08 to 38. 14)	24. 49 (20. 44 to 29. 8)	0.27 (-0.16 to 0.69)
Estonia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.34 (-0.45 to -0.19)	0.01 (0.01 to 0.01)	0.01 (0 to 0.01)	0.28 (-0.14 to 0.71)
Estonia	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.36 (-0.42 to -0.28)	6. 26 (5. 07 to 7. 74)	4. 81 (3. 89 to 5. 92)	0.26 (-0.17 to 0.69)
Estonia	G6PD deficiency	0 (0 to 1)	0 (0 to 0)	-0.32 (-0.32 to -0.32)	25. 95 (19. 87 to 32. 31)	20. 99 (16. 07 to 26. 13)	0.1 (-0.35 to 0.55)
Estonia	G6PD trait	2 (1 to 2)	1 (1 to 1)	-0.37 (-0.37 to -0.37)	101. 27 (90. 12 to 113. 15)	76. 17 (67. 79 to 85. 11)	0. 23 (-0. 21 to 0. 68)
Eswatini	Inherited anemias	9 (8 to 10)	8 (7 to 9)	-0.1 (-0.12 to -0.07)	1140.83 (997.98 to 1294.1)	725. 27 (636. 76 to 819. 29)	-1. 4 (-1. 52 to -1. 28)
Eswatini	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.96 (0.69 to 1.3)	0.09 (0.06 to 0.13)	0. 12 (0. 07 to 0. 19)	1.01 (0.85 to 1.16)
Eswatini	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.2 (0.1 to 0.31)	31. 03 (25. 78 to 37. 1)	26. 22 (21. 51 to 31. 13)	-0.53 (-0.61 to -0.45)
Eswatini	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.06 (-0.13 to 0.01)	0.15 (0.1 to 0.22)	0. 1 (0. 07 to 0. 15)	-1.31 (-1.39 to -1.23)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Eswatini	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.06 (-0.1 to -0.02)	41.34 (32.16 to 53.03)	27. 31 (21. 34 to 34. 81)	-1.31 (-1.39 to -1.23)
Eswatini	G6PD deficiency	3 (2 to 4)	3 (2 to 3)	-0.14 (-0.18 to -0.09)	363. 3 (280. 83 to 456. 72)	221. 76 (171. 2 to 276. 15)	-1.55 (-1.7 to -1.39)
Eswatini	G6PD trait	6 (5 to 6)	5 (5 to 6)	-0. 1 (-0. 12 to -0. 06)	704. 91 (644. 13 to 761. 16)	449.76 (410.34 to 487.11)	-1.37 (-1.48 to -1.27)
Ethiopia	Inherited anemias	786 (762 to 810)	1067 (1038 to 1100)	0.36 (0.35 to 0.37)	1528. 58 (1483. 7 to 1576. 91)	992. 13 (964. 53 to 1022. 7)	-1.36 (-1.46 to -1.26)
Ethiopia	Thalassemi as	0 (0 to 1)	1 (1 to 1)	0.65 (0.51 to 0.83)	0.95 (0.63 to 1.43)	0.75 (0.51 to 1.06)	-0. 94 (-1 to -0. 87)
Ethiopia	Thalassemi as trait	75 (62 to 91)	119 (99 to 142)	0.59 (0.53 to 0.64)	145. 96 (120. 41 to 177. 2)	110. 59 (92. 15 to 131. 65)	-1.05 (-1.11 to -0.99)
Ethiopia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 5 (0. 45 to 0. 58)	0. 42 (0. 28 to 0. 63)	0.3 (0.2 to 0.45)	-1.21 (-1.27 to -1.15)
Ethiopia	Sickle cell trait	42 (33 to 53)	63 (50 to 80)	0. 5 (0. 46 to 0. 53)	81. 84 (64. 37 to 102. 75)	58. 49 (46. 1 to 74. 38)	-1.22 (-1.27 to -1.16)
Ethiopia	G6PD deficiency	209 (199 to 218)	199 (190 to 208)	-0.05 (-0.06 to -0.03)	406. 27 (387. 46 to 424. 1)	185. 32 (176. 61 to 193. 46)	-1. 93 (-2. 24 to -1. 63)
Ethiopia	G6PD trait	459 (452 to 465)	685 (674 to 695)	0.49 (0.49 to 0.5)	893. 14 (879. 68 to 905. 08)	636. 69 (626. 79 to 645. 81)	-1.19 (-1.24 to -1.14)
Fiji	Inherited anemias	4 (3 to 4)	4 (3 to 4)	0.03 (0 to 0.06)	474. 01 (425. 64 to 526. 15)	408.34 (367.41 to 451.61)	-0.14 (-0.33 to 0.05)
Fiji	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.15 (-0.27 to -0.01)	2. 85 (1. 57 to 4. 24)	2. 03 (1. 13 to 3. 08)	0.28 (-0.73 to 1.31)
Fiji	Thalassemi as trait	1 (0 to 1)	1 (0 to 1)	-0.09 (-0.15 to -0.03)	80. 44 (61. 3 to 97. 75)	60. 92 (46. 61 to 74. 77)	-0.15 (-0.62 to 0.33)
Fiji	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.05 (-0.07 to 0.29)	0 (0 to 0)	0 (0 to 0)	-0.36 (-0.62 to -0.11)
Fiji	Sickle	0	0	-0.06	3. 43	2. 7	-0.44

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	cell trait	(0 to 0)	(0 to 0)	(-0.07 to 0.2)	(1. 43 to 5. 17)	(1. 1 to 4. 24)	(-0.65 to -0.23)
Fiji	G6PD deficiency	0 (0 to 1)	1 (0 to 1)	0. 17 (0. 13 to 0. 21)	59. 56 (46. 07 to 74. 12)	57. 9 (44. 86 to 71. 65)	0. 19 (-0. 04 to 0. 42)
Fiji	G6PD trait	2 (2 to 3)	3 (2 to 3)	0.04 (0 to 0.07)	327.73 (294.9 to 360.31)	284. 78 (258. 23 to 309. 22)	-0.22 (-0.34 to -0.09)
Finland	Inherited anemias	12 (11 to 13)	9 (8 to 10)	-0.27 (-0.29 to -0.25)	236. 56 (213. 1 to 262. 05)	156. 09 (139. 83 to 173. 22)	-1.19 (-1.4 to -0.98)
Finland	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.31 (-0.4 to -0.21)	0. 17 (0. 11 to 0. 23)	0. 1 (0. 07 to 0. 14)	-2.22 (-2.9 to -1.54)
Finland	Thalassemi as trait	1 (1 to 1)	1 (1 to 1)	-0.24 (-0.29 to -0.19)	21.05 (18.18 to 24.2)	14. 44 (12. 46 to 16. 62)	-1.29 (-1.46 to -1.11)
Finland	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.47 (-0.54 to -0.41)	0. 24 (0. 17 to 0. 33)	0. 11 (0. 08 to 0. 15)	-1.88 (-2.5 to -1.25)
Finland	Sickle cell trait	2 (1 to 2)	1 (1 to 1)	-0. 4 (-0. 44 to -0. 36)	31. 18 (25. 74 to 37. 77)	16. 98 (14. 03 to 20. 16)	-1.59 (-2.06 to -1.12)
Finland	G6PD deficiency	2 (1 to 2)	1 (1 to 2)	-0.21 (-0.26 to -0.17)	34.68 (26.92 to 43.19)	24.72 (19.06 to 31.24)	-0.97 (-1.16 to -0.78)
Finland	G6PD trait	7 (7 to 8)	6 (5 to 6)	-0. 26 (-0. 28 to -0. 24)	149. 25 (133. 59 to 165. 05)	99. 74 (89. 31 to 110. 25)	-1.15 (-1.36 to -0.94)
France	Inherited anemias	120 (109 to 131)	98 (89 to 108)	-0. 18 (-0. 2 to -0. 16)	207. 56 (189. 48 to 225. 97)	148. 11 (134. 71 to 162. 69)	-0.79 (-0.96 to -0.62)
France	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.12 (-0.25 to 0.01)	0. 17 (0. 11 to 0. 23)	0. 13 (0. 09 to 0. 18)	-1.54 (-2.39 to -0.69)
France	Thalassemi as trait	12 (11 to 14)	12 (10 to 13)	-0.05 (-0.11 to 0.01)	21. 25 (18. 58 to 24. 1)	17. 7 (15. 46 to 20. 09)	-0.63 (-0.91 to -0.35)
France	Sickle cell disorders	1 (0 to 1)	0 (0 to 0)	-0.62 (-0.66 to -0.56)	1 (0.84 to 1.2)	0. 34 (0. 27 to 0. 42)	-2.35 (-2.75 to -1.96)
France	Sickle cell trait	34 (30 to 38)	19 (16 to 22)	-0.44 (-0.49 to	58. 59 (52. 63 to	28. 56 (24. 85 to	-1.62 (-1.9 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
				-0.4)	65. 93)	32. 71)	-1.34)
France	G6PD deficiency	13 (10 to 16)	10 (8 to 12)	-0.24 (-0.29 to -0.18)	22.06 (17.05 to 27.45)	14. 69 (11. 44 to 18. 45)	-1.17 (-1.55 to -0.8)
France	G6PD trait	60 (54 to 67)	57 (51 to 64)	-0.05 (-0.09 to -0.02)	104. 48 (92. 99 to 116. 25)	86. 69 (77. 11 to 96. 33)	-0.34 (-0.48 to -0.2)
Gabon	Inherited anemias	22 (20 to 24)	23 (21 to 25)	0.06 (0.03 to 0.1)	2172. 28 (1975. 65 to 2381. 62)	1309. 12 (1178. 53 to 1444. 6)	-1.74 (-1.8 to -1.68)
Gabon	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.11 (0.77 to 1.53)	0.08 (0.05 to 0.12)	0.1 (0.06 to 0.15)	0.35 (0.2 to 0.51)
Gabon	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.35 (0.23 to 0.48)	29. 87 (25. 17 to 35. 16)	22. 77 (18. 68 to 27. 1)	-1.07 (-1.13 to -1.01)
Gabon	Sickle cell disorders	1 (0 to 1)	1 (0 to 1)	-0.03 (-0.1 to 0.06)	61. 27 (47. 24 to 77. 78)	33. 81 (26. 2 to 42. 34)	-2.06 (-2.12 to -2.01)
Gabon	Sickle cell trait	6 (5 to 7)	6 (5 to 7)	0.03 (-0.02 to 0.08)	590. 58 (526. 82 to 671. 28)	345 (309. 54 to 390. 68)	-1.65 (-1.79 to -1.51)
Gabon	G6PD deficiency	6 (5 to 8)	7 (5 to 8)	0. 1 (0. 01 to 0. 2)	619. 8 (495. 75 to 763. 43)	385. 74 (299. 24 to 477. 1)	-1.71 (-1.75 to -1.66)
Gabon	G6PD trait	9 (8 to 9)	9 (9 to 10)	0.06 (0.04 to 0.08)	870. 68 (810. 53 to 920. 18)	521.71 (485.84 to 553)	-1.83 (-1.86 to -1.8)
Gambia	Inherited anemias	18 (16 to 19)	24 (22 to 26)	0.35 (0.31 to 0.38)	1787. 19 (1633. 76 to 1951. 13)	1062. 23 (973. 37 to 1152. 3)	-1.89 (-2.07 to -1.71)
Gambia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.9 (0.63 to 1.23)	0.35 (0.24 to 0.51)	0.3 (0.2 to 0.41)	-0.68 (-0.8 to -0.55)
Gambia	Thalassemi as trait	1 (1 to 1)	1 (1 to 2)	0.61 (0.5 to 0.71)	92. 07 (76. 38 to 111. 52)	65. 58 (54. 73 to 78. 45)	-1.25 (-1.37 to -1.12)
Gambia	Sickle cell disorders	0 (0 to 0)	0 (0 to 1)	0.31 (0.2 to 0.42)	33. 18 (27. 36 to 40)	19. 23 (15. 52 to 23. 67)	-2.08 (-2.25 to -1.92)
Gambia	Sickle cell trait	7 (6 to 7)	9 (8 to 11)	0.41 (0.34 to 0.48)	676. 78 (613. 5 to 750. 46)	421. 1 (377. 5 to 469. 59)	-1.74 (-1.9 to -1.59)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Gambia	G6PD deficiency	3 (2 to 4)	3 (2 to 3)	-0.11 (-0.17 to -0.05)	290. 29 (224. 5 to 359. 25)	114. 17 (88. 48 to 141. 72)	-3. 34 (-3. 82 to -2. 86)
Gambia	G6PD trait	7 (6 to 8)	10 (9 to 11)	0.44 (0.4 to 0.49)	694. 52 (625. 12 to 758. 98)	441.86 (397.64 to 482.79)	-1.61 (-1.73 to -1.49)
Georgia	Inherited anemias	12 (11 to 13)	7 (6 to 8)	-0.41 (-0.42 to -0.39)	220. 42 (198. 45 to 244. 32)	196. 3 (176. 72 to 218. 03)	0.81 (0.33 to 1.29)
Georgia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.41 (-0.49 to -0.31)	1.83 (1.35 to 2.52)	1. 62 (1. 18 to 2. 21)	0.92 (0.42 to 1.43)
Georgia	Thalassemi as trait	4 (4 to 5)	3 (2 to 3)	-0.36 (-0.4 to -0.32)	77. 58 (65. 3 to 92. 17)	74. 83 (63. 5 to 87. 94)	1.09 (0.63 to 1.56)
Georgia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.52 to -0.28)	0.01 (0.01 to 0.01)	0.01 (0 to 0.01)	0.72 (0.26 to 1.18)
Georgia	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.43 (-0.49 to -0.36)	6. 56 (5. 21 to 8. 28)	5. 66 (4. 51 to 7. 06)	0.65 (0.19 to 1.11)
Georgia	G6PD deficiency	1 (1 to 1)	1 (0 to 1)	-0.42 (-0.46 to -0.39)	20.38 (15.66 to 25.96)	17. 66 (13. 6 to 22. 31)	0.69 (0.23 to 1.15)
Georgia	G6PD trait	6 (6 to 7)	4 (3 to 4)	-0.44 (-0.44 to -0.44)	114.06 (101.76 to 126.84)	96. 52 (86. 11 to 107. 34)	0.63 (0.13 to 1.14)
Germany	Inherited anemias	173 (157 to 190)	149 (135 to 164)	-0.14 (-0.17 to -0.12)	216.79 (196.03 to 238.24)	175. 25 (158. 44 to 192. 89)	-0.66 (-0.84 to -0.48)
Germany	Thalassemi as	0 (0 to 1)	0 (0 to 0)	-0.17 (-0.34 to 0.02)	0.55 (0.39 to 0.74)	0. 43 (0. 32 to 0. 55)	-1.64 (-2.52 to -0.75)
Germany	Thalassemi as trait	33 (28 to 38)	32 (28 to 37)	-0.03 (-0.1 to 0.04)	41.67 (35.59 to 48.07)	38. 02 (32. 95 to 43. 39)	-0. 43 (-0. 79 to -0. 07)
Germany	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.01 (-0.17 to 0.19)	0.09 (0.06 to 0.12)	0.08 (0.07 to 0.1)	1.22 (0.73 to 1.71)
Germany	Sickle cell trait	14 (11 to 16)	12 (10 to 13)	-0.15 (-0.23 to -0.05)	17. 22 (14. 25 to 20. 44)	13. 85 (12. 2 to 15. 66)	0. 12 (-0. 21 to 0. 45)
Germany	G6PD	24	21	-0.13	30. 43	24. 95	-0.66

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	deficiency	(19 to 30)	(16 to 26)	(-0.16 to -0.09)	(23. 39 to 37. 99)	(19. 24 to 30. 96)	(-0.9 to -0.43)
Germany	G6PD trait	101 (91 to 111)	83 (75 to 91)	-0.18 (-0.21 to -0.15)	126.83 (113.86 to 139.1)	97. 93 (87. 76 to 107. 11)	-0.83 (-1.02 to -0.63)
Ghana	Inherited anemias	300 (273 to 327)	401 (365 to 439)	0.34 (0.29 to 0.39)	1996. 15 (1815. 77 to 2179. 78)	1271.75 (1158.04 to 1392.48)	-1. 03 (-1. 24 to -0. 82)
Ghana	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.46 (1 to 1.92)	0. 12 (0. 08 to 0. 16)	0.14 (0.08 to 0.2)	0.47 (0.36 to 0.58)
Ghana	Thalassemi as trait	6 (5 to 8)	11 (9 to 13)	0.67 (0.54 to 0.8)	43. 19 (36. 27 to 51. 06)	34. 34 (28. 61 to 40. 45)	-0.77 (-0.86 to -0.69)
Ghana	Sickle cell disorders	12 (11 to 13)	16 (13 to 19)	0. 34 (0. 18 to 0. 51)	78. 63 (72 to 86. 92)	50. 11 (42. 77 to 58. 86)	-1.41 (-1.53 to -1.3)
Ghana	Sickle cell trait	113 (105 to 121)	154 (137 to 173)	0.36 (0.26 to 0.47)	751. 01 (702. 46 to 808. 59)	487. 51 (434. 26 to 547. 65)	-1.36 (-1.47 to -1.26)
Ghana	G6PD deficiency	71 (55 to 87)	82 (63 to 102)	0. 16 (0. 07 to 0. 25)	469. 68 (363. 72 to 580. 6)	258. 85 (200. 16 to 322. 33)	-0.36 (-0.96 to 0.23)
Ghana	G6PD trait	98 (89 to 107)	139 (126 to 151)	0. 42 (0. 37 to 0. 45)	653. 52 (592. 73 to 710. 5)	440.81 (400.64 to 478.1)	-1.01 (-1.2 to -0.81)
Greece	Inherited anemias	21 (21 to 22)	18 (16 to 19)	-0.17 (-0.25 to -0.1)	206. 35 (198. 4 to 215. 22)	171. 26 (155. 22 to 188. 52)	-0.38 (-0.77 to 0)
Greece	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.16 (-0.25 to -0.06)	0.73 (0.55 to 0.93)	0. 62 (0. 46 to 0. 8)	-0.38 (-0.63 to -0.12)
Greece	Thalassemi as trait	6 (5 to 6)	5 (4 to 6)	-0.15 (-0.2 to -0.1)	55. 25 (48. 06 to 62. 24)	47. 19 (40. 87 to 53. 52)	-0.26 (-0.48 to -0.03)
Greece	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.09 (-0.17 to 0.01)	0.09 (0.06 to 0.13)	0.09 (0.06 to 0.12)	0.04 (-0.13 to 0.22)
Greece	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	0.04 (-0.04 to 0.13)	7. 94 (6. 9 to 9. 19)	8.33 (7.02 to 9.81)	0.49 (0.35 to 0.64)
Greece	G6PD deficiency	3 (3 to 3)	3 (2 to 3)	-0. 23 (-0. 39 to	31.34 (30.2 to	24. 29 (18. 86 to	-0.04 (-0.83 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
		,	,	-0.04)	32.7)	30. 42)	0.77)
		12	9	-0.19	110.98	90.73	-0.63
Greece	G6PD trait	(11 to 12)	(8 to 10)	(-0.27 to	(108.13 to	(81.21 to	(-1.02 to
		(11 to 12)	(0 to 10)	-0.11)	114. 24)	100.3)	-0.23)
	Inherited	0	0	-0. 47	390. 39	203.64	-2. 28
Greenland	anemias	(0 to 0)	(0 to 0)	(-0.49 to	(338. 56 to	(175. 95 to	(-2.42 to
		(1 1 1 7)	(-0.45)	441.65)	234. 35)	-2.14)
	Thalassemi	0	0	-0.62	0. 27	0.1	-3.31
Greenland	as	(0 to 0)	(0 to 0)	(-0.66 to	(0.16 to	(0.06 to	(-3.56 to
				-0. 58)	0.42)	0.16)	-3. 07)
C11	Thalassemi	0	0	-0.24	4. 23	3. 19	-0.93
Greenland	as trait	(0 to 0)	(0 to 0)	(-0.37 to 0.19)	(2. 45 to 5. 97)	(2. 16 to	(-1. 18 to
	Sickle			-0.37	0.08	4. 31) 0. 05	-0. 68) -1. 63
Greenland	cell	0	0	(-0.45 to	(0.05 to	(0.03 to	(-1.87 to
Greenrand	disorders	(0 to 0)	(0 to 0)	-0.3)	0. 12)	0.08)	-1.38)
				-0.37	3. 31	2.08	-1.61
Greenland	Sickle	0	0	(-0.37 to	(1.41 to	(0.88 to	(-1.85 to
	cell trait	(0 to 0)	(0 to 0)	-0. 26)	5. 83)	3. 61)	-1. 37)
	CODE	0	0	-0.46	103.33	55. 65	-2.23
Greenland	G6PD	0	0	(-0.49 to	(79.74 to	(43.11 to	(-2.38 to
	deficiency	(0 to 0)	(0 to 0)	-0.42)	128. 51)	69. 48)	-2.08)
		0	0	-0.48	279. 18	142. 58	-2.33
${\tt Greenland}$	G6PD trait	(0 to 0)	(0 to 0)	(-0.5 to	(250. 32 to	(127.02 to	(-2.47 to
		(0 to 0)	(0 (0 0)	-0.46)	305. 53)	158. 85)	-2. 2)
	Inherited	1	0	-0. 26	611.7	375. 36	-1.86
Grenada	anemias	(0 to 1)	(0 to 0)	(-0.29 to	(536. 95 to	(331. 23 to	(-1.93 to
		(0 00 1)	(3 22 2)	-0. 23)	692. 22)	424. 73)	-1. 78)
	Thalassemi	0	0	0. 17	0.01	0.01	-0.33
Grenada	as	(0 to 0)	(0 to 0)	(-0. 29 to	(0.01 to	(0.01 to	(-0.57 to
				1. 34)	0.02)	0.02)	-0.09)
Cranada	Thalassemi	0	0	-0.16	8. 26	5. 76	-1.37
Grenada	as trait	(0 to 0)	(0 to 0)	(-0. 29 to 0. 08)	(6. 29 to 10. 5)	(4. 45 to 7. 02)	(-1.45 to -1.29)
	Sickle			-0.15	6.66	4.71	-1. 74
Grenada	cell	0	0	(-0. 24 to	(4. 79 to	(3. 37 to	(-2 to
or onada	disorders	(0 to 0)	(0 to 0)	-0.04)	8.89)	6. 36)	-1. 47)
				-0.22	196. 58	127. 25	-1.83
Grenada	Sickle	0	0	(-0.28 to	(165.46 to	(105. 15 to	(-1.98 to
	cell trait	(0 to 0)	(0 to 0)	-0.16)	234. 23)	150. 6)	-1.68)
	CODE	0	^	-0.29	183. 37	108.58	-1.88
Grenada	G6PD	(0 + - 0)	0	(-0.34 to	(141.48 to	(83.83 to	(-1.92 to
	deficiency	(0 to 0)	(0 to 0)	-0.23)	227.88)	136. 26)	-1.85)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Grenada	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0. 28 (-0. 31 to -0. 26)	216. 82 (193. 17 to 241. 3)	129. 05 (114. 81 to 143. 75)	-1.88 (-1.93 to -1.84)
Guam	Inherited anemias	1 (1 to 1)	1 (1 to 1)	-0.06 (-0.09 to -0.02)	592. 05 (526. 05 to 659. 26)	446. 99 (396. 23 to 499. 37)	-1.08 (-1.48 to -0.68)
Guam	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0. 23 (-0. 33 to -0. 12)	2. 62 (1. 39 to 4. 14)	1. 62 (0. 86 to 2. 53)	-0.64 (-1.82 to 0.56)
Guam	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.17 (-0.22 to -0.12)	87. 14 (66. 11 to 108. 06)	57. 9 (44. 17 to 71. 39)	-1.08 (-1.68 to -0.48)
Guam	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.11 (-0.15 to 0.42)	0 (0 to 0)	0 (0 to 0)	-1.33 (-1.65 to -1.01)
Guam	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.15 to 0.18)	3. 48 (1. 53 to 5. 59)	2.44 (1.04 to 3.86)	-1.38 (-1.68 to -1.08)
Guam	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0.03 (-0.03 to 0.08)	122. 51 (94. 51 to 151. 54)	101.01 (78.06 to 126.39)	-0.86 (-1.28 to -0.43)
Guam	G6PD trait	1 (0 to 1)	0 (0 to 1)	-0.06 (-0.09 to -0.02)	376. 3 (338. 37 to 410. 43)	284. 03 (256. 94 to 309. 01)	-1.17 (-1.53 to -0.8)
Guatemala	Inherited anemias	60 (53 to 68)	64 (56 to 71)	0.05 (0.02 to 0.08)	759. 38 (666. 87 to 849. 16)	358. 75 (315. 72 to 399. 73)	-2.69 (-2.78 to -2.6)
Guatemala	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.09 (0.2 to 3.36)	0. 02 (0. 01 to 0. 04)	0. 02 (0. 01 to 0. 03)	-0.41 (-0.65 to -0.17)
Guatemala	Thalassemi as trait	1 (1 to 1)	1 (1 to 2)	0.52 (0.2 to 1.09)	11. 75 (8. 43 to 15. 76)	8 (5.89 to 10.08)	-1.47 (-1.56 to -1.39)
Guatemala	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 23 (0. 13 to 0. 41)	0.1 (0.05 to 0.16)	0.05 (0.03 to 0.09)	-2. 21 (-2. 32 to -2. 09)
Guatemala	Sickle cell trait	0 (0 to 1)	0 (0 to 1)	0.15 (-0.32 to 0.2)	4. 91 (1. 95 to 8. 25)	2.54 (1.03 to 4.44)	-2. 34 (-2. 44 to -2. 23)
Guatemala	G6PD deficiency	12 (9 to 15)	11 (8 to 13)	-0. 1 (-0. 15 to -0. 06)	150. 76 (115. 96 to 188. 57)	60.77 (46.74 to 75.33)	-3. 18 (-3. 4 to -2. 96)
Guatemala	G6PD trait	47	51	0.08	591.83	287. 37	-2.61

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
		(42 to 51)	(46 to 56)	(0.05 to 0.11)	(532. 13 to 646. 09)	(258. 02 to 313. 75)	(-2.68 to -2.54)
Guinea	Inherited anemias	130 (120 to 141)	203 (187 to 220)	0. 56 (0. 52 to 0. 6)	2105. 97 (1940. 88 to 2279. 32)	1605. 14 (1480. 38 to 1739. 12)	-0.86 (-0.91 to -0.8)
Guinea	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.04 (0.77 to 1.34)	0. 41 (0. 28 to 0. 58)	0.41 (0.28 to 0.57)	0.06 (-0.05 to 0.16)
Guinea	Thalassemi as trait	6 (5 to 7)	11 (9 to 13)	0.73 (0.63 to 0.83)	98. 91 (82. 26 to 118. 45)	83. 76 (70. 44 to 100. 29)	-0. 5 (-0. 57 to -0. 43)
Guinea	Sickle cell disorders	6 (5 to 7)	9 (7 to 11)	0.54 (0.42 to 0.68)	92. 46 (75. 86 to 111. 36)	69. 76 (56. 59 to 84. 33)	-0.89 (-0.94 to -0.84)
Guinea	Sickle cell trait	67 (61 to 73)	103 (93 to 113)	0.54 (0.48 to 0.61)	1083.04 (980.81 to 1185.09)	817. 21 (739. 51 to 894. 26)	-0.89 (-0.94 to -0.84)
Guinea	G6PD deficiency	16 (12 to 20)	25 (19 to 31)	0.56 (0.45 to 0.68)	259. 93 (200. 88 to 328. 36)	198. 08 (152. 89 to 247. 01)	-0.76 (-0.84 to -0.68)
Guinea	G6PD trait	35 (32 to 39)	55 (50 to 60)	0.56 (0.5 to 0.62)	571. 23 (511. 31 to 631. 78)	435. 91 (392. 17 to 476. 8)	-0.9 (-0.96 to -0.83)
Guinea-Biss au	Inherited anemias	14 (12 to 15)	19 (17 to 21)	0.35 (0.32 to 0.38)	1369. 25 (1222. 09 to 1527. 38)	979. 13 (873. 1 to 1088. 89)	-1.09 (-1.2 to -0.97)
Guinea-Biss au	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.76 (0.5 to 1.06)	0.39 (0.26 to 0.57)	0.36 (0.25 to 0.5)	-0. 2 (-0. 29 to -0. 1)
Guinea-Biss au	Thalassemi as trait	1 (1 to 1)	1 (1 to 2)	0.51 (0.41 to 0.61)	92.58 (76.76 to 113.41)	73. 84 (61. 87 to 88. 25)	-0.73 (-0.82 to -0.63)
Guinea-Biss au	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.34 (0.25 to 0.44)	2. 82 (2. 22 to 3. 52)	2 (1.56 to 2.5)	-1.26 (-1.46 to -1.05)
Guinea-Biss au	Sickle cell trait	2 (2 to 2)	3 (2 to 3)	0.34 (0.29 to 0.4)	196. 56 (171. 01 to 224. 04)	139. 97 (122. 08 to 160. 13)	-1.19 (-1.35 to -1.02)
Guinea-Biss au	G6PD deficiency	4 (3 to 4)	5 (4 to 6)	0. 3 (0. 24 to 0. 37)	348. 96 (270. 16 to 441. 21)	240. 4 (184. 97 to 301. 1)	-1.16 (-1.29 to -1.03)
Guinea-Biss au	G6PD trait	7 (7 to 8)	10 (9 to 11)	0.35 (0.32 to	727. 95 (662. 21 to	522.57 (473.78 to	-1.08 (-1.17 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
		,	,	0.4)	790. 34)	568. 2)	-0.98)
Guyana	Inherited anemias	6 (6 to 7)	4 (4 to 5)	-0.35 (-0.38 to -0.33)	817. 73 (724. 2 to 925. 47)	527. 65 (463. 65 to 596. 34)	-1.61 (-1.85 to -1.37)
Guyana	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.05 (-0.37 to 1.01)	0.02 (0.01 to 0.03)	0. 02 (0. 01 to 0. 02)	-0.03 (-0.16 to 0.09)
Guyana	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0. 25 (-0. 37 to -0. 07)	11. 22 (8. 61 to 14. 19)	8. 4 (6. 46 to 10. 07)	-1.14 (-1.27 to -1)
Guyana	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.29 (-0.37 to -0.2)	9. 2 (6. 67 to 12. 23)	6. 54 (4. 7 to 8. 79)	-1.3 (-1.7 to -0.9)
Guyana	Sickle cell trait	2 (2 to 2)	1 (1 to 2)	-0.33 (-0.38 to -0.29)	267. 5 (224. 62 to 315. 82)	178. 29 (147. 28 to 211. 67)	-1.49 (-1.8 to -1.19)
Guyana	G6PD deficiency	2 (1 to 2)	1 (1 to 1)	-0.37 (-0.43 to -0.32)	246. 5 (189. 74 to 305. 61)	154. 26 (118. 94 to 192. 13)	-1.72 (-1.92 to -1.51)
Guyana	G6PD trait	2 (2 to 2)	1 (1 to 2)	-0.36 (-0.39 to -0.33)	283. 3 (252. 19 to 313. 19)	180. 13 (160. 34 to 200. 68)	-1.67 (-1.89 to -1.46)
Haiti	Inherited anemias	86 (75 to 97)	117 (103 to 132)	0.36 (0.3 to 0.41)	1347. 88 (1181. 23 to 1528. 27)	941. 32 (827. 08 to 1066. 97)	-1.17 (-1.21 to -1.12)
Haiti	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.73 (0.32 to 1.37)	0.06 (0.04 to 0.08)	0.05 (0.04 to 0.07)	-0.34 (-0.48 to -0.2)
Haiti	Thalassemi as trait	2 (2 to 2)	3 (3 to 4)	0. 48 (0. 32 to 0. 67)	32. 25 (27. 1 to 37. 95)	24. 47 (20. 78 to 28. 62)	-0.85 (-0.92 to -0.78)
Haiti	Sickle cell disorders	1 (1 to 2)	2 (2 to 3)	0.41 (0.3 to 0.53)	22. 61 (18. 82 to 27. 59)	16. 37 (13. 64 to 20. 34)	-0.99 (-1.07 to -0.91)
Haiti	Sickle cell trait	30 (27 to 34)	42 (38 to 47)	0.38 (0.31 to 0.45)	475. 88 (428. 96 to 534. 47)	336. 91 (303. 06 to 378. 73)	-1.06 (-1.12 to -1)
Haiti	G6PD deficiency	36 (28 to 46)	49 (38 to 60)	0.34 (0.2 to 0.46)	569. 05 (440. 34 to 716. 84)	392. 03 (302. 68 to 483. 51)	-1.25 (-1.29 to -1.21)
Haiti	G6PD trait	16 (14 to 18)	21 (19 to 24)	0.35 (0.29 to 0.42)	248. 03 (218. 32 to 279. 57)	171. 49 (150. 57 to 193. 18)	-1.24 (-1.28 to -1.2)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Honduras	Inherited anemias	32 (28 to 36)	36 (32 to 40)	0.13 (0.09 to 0.17)	678. 05 (596. 13 to 757. 26)	368. 24 (325. 01 to 411. 58)	-2. 23 (-2. 29 to -2. 16)
Honduras	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1. 25 (0. 29 to 3. 74)	0. 02 (0. 01 to 0. 03)	0. 02 (0. 01 to 0. 03)	0.07 (-0.14 to 0.28)
Honduras	Thalassemi as trait	0 (0 to 1)	1 (1 to 1)	0. 63 (0. 29 to 1. 23)	10. 42 (7. 54 to 14. 05)	8. 12 (6. 05 to 10. 3)	-1.01 (-1.07 to -0.94)
Honduras	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 31 (0. 15 to 0. 94)	0. 02 (0. 01 to 0. 04)	0. 01 (0. 01 to 0. 02)	-1.71 (-1.85 to -1.58)
Honduras	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0. 21 (-0. 28 to 0. 29)	3. 91 (1. 48 to 6. 22)	2. 26 (0. 92 to 3. 63)	-1.87 (-2.02 to -1.73)
Honduras	G6PD deficiency	6 (5 to 8)	6 (5 to 8)	-0.03 (-0.07 to 0.02)	136. 05 (104. 87 to 168. 52)	63. 27 (48. 75 to 78. 8)	-2.71 (-2.9 to -2.53)
Honduras	G6PD trait	25 (22 to 27)	29 (26 to 32)	0. 16 (0. 12 to 0. 2)	527. 63 (474. 52 to 575. 26)	294. 55 (265. 11 to 322. 72)	-2. 14 (-2. 2 to -2. 08)
Hungary	Inherited anemias	18 (16 to 20)	12 (11 to 14)	-0.32 (-0.34 to -0.3)	170.38 (150.01 to 191.74)	124. 56 (109. 69 to 140. 57)	-0.95 (-1.13 to -0.76)
Hungary	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.59 (-0.64 to -0.52)	0.92 (0.59 to 1.46)	0. 4 (0. 27 to 0. 64)	-2.42 (-2.62 to -2.22)
Hungary	Thalassemi as trait	2 (2 to 3)	2 (1 to 2)	-0.3 (-0.35 to -0.25)	21. 94 (18. 16 to 27. 02)	16.41 (13.73 to 19.81)	-0.69 (-0.9 to -0.48)
Hungary	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.34 (-0.4 to -0.29)	0.09 (0.07 to 0.12)	0.06 (0.05 to 0.08)	-1.12 (-1.29 to -0.94)
Hungary	Sickle cell trait	2 (2 to 2)	1 (1 to 2)	-0.34 (-0.36 to -0.31)	19.58 (16.95 to 22.58)	13. 94 (12 to 16. 14)	-0.93 (-1.1 to -0.76)
Hungary	G6PD deficiency	4 (3 to 5)	3 (2 to 4)	-0. 28 (-0. 35 to -0. 21)	41. 48 (32. 09 to 52. 58)	32. 21 (24. 89 to 40. 32)	-1.49 (-1.83 to -1.15)
Hungary	G6PD trait	9 (8 to 10)	6 (5 to 7)	-0.34 (-0.34 to -0.34)	86.36 (76.03 to 96.92)	61. 54 (54. 17 to 69. 06)	-0.78 (-0.98 to -0.57)
Iceland	Inherited	1	1	-0.08	318.69	215. 07	-1.14

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	anemias	(1 to 1)	(1 to 1)	(-0.12 to	(286. 18 to	(192. 18 to	(-1.3 to
				-0.05)	353. 99)	239. 49)	-0. 98)
Iceland	Thalassemi	0	0	-0.15 (-0.25 to	0. 22 (0. 15 to	0.14 (0.1 to	-2. 2 (-2. 87 to
icerand	as	(0 to 0)	(0 to 0)	-0.03)	0. 3)	0.19)	-1. 52)
				-0.07	28. 86	19. 73	-1. 29
Iceland	Thalassemi	0	0	(-0.12 to	(24.8 to	(17. 15 to	(-1.44 to
	as trait	(0 to 0)	(0 to 0)	-0.01)	32. 99)	22. 56)	-1. 15)
	Sickle	0	0	-0.12	0.19	0. 12	-1.29
Iceland	cell	(0 to 0)	(0 to 0)	(-0.22 to	(0.13 to	(0.08 to	(-1.47 to
	disorders	(0 to 0)	(0 to 0)	-0.02)	0.27)	0.17)	-1.1)
	Sickle	0	0	-0.1	35. 53	23. 58	-1.19
Iceland	cell trait	(0 to 0)	(0 to 0)	(-0.15 to	(28.99 to	(19. 43 to	(-1.36 to
				-0.05)	42. 8)	28. 11)	-1.01)
Toolond	G6PD	0	0	-0.04	48. 1	33.95	-1 (1 17 +c
Iceland	deficiency	(0 to 0)	(0 to 0)	(-0.08 to 0.02)	(36. 88 to 59. 7)	(26.05 to 42.56)	(-1.17 to -0.83)
				-0.09	205. 8	137. 55	-1.14
Iceland	G6PD trait	1	0	(-0.13 to	(184. 26 to	(122.51 to	(-1.31 to
		(0 to 1)	(0 to 1)	-0.05)	227. 8)	152. 07)	-0.96)
	T.1	9437	10728	0.14	1102.97	771.38	-1.64
India	Inherited anemias	(8826 to	(10107 to	(0.12 to	(1031.63 to	(726.72 to	(-1.97 to
	allemias	10149)	11424)	0.15)	1186. 22)	821. 43)	-1.31)
	Thalassemi	14	22	0.55	1.68	1.6	0.63
India	as	(10 to 20)	(15 to 32)	(0.39 to	(1. 2 to	(1.1 to	(0.07 to
		1007	1516	0.7)	2. 34)	2. 3)	1. 19)
India	Thalassemi	1307 (1101 to	1516 (1275 to	0.16 (0.12 to	152.76 (128.68 to	109.03 (91.68 to	-0.79 (-1.08 to
Illula	as trait	1549)	1805)	0. 12 10	181. 04)	129. 79)	-0.51)
	Sickle		·	0.11	13.06	8. 94	-1.42
India	cell	112	124	(0.07 to	(8. 79 to	(5.98 to	(-1.76 to
	disorders	(75 to 163)	(83 to 179)	0.16)	19. 01)	12. 88)	-1.09)
	C: -1-1 -	3161	3131	-0.01	369. 51	225. 15	-1.76
India	Sickle cell trait	(2639 to	(2613 to	(-0.03 to	(308.39 to	(187.87 to	(-1.95 to
	cerr trait	3778)	3717)	0.01)	441.51)	267. 3)	-1.58)
	G6PD	1240	1956	0.58	144. 94	140.66	-1.75
India	deficiency	(1190 to	(1873 to	(0.53 to	(139. 13 to	(134.65 to	(-2.56 to
		1286)	2034)	0.61)	150. 3)	146. 27)	-0. 93)
Tndia	CGDD +moit	3602	3978	0.1	421.01	286. 01	-1.76
India	G6PD trait	(3543 to 3654)	(3914 to 4034)	(0.09 to 0.11)	(414. 16 to 427. 11)	(281.41 to 290.09)	(-2. 12 to -1. 41)
	Inherited	1311	878	-0.33	707. 23	338. 38	-1. 41) -2. 52
Indonesia	Timetted	1 1 1 1 1	010	1 (1 (1))	1 (1)(1, 4)	• 1• 1(1, •)(1)	//- • 1//

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
		1367)	923)	-0.32)	737. 38)	355. 6)	-2.32)
Indonesia	Thalassemi as	9 (7 to 12)	6 (5 to 8)	-0.34 (-0.38 to -0.29)	4. 94 (3. 73 to 6. 64)	2. 33 (1. 76 to 3. 11)	-2.46 (-2.61 to -2.32)
Indonesia	Thalassemi as trait	297 (254 to 346)	240 (205 to 279)	-0.19 (-0.21 to -0.18)	160. 48 (137. 03 to 186. 44)	92.31 (78.98 to 107.59)	-1.78 (-1.93 to -1.63)
Indonesia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.18 (-0.22 to -0.12)	0.02 (0.02 to 0.03)	0.01 (0.01 to 0.02)	-1.75 (-1.89 to -1.61)
Indonesia	Sickle cell trait	26 (22 to 31)	21 (18 to 25)	-0.19 (-0.21 to -0.15)	14. 23 (11. 95 to 16. 84)	8. 24 (6. 91 to 9. 77)	-1.76 (-1.91 to -1.62)
Indonesia	G6PD deficiency	329 (316 to 341)	161 (153 to 168)	-0.51 (-0.53 to -0.5)	177. 55 (170. 56 to 184. 21)	62. 01 (59. 14 to 64. 75)	-3.72 (-4.3 to -3.13)
Indonesia	G6PD trait	649 (637 to 659)	450 (441 to 458)	-0.31 (-0.31 to -0.3)	350 (343. 62 to 355. 64)	173. 47 (170. 06 to 176. 6)	-2.45 (-2.71 to -2.2)
Iran (Islamic Republic of)	Inherited anemias	582 (553 to 615)	498 (477 to 523)	-0.14 (-0.16 to -0.13)	993. 37 (944. 92 to 1049. 98)	590.88 (566.09 to 620.96)	-1.38 (-1.55 to -1.2)
Iran (Islamic Republic of)	Thalassemi as	2 (1 to 3)	2 (1 to 2)	-0. 19 (-0. 22 to -0. 16)	3. 23 (2. 14 to 4. 86)	1.81 (1.22 to 2.69)	-1.46 (-1.67 to -1.24)
Iran (Islamic Republic of)	Thalassemi as trait	117 (98 to 143)	95 (79 to 114)	-0.19 (-0.21 to -0.18)	200. 55 (166. 63 to 243. 59)	112.35 (94.05 to 135.31)	-1.45 (-1.66 to -1.23)
Iran (Islamic Republic of)	Sickle cell disorders	4 (3 to 5)	2 (2 to 3)	-0.49 (-0.5 to -0.46)	6. 59 (5. 07 to 8. 59)	2.35 (1.82 to 3.06)	-3.78 (-4.15 to -3.4)
Iran (Islamic Republic of)	Sickle cell trait	153 (133 to 174)	96 (84 to 110)	-0.37 (-0.38 to -0.36)	260. 91 (228. 04 to 297. 49)	113. 86 (99. 39 to 130. 12)	-2.69 (-2.84 to -2.55)
Iran (Islamic Republic of)	G6PD deficiency	100 (96 to 104)	89 (85 to 93)	-0.12 (-0.15 to -0.09)	171. 56 (164. 76 to 177. 97)	105. 21 (100. 25 to 110. 03)	-1 (-1.42 to -0.58)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Iran (Islamic Republic of)	G6PD trait	205 (201 to 209)	215 (211 to 219)	0.05 (0.03 to 0.06)	350. 53 (344. 18 to 356. 19)	255. 31 (250. 84 to 259. 38)	-0.76 (-0.99 to -0.52)
Iraq	Inherited anemias	265 (242 to 289)	351 (322 to 383)	0.33 (0.3 to 0.35)	1506. 19 (1376. 53 to 1643. 71)	834. 32 (763. 61 to 908. 79)	-2. 2 (-2. 28 to -2. 13)
Iraq	Thalassemi as	0 (0 to 1)	1 (0 to 1)	0.39 (0.26 to 0.53)	2.38 (1.85 to 3.06)	1.38 (1.08 to 1.77)	-2. 19 (-2. 28 to -2. 09)
Iraq	Thalassemi as trait	37 (33 to 42)	51 (45 to 57)	0.37 (0.31 to 0.44)	210. 54 (187. 38 to 236. 34)	120. 75 (107. 32 to 136. 13)	-2. 2 (-2. 29 to -2. 11)
Iraq	Sickle cell disorders	2 (1 to 2)	2 (2 to 2)	0. 29 (0. 21 to 0. 38)	8. 89 (7. 37 to 10. 86)	4. 81 (3. 95 to 5. 86)	-2.12 (-2.36 to -1.88)
Iraq	Sickle cell trait	64 (59 to 71)	84 (76 to 92)	0. 3 (0. 25 to 0. 34)	365. 44 (334. 34 to 401. 87)	198. 4 (180. 77 to 218. 41)	-2. 23 (-2. 37 to -2. 1)
Iraq	G6PD deficiency	46 (35 to 57)	61 (47 to 75)	0. 32 (0. 25 to 0. 4)	260. 08 (200. 54 to 321. 87)	143.64 (111.17 to 178.34)	-1.98 (-2.11 to -1.86)
Iraq	G6PD trait	116 (105 to 125)	154 (140 to 167)	0.33 (0.3 to 0.38)	658. 87 (598. 31 to 711. 92)	365. 33 (331. 54 to 396. 56)	-2. 28 (-2. 36 to -2. 19)
Ireland	Inherited anemias	9 (8 to 10)	11 (10 to 12)	0. 14 (0. 11 to 0. 18)	261. 07 (234. 01 to 289. 78)	218. 64 (195. 8 to 242. 68)	-0.2 (-0.5 to 0.1)
Ireland	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.09 (-0.06 to 0.26)	0. 18 (0. 13 to 0. 25)	0. 15 (0. 1 to 0. 2)	-1.16 (-2.02 to -0.29)
Ireland	Thalassemi as trait	1 (1 to 1)	1 (1 to 1)	0. 17 (0. 1 to 0. 25)	23. 3 (20. 34 to 26. 63)	20. 07 (17. 21 to 23. 02)	-0.24 (-0.62 to 0.15)
Ireland	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.07 (-0.18 to 0.04)	0. 25 (0. 18 to 0. 35)	0. 17 (0. 13 to 0. 23)	-1.67 (-2.09 to -1.25)
Ireland	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	0 (-0.07 to 0.07)	32. 75 (26. 92 to 39. 96)	24. 11 (19. 78 to 29. 05)	-1.13 (-1.42 to -0.85)
Ireland	G6PD deficiency	1 (1 to 2)	2 (1 to 2)	0. 21 (0. 17 to 0. 26)	39.66 (30.34 to 49.36)	35. 22 (27. 05 to 43. 95)	0.05 (-0.23 to 0.34)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Ireland	G6PD trait	6 (5 to 7)	7 (6 to 8)	0. 15 (0. 1 to 0. 2)	164. 92 (147. 61 to 180. 99)	138. 92 (124. 26 to 153. 91)	-0. 08 (-0. 41 to 0. 26)
Israel	Inherited anemias	22 (20 to 24)	43 (38 to 49)	0.96 (0.89 to 1.03)	443. 23 (395. 23 to 492. 85)	463. 55 (410. 22 to 521. 67)	0. 19 (0. 1 to 0. 28)
Israel	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.74 (0.46 to 1.01)	0. 24 (0. 16 to 0. 34)	0. 22 (0. 15 to 0. 32)	-1. 29 (-2. 22 to -0. 34)
Israel	Thalassemi as trait	1 (1 to 1)	2 (2 to 3)	0.92 (0.79 to 1.05)	25.05 (21.66 to 28.67)	25. 68 (22. 01 to 29. 75)	-0.25 (-0.54 to 0.05)
Israel	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.35 (0.1 to 0.63)	1. 25 (0. 95 to 1. 6)	0. 9 (0. 64 to 1. 27)	-1.1 (-1.4 to -0.8)
Israel	Sickle cell trait	5 (4 to 5)	7 (6 to 9)	0.55 (0.38 to 0.73)	93. 25 (80. 22 to 106. 51)	77. 16 (62. 36 to 93. 15)	-0.63 (-0.81 to -0.45)
Israel	G6PD deficiency	5 (4 to 6)	11 (9 to 14)	1. 19 (1. 05 to 1. 37)	101. 27 (78. 3 to 125. 24)	118.37 (92.02 to 148.2)	0.43 (0.26 to 0.61)
Israel	G6PD trait	11 (10 to 12)	22 (20 to 25)	1.04 (0.97 to 1.12)	222. 17 (199. 27 to 243. 68)	241. 21 (216. 59 to 265. 51)	0.43 (0.35 to 0.52)
Italy	Inherited anemias	229 (216 to 243)	141 (135 to 148)	-0.38 (-0.41 to -0.36)	403.05 (379.9 to 428.35)	233. 67 (223. 14 to 245. 54)	-1.82 (-2.13 to -1.5)
Italy	Thalassemi as	1 (1 to 2)	1 (1 to 1)	-0. 24 (-0. 28 to -0. 19)	2. 59 (1. 88 to 3. 45)	1. 85 (1. 38 to 2. 4)	-0.81 (-1.05 to -0.57)
Italy	Thalassemi as trait	53 (46 to 61)	41 (35 to 47)	-0.23 (-0.24 to -0.21)	92. 97 (80. 17 to 107. 14)	67. 51 (58. 76 to 77. 51)	-0.88 (-1.09 to -0.67)
Italy	Sickle cell disorders	7 (4 to 10)	0 (0 to 0)	-0.98 (-0.98 to -0.98)	11. 73 (7. 9 to 16. 78)	0. 21 (0. 16 to 0. 28)	-13.58 (-15.82 to -11.29)
Italy	Sickle cell trait	55 (47 to 63)	11 (10 to 13)	-0.79 (-0.81 to -0.77)	96. 1 (82. 34 to 111. 64)	18.64 (16.57 to 21.09)	-5. 38 (-6. 14 to -4. 61)
Italy	G6PD deficiency	27 (26 to 28)	23 (22 to 24)	-0.13 (-0.16 to -0.11)	47.16 (45.36 to 48.95)	38.6 (36.78 to 40.24)	-1.75 (-2.78 to -0.71)
Italy	G6PD trait	87	64	-0.26	152. 5	106.87	-1.25

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
		(85 to 88)	(63 to 66)	(-0. 26 to -0. 25)	(149. 99 to 154. 96)	(104. 77 to 108. 85)	(-1.51 to -0.98)
Jamaica	Inherited anemias	19 (17 to 21)	12 (11 to 14)	-0.36 (-0.38 to -0.33)	816. 28 (735. 19 to 897. 58)	439. 65 (393. 34 to 490. 25)	-2. 2 (-2. 32 to -2. 07)
Jamaica	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0 (-0.37 to 0.85)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.02)	-0.74 (-0.83 to -0.65)
Jamaica	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.26 (-0.37 to -0.09)	10.01 (8.1 to 12.11)	6. 25 (5. 07 to 7. 45)	-1.69 (-1.78 to -1.61)
Jamaica	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.39 (-0.47 to -0.29)	13.61 (12.46 to 14.87)	7. 02 (5. 72 to 8. 51)	-2. 25 (-2. 38 to -2. 13)
Jamaica	Sickle cell trait	6 (6 to 7)	4 (3 to 4)	-0.38 (-0.43 to -0.32)	262. 47 (248. 45 to 276. 82)	136. 78 (121. 85 to 153. 36)	-2. 3 (-2. 41 to -2. 2)
Jamaica	G6PD deficiency	5 (4 to 6)	3 (3 to 4)	-0.35 (-0.4 to -0.28)	210. 91 (162. 27 to 260. 39)	115.65 (89.02 to 143.23)	-2. 16 (-2. 29 to -2. 02)
Jamaica	G6PD trait	8 (7 to 8)	5 (4 to 5)	-0.35 (-0.35 to -0.35)	319. 26 (287. 2 to 349. 09)	173. 94 (156. 72 to 190. 13)	-2.15 (-2.29 to -2.01)
Japan	Inherited anemias	85 (79 to 91)	64 (60 to 69)	-0.24 (-0.29 to -0.2)	67. 29 (62. 68 to 72. 25)	50. 28 (46. 7 to 54. 08)	-0.9 (-1.2 to -0.61)
Japan	Thalassemi as	1 (1 to 1)	1 (1 to 1)	0. 2 (0. 05 to 0. 39)	0.6 (0.44 to 0.86)	0.71 (0.51 to 1)	0.64 (-0.08 to 1.36)
Japan	Thalassemi as trait	24 (18 to 30)	22 (18 to 26)	-0.07 (-0.25 to 0.08)	18.82 (14.38 to 23.58)	17. 26 (13. 81 to 20. 66)	0.01 (-0.57 to 0.6)
Japan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 2 (-0. 52 to 0. 14)	0 (0 to 0.01)	0 (0 to 0)	-0.62 (-0.89 to -0.34)
Japan	Sickle cell trait	3 (2 to 4)	2 (2 to 3)	-0.19 (-0.25 to -0.08)	2. 26 (1. 32 to 3. 2)	1. 79 (1. 18 to 2. 43)	-0.61 (-0.74 to -0.49)
Japan	G6PD deficiency	4 (3 to 4)	3 (3 to 3)	-0.08 (-0.1 to -0.06)	2. 88 (2. 76 to 3. 02)	2. 61 (2. 48 to 2. 74)	-0.77 (-1.04 to -0.5)
Japan	G6PD trait	54 (52 to 55)	36 (35 to 37)	-0.34 (-0.35 to	42.73 (41.64 to	27. 92 (27. 1 to	-1.4 (-1.59 to

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
		, ,	,	-0.32)	43. 88)	28. 74)	-1.21)
Jordan	Inherited anemias	49 (44 to 53)	83 (76 to 90)	0.7 (0.66 to 0.74)	1286. 87 (1177. 41 to 1399. 85)	709. 25 (649. 32 to 772. 35)	-1.97 (-2.05 to -1.9)
Jordan	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.8 (0.62 to 1)	2. 23 (1. 66 to 2. 93)	1. 3 (0. 97 to 1. 7)	-1.82 (-1.89 to -1.75)
Jordan	Thalassemi as trait	7 (6 to 8)	13 (11 to 15)	0.81 (0.73 to 0.9)	189. 38 (165. 4 to 215. 87)	111. 17 (97. 39 to 126. 59)	-1.77 (-1.84 to -1.7)
Jordan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.68 (0.55 to 0.81)	4 (3. 07 to 5. 03)	2. 18 (1. 68 to 2. 75)	-2.67 (-2.94 to -2.39)
Jordan	Sickle cell trait	9 (8 to 10)	15 (13 to 17)	0.71 (0.64 to 0.77)	229. 66 (201. 6 to 258. 21)	127. 08 (112. 29 to 143. 05)	-2. 27 (-2. 41 to -2. 12)
Jordan	G6PD deficiency	8 (6 to 10)	13 (10 to 16)	0.61 (0.51 to 0.71)	207. 71 (162. 01 to 257. 59)	108.63 (84.38 to 136.44)	-2.05 (-2.16 to -1.94)
Jordan	G6PD trait	25 (23 to 27)	42 (38 to 45)	0. 69 (0. 64 to 0. 74)	653. 9 (598. 18 to 704. 27)	358. 9 (328. 01 to 387. 13)	-1.9 (-1.99 to -1.81)
Kazakhstan	Inherited anemias	51 (45 to 56)	51 (45 to 56)	-0.01 (-0.03 to 0.01)	311. 51 (277. 64 to 345. 02)	275. 08 (246. 24 to 305. 97)	0.74 (0.27 to 1.2)
Kazakhstan	Thalassemi as	0 (0 to 1)	0 (0 to 0)	-0.21 (-0.3 to -0.1)	2.31 (1.65 to 3.18)	1. 62 (1. 17 to 2. 27)	-0.06 (-0.53 to 0.41)
Kazakhstan	Thalassemi as trait	17 (14 to 21)	17 (14 to 21)	0 (-0.06 to 0.07)	103. 84 (86. 12 to 126)	92. 46 (76. 8 to 113. 74)	0.74 (0.28 to 1.21)
Kazakhstan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.01 (-0.21 to 0.11)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.02)	0.75 (0.28 to 1.22)
Kazakhstan	Sickle cell trait	2 (1 to 2)	2 (1 to 2)	-0.01 (-0.12 to 0.06)	9.8 (7.74 to 12.25)	8.63 (6.76 to 10.75)	0.74 (0.28 to 1.21)
Kazakhstan	G6PD deficiency	5 (4 to 6)	5 (4 to 6)	0.01 (-0.03 to 0.08)	29. 09 (22. 6 to 36. 35)	26. 19 (20. 18 to 33. 08)	0.87 (0.39 to 1.35)
Kazakhstan	G6PD trait	27 (24 to 30)	27 (24 to 30)	-0.01 (-0.01 to -0.01)	166. 46 (148. 14 to 185. 56)	146. 16 (130. 08 to 162. 93)	0.72 (0.26 to 1.19)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Kenya	Inherited anemias	574 (533 to 618)	692 (643 to 746)	0. 21 (0. 2 to 0. 22)	2475. 46 (2298. 91 to 2665. 59)	1378. 44 (1279. 25 to 1485. 61)	-1. 99 (-2. 12 to -1. 86)
Kenya	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1. 93 (1. 65 to 2. 37)	0.09 (0.05 to 0.13)	0. 12 (0. 07 to 0. 18)	0.75 (0.55 to 0.95)
Kenya	Thalassemi as trait	6 (5 to 7)	11 (9 to 13)	0.82 (0.7 to 0.95)	25. 83 (20. 72 to 31. 31)	21. 7 (17. 17 to 26. 49)	-0.73 (-0.84 to -0.61)
Kenya	Sickle cell disorders	19 (14 to 27)	24 (17 to 33)	0. 22 (0. 18 to 0. 26)	83.81 (58.35 to 116.76)	47.06 (33.47 to 64.81)	-1.7 (-1.82 to -1.59)
Kenya	Sickle cell trait	234 (201 to 269)	299 (260 to 344)	0. 28 (0. 26 to 0. 3)	1007. 62 (866. 5 to 1158. 24)	596. 17 (516. 72 to 684. 21)	-1.67 (-1.77 to -1.58)
Kenya	G6PD deficiency	108 (103 to 113)	128 (122 to 133)	0. 18 (0. 17 to 0. 21)	466. 68 (445. 04 to 486. 36)	255. 19 (243. 77 to 265. 43)	-2. 29 (-2. 42 to -2. 15)
Kenya	G6PD trait	207 (204 to 209)	230 (226 to 234)	0. 11 (0. 11 to 0. 12)	891. 43 (879. 12 to 902. 79)	458. 2 (450. 57 to 465. 47)	-2.31 (-2.53 to -2.09)
Kiribati	Inherited anemias	1 (1 to 1)	1 (1 to 1)	0. 29 (0. 25 to 0. 33)	769. 72 (683. 21 to 859. 31)	620. 91 (551. 89 to 692. 42)	-0.51 (-0.73 to -0.28)
Kiribati	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.05 (-0.08 to 0.18)	4.9 (2.69 to 7.37)	3. 23 (1. 78 to 4. 81)	-0.07 (-1.06 to 0.93)
Kiribati	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0. 14 (0. 07 to 0. 2)	132. 35 (101. 74 to 159. 97)	93.84 (71.51 to 113.58)	-0.52 (-0.95 to -0.09)
Kiribati	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 24 (0. 16 to 1. 48)	0 (0 to 0.01)	0 (0 to 0)	-0.68 (-0.86 to -0.5)
Kiribati	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0. 21 (0. 16 to 0. 82)	4. 96 (2. 11 to 7. 48)	3. 75 (1. 58 to 6. 36)	-0.78 (-0.93 to -0.63)
Kiribati	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0. 42 (0. 32 to 0. 52)	157. 56 (121. 17 to 198. 34)	139. 64 (108. 13 to 175. 78)	-0.26 (-0.53 to 0)
Kiribati	G6PD trait	0 (0 to 0)	0 (0 to 0)	0.3 (0.25 to 0.34)	469. 94 (422. 35 to 517. 13)	380. 46 (345. 3 to 412. 73)	-0.6 (-0.78 to -0.42)
Kuwait	Inherited	9	14	0.55	526. 25	323. 96	-1.85

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
	anemias	(8 to 10)	(13 to 16)	(0. 52 to 0. 59)	(475. 09 to 581. 09)	(292. 31 to 357. 94)	(-2.02 to -1.69)
Kuwait	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0. 82 (0. 62 to 1. 05)	0. 31 (0. 21 to 0. 43)	0. 22 (0. 16 to 0. 3)	-1. 23 (-1. 47 to -0. 99)
Kuwait	Thalassemi as trait	1 (1 to 1)	2 (1 to 2)	0. 67 (0. 58 to 0. 75)	57. 39 (48. 56 to 68. 19)	38. 01 (32. 47 to 44. 8)	-1. 49 (-1. 73 to -1. 25)
Kuwait	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 55 (0. 44 to 0. 66)	1. 7 (1. 34 to 2. 13)	1. 05 (0. 82 to 1. 32)	-1. 69 (-1. 93 to -1. 45)
Kuwait	Sickle cell trait	2 (2 to 2)	3 (3 to 4)	0.54 (0.48 to 0.59)	119. 52 (106. 46 to 133. 77)	73 (65.04 to 81.8)	-1.72 (-1.96 to -1.48)
Kuwait	G6PD deficiency	2 (1 to 2)	3 (2 to 3)	0.54 (0.48 to 0.63)	97. 7 (75. 93 to 122. 06)	59. 75 (46. 19 to 74. 51)	-1.39 (-1.65 to -1.13)
Kuwait	G6PD trait	4 (4 to 5)	7 (6 to 7)	0.53 (0.47 to 0.59)	249. 63 (222. 95 to 274. 46)	151. 93 (136 to 168. 5)	-2.18 (-2.47 to -1.9)
Kyrgyzstan	Inherited anemias	18 (16 to 20)	21 (19 to 24)	0. 19 (0. 16 to 0. 22)	405. 46 (363. 32 to 453. 23)	328. 12 (293. 81 to 364. 99)	0.14 (-0.29 to 0.57)
Kyrgyzstan	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0 (-0.12 to 0.14)	3.06 (2.19 to 4.28)	2. 08 (1. 49 to 2. 88)	-0.46 (-0.9 to -0.02)
Kyrgyzstan	Thalassemi as trait	6 (5 to 7)	7 (6 to 9)	0. 23 (0. 15 to 0. 32)	136. 18 (113. 86 to 166. 1)	114. 74 (95. 55 to 139. 2)	0.26 (-0.17 to 0.69)
Kyrgyzstan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.17 (0 to 0.43)	0.02 (0.01 to 0.02)	0.01 (0.01 to 0.02)	0.12 (-0.31 to 0.56)
Kyrgyzstan	Sickle cell trait	1 (0 to 1)	1 (1 to 1)	0.17 (0.07 to 0.3)	12.8 (10.09 to 15.93)	10. 23 (8. 11 to 12. 7)	0.1 (-0.33 to 0.54)
Kyrgyzstan	G6PD deficiency	2 (1 to 2)	2 (2 to 3)	0. 19 (0. 12 to 0. 28)	38. 13 (29. 27 to 47. 4)	31.01 (24.06 to 39.03)	0. 22 (-0. 24 to 0. 67)
Kyrgyzstan	G6PD trait	10 (9 to 11)	11 (10 to 12)	0.16 (0.16 to 0.16)	215. 27 (191. 46 to 238. 68)	170.05 (151.24 to 188.54)	0.06 (-0.36 to 0.49)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Lao People's Democratic Republic	Inherited anemias	49 (45 to 54)	51 (47 to 57)	0.04 (0.01 to 0.07)	1191. 21 (1079. 46 to 1309. 6)	718. 27 (651. 45 to 791. 38)	-1.93 (-2 to -1.85)
Lao People's Democratic Republic	Thalassemi as	1 (1 to 1)	1 (1 to 2)	0.63 (0.49 to 0.78)	21. 38 (16. 51 to 27. 21)	20. 21 (15. 71 to 26. 56)	-0. 37 (-0. 45 to -0. 29)
Lao People's Democratic Republic	Thalassemi as trait	15 (14 to 17)	19 (17 to 21)	0. 26 (0. 21 to 0. 3)	366. 35 (328. 32 to 410. 01)	267. 09 (242. 66 to 296. 82)	-1.26 (-1.33 to -1.19)
Lao People's Democratic Republic	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.05 (-0.07 to 0.21)	0.04 (0.02 to 0.05)	0.02 (0.01 to 0.03)	-1.87 (-1.92 to -1.81)
Lao People's Democratic Republic	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	0.05 (-0.01 to 0.13)	22. 43 (18. 45 to 27. 13)	13. 63 (11. 22 to 16. 43)	-1.87 (-1.93 to -1.8)
Lao People's Democratic Republic	G6PD deficiency	9 (7 to 11)	9 (7 to 11)	-0.01 (-0.08 to 0.06)	214. 08 (164. 77 to 266. 4)	123. 02 (95. 4 to 153. 59)	-2. 14 (-2. 22 to -2. 06)
Lao People's Democratic Republic	G6PD trait	24 (21 to 26)	21 (19 to 23)	-0. 1 (-0. 14 to -0. 08)	566. 94 (510. 69 to 618. 45)	294. 31 (265. 12 to 324. 67)	-2. 42 (-2. 57 to -2. 28)
Latvia	Inherited anemias	5 (4 to 5)	2 (2 to 3)	-0.46 (-0.47 to -0.46)	170. 47 (150. 79 to 191. 29)	126. 78 (111. 85 to 141. 56)	0.17 (-0.4 to 0.75)
Latvia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.64 (-0.67 to -0.59)	0.71 (0.49 to 1.04)	0.36 (0.26 to 0.51)	-1. 11 (-1. 7 to -0. 52)
Latvia	Thalassemi as trait	1 (1 to 1)	0 (0 to 1)	-0.45 (-0.49 to -0.42)	33.06 (27.45 to 40.6)	25. 11 (20. 95 to 29. 97)	0.24 (-0.35 to 0.83)
Latvia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.44 (-0.54 to -0.32)	0.01 (0.01 to 0.01)	0.01 (0 to 0.01)	0.34 (-0.19 to 0.88)
Latvia	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.46 (-0.52 to -0.41)	6. 44 (5. 18 to 7. 97)	4. 79 (3. 9 to 5. 92)	0. 23 (-0. 33 to 0. 79)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Latvia	G6PD deficiency	1 (1 to 1)	0 (0 to 0)	-0. 43 (-0. 46 to -0. 41)	26. 6 (20. 4 to 33. 03)	20. 97 (16. 08 to 26. 01)	0.07 (-0.49 to 0.63)
Latvia	G6PD trait	3 (2 to 3)	1 (1 to 2)	-0.48 (-0.48 to -0.48)	103.66 (91.74 to 115.99)	75. 54 (66. 85 to 84. 53)	0.18 (-0.4 to 0.77)
Lebanon	Inherited anemias	35 (32 to 38)	34 (31 to 36)	-0.03 (-0.06 to -0.01)	1063.95 (978.01 to 1155.03)	649.95 (598.4 to 703.83)	-1.32 (-1.48 to -1.16)
Lebanon	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.02 (-0.12 to 0.11)	3. 1 (2. 23 to 4. 21)	1. 92 (1. 41 to 2. 55)	-1.33 (-1.47 to -1.19)
Lebanon	Thalassemi as trait	7 (6 to 8)	7 (6 to 8)	-0.02 (-0.07 to 0.04)	214. 11 (183. 89 to 247. 27)	132.65 (115.77 to 152.06)	-1.31 (-1.45 to -1.16)
Lebanon	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.06 (-0.02 to 0.14)	2. 33 (1. 85 to 2. 94)	1.56 (1.24 to 1.93)	-1.02 (-1.14 to -0.9)
Lebanon	Sickle cell trait	6 (5 to 6)	6 (5 to 6)	0 (-0.04 to 0.03)	173. 74 (155. 52 to 195. 04)	109.37 (98.07 to 122.07)	-1.22 (-1.34 to -1.09)
Lebanon	G6PD deficiency	4 (3 to 5)	4 (3 to 5)	-0.04 (-0.09 to 0.01)	117. 89 (91. 2 to 147. 47)	71.3 (55.27 to 88.36)	-1.32 (-1.8 to -0.85)
Lebanon	G6PD trait	18 (16 to 20)	17 (16 to 19)	-0.05 (-0.08 to -0.02)	552. 79 (501. 49 to 601. 58)	333. 15 (303. 27 to 361. 48)	-1.37 (-1.51 to -1.22)
Lesotho	Inherited anemias	18 (16 to 20)	13 (11 to 15)	-0. 27 (-0. 3 to -0. 26)	982.6 (859.19 to 1112.3)	615. 81 (539. 93 to 694. 52)	-1.58 (-1.68 to -1.48)
Lesotho	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.56 (0.35 to 0.85)	0.08 (0.05 to 0.12)	0.11 (0.06 to 0.16)	0.82 (0.66 to 0.98)
Lesotho	Thalassemi as trait	0 (0 to 1)	0 (0 to 1)	-0.04 (-0.11 to 0.04)	27. 16 (22. 71 to 32. 3)	22. 51 (18. 45 to 26. 77)	-0.72 (-0.79 to -0.65)
Lesotho	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.25 (-0.31 to -0.18)	0. 12 (0. 08 to 0. 17)	0.08 (0.05 to 0.11)	-1.49 (-1.55 to -1.43)
Lesotho	Sickle cell trait	1 (0 to 1)	0 (0 to 1)	-0.25 (-0.29 to -0.22)	34. 18 (26. 45 to 43. 54)	22. 12 (17. 17 to 28. 19)	-1.5 (-1.56 to -1.44)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Lesotho	G6PD deficiency	6 (4 to 7)	4 (3 to 5)	-0.31 (-0.35 to -0.26)	312. 17 (242. 35 to 393. 09)	187. 13 (145. 36 to 233. 02)	-1.74 (-1.88 to -1.6)
Lesotho	G6PD trait	11 (10 to 12)	8 (7 to 9)	-0.27 (-0.29 to -0.25)	608. 89 (557. 73 to 657. 37)	383. 88 (350 to 415. 54)	-1.55 (-1.64 to -1.47)
Liberia	Inherited anemias	39 (36 to 43)	61 (56 to 66)	0.54 (0.52 to 0.57)	2006. 89 (1841. 24 to 2190. 34)	1270. 33 (1163. 38 to 1385. 61)	-1.63 (-1.85 to -1.4)
Liberia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.59 (0.45 to 0.76)	6. 54 (4. 97 to 8. 68)	4. 26 (3. 26 to 5. 71)	-1.55 (-1.78 to -1.32)
Liberia	Thalassemi as trait	7 (6 to 8)	11 (10 to 12)	0.59 (0.52 to 0.66)	346. 52 (306. 4 to 394. 64)	225. 48 (200. 16 to 257. 55)	-1.55 (-1.78 to -1.32)
Liberia	Sickle cell disorders	0 (0 to 1)	1 (1 to 1)	0.55 (0.47 to 0.64)	22. 07 (18. 61 to 25. 78)	14 (11.82 to 16.51)	-1.63 (-1.86 to -1.4)
Liberia	Sickle cell trait	10 (9 to 11)	16 (15 to 17)	0.54 (0.49 to 0.59)	522. 1 (480. 23 to 565. 71)	328. 74 (303. 09 to 356. 84)	-1.65 (-1.88 to -1.42)
Liberia	G6PD deficiency	8 (6 to 10)	12 (9 to 15)	0.53 (0.43 to 0.63)	398. 24 (307 to 498. 41)	250.65 (193.84 to 315.29)	-1.61 (-1.82 to -1.39)
Liberia	G6PD trait	14 (13 to 15)	21 (19 to 23)	0.53 (0.53 to 0.53)	711. 44 (644. 9 to 772. 73)	447. 21 (405. 46 to 485. 6)	-1.66 (-1.89 to -1.44)
Libya	Inherited anemias	74 (68 to 80)	38 (35 to 41)	-0.48 (-0.49 to -0.47)	1745. 25 (1604. 29 to 1887. 46)	567.07 (521.76 to 614.78)	-3.85 (-3.92 to -3.77)
Libya	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.38 (-0.45 to -0.28)	2. 18 (1. 42 to 3. 3)	0.85 (0.57 to 1.27)	-3.32 (-3.4 to -3.24)
Libya	Thalassemi as trait	8 (7 to 10)	5 (4 to 6)	-0.42 (-0.45 to -0.38)	187. 44 (154. 22 to 228. 74)	68. 26 (56. 88 to 82. 43)	-3. 52 (-3. 59 to -3. 46)
Libya	Sickle cell disorders	1 (1 to 1)	1 (0 to 1)	-0.44 (-0.49 to -0.38)	22.99 (17.06 to 31.7)	8. 16 (6. 11 to 11. 1)	-3.49 (-3.64 to -3.35)
Libya	Sickle cell trait	23 (20 to 26)	12 (11 to 14)	-0.46 (-0.48 to -0.43)	532. 55 (465. 86 to 617. 91)	181. 38 (159. 27 to 209. 05)	-3.67 (-3.75 to -3.58)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Libya	G6PD deficiency	10 (8 to 13)	5 (4 to 6)	-0.54 (-0.56 to -0.51)	238. 79 (184. 15 to 301. 86)	69. 53 (53. 54 to 86. 89)	-4. 23 (-4. 38 to -4. 08)
Libya	G6PD trait	32 (30 to 34)	16 (15 to 17)	-0.5 (-0.51 to -0.49)	761. 3 (707. 35 to 808. 97)	238. 89 (220. 36 to 255. 29)	-3.96 (-4.05 to -3.88)
Lithuania	Inherited anemias	7 (6 to 8)	3 (3 to 4)	-0.51 (-0.52 to -0.5)	188. 22 (166. 58 to 210. 84)	121.91 (107.83 to 136.9)	-0.75 (-1.24 to -0.25)
Lithuania	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0. 67 (-0. 7 to -0. 62)	0.75 (0.52 to 1.1)	0.33 (0.24 to 0.46)	-2.04 (-2.55 to -1.53)
Lithuania	Thalassemi as trait	1 (1 to 2)	1 (1 to 1)	-0. 5 (-0. 53 to -0. 47)	35. 73 (29. 7 to 43. 75)	23. 57 (19. 71 to 28. 5)	-0.69 (-1.19 to -0.19)
Lithuania	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.51 (-0.6 to -0.42)	0.01 (0.01 to 0.01)	0.01 (0 to 0.01)	-0.75 (-1.22 to -0.28)
Lithuania	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.51 (-0.57 to -0.47)	7. 11 (5. 74 to 8. 83)	4.56 (3.69 to 5.65)	-0.74 (-1.22 to -0.26)
Lithuania	G6PD deficiency	1 (1 to 1)	1 (0 to 1)	-0.48 (-0.52 to -0.45)	29. 67 (22. 94 to 36. 89)	20. 3 (15. 75 to 25. 81)	-0.87 (-1.35 to -0.39)
Lithuania	G6PD trait	4 (4 to 5)	2 (2 to 2)	-0.52 (-0.52 to -0.52)	114.96 (102.07 to 128.28)	73. 16 (64. 96 to 81. 64)	-0.73 (-1.23 to -0.23)
Luxembourg	Inherited anemias	1 (1 to 1)	1 (1 to 1)	0. 29 (0. 25 to 0. 33)	232. 02 (208. 89 to 256. 93)	183. 98 (164. 34 to 204. 22)	-1.1 (-1.2 to -1)
Luxembourg	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0. 22 (0. 08 to 0. 4)	0.16 (0.11 to 0.22)	0. 12 (0. 09 to 0. 17)	-2.12 (-2.92 to -1.31)
Luxembourg	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.33 (0.25 to 0.41)	20.46 (17.61 to 23.46)	16.82 (14.58 to 19.27)	-1.19 (-1.43 to -0.96)
Luxembourg	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 21 (0. 05 to 0. 38)	0.53 (0.38 to 0.72)	0. 4 (0. 28 to 0. 53)	-1.18 (-1.36 to -1)
Luxembourg	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0.09 (0 to 0.17)	29. 3 (23. 6 to 35. 79)	19.61 (16.05 to 23.52)	-1.55 (-1.72 to -1.37)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Luxembourg	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0. 38 (0. 32 to 0. 45)	35. 27 (27. 33 to 44. 02)	29. 97 (23. 01 to 37. 3)	-0.9 (-1.02 to -0.79)
Luxembourg	G6PD trait	1 (0 to 1)	1 (1 to 1)	0.3 (0.25 to 0.35)	146. 29 (131. 12 to 161. 96)	117.05 (104.89 to 128.65)	-1.05 (-1.17 to -0.94)
Madagascar	Inherited anemias	253 (226 to 282)	330 (299 to 363)	0.3 (0.27 to 0.34)	2114. 4 (1890. 96 to 2355. 65)	1234.68 (1121.44 to 1358.68)	-1.7 (-2 to -1.4)
Madagascar	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2.61 (2.04 to 3.25)	0.09 (0.05 to 0.14)	0.15 (0.08 to 0.23)	1. 25 (1. 01 to 1. 49)
Madagascar	Thalassemi as trait	3 (2 to 4)	7 (5 to 9)	1. 22 (1. 04 to 1. 42)	26. 34 (20. 77 to 31. 87)	26. 18 (20. 5 to 32. 13)	-0.24 (-0.38 to -0.1)
Madagascar	Sickle cell disorders	2 (2 to 3)	3 (3 to 4)	0.56 (0.41 to 0.72)	18. 11 (14. 43 to 23. 03)	12.65 (10.15 to 16.17)	-1.45 (-1.63 to -1.26)
Madagascar	Sickle cell trait	64 (57 to 71)	101 (91 to 113)	0.58 (0.5 to 0.65)	533. 12 (480. 22 to 597. 3)	376. 84 (340. 34 to 423. 52)	-1.33 (-1.46 to -1.19)
Madagascar	G6PD deficiency	78 (60 to 97)	70 (54 to 88)	-0. 1 (-0. 17 to -0. 05)	652. 39 (505. 18 to 810. 96)	262. 47 (203. 77 to 329. 44)	-2.58 (-3.25 to -1.91)
Madagascar	G6PD trait	106 (97 to 113)	149 (136 to 161)	0.41 (0.37 to 0.44)	884. 34 (815. 07 to 947. 23)	556. 39 (507. 75 to 601. 7)	-1.47 (-1.69 to -1.25)
Malawi	Inherited anemias	166 (148 to 185)	178 (159 to 198)	0.08 (0.06 to 0.09)	1733.65 (1544.03 to 1934.37)	965. 65 (864. 22 to 1076. 29)	-2.19 (-2.48 to -1.9)
Malawi	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.61 (1.31 to 1.98)	0. 1 (0. 06 to 0. 15)	0.14 (0.08 to 0.21)	0.53 (0.22 to 0.84)
Malawi	Thalassemi as trait	3 (2 to 3)	4 (4 to 5)	0.61 (0.51 to 0.74)	29 (23.06 to 35.64)	24. 23 (19. 21 to 29. 34)	-0.97 (-1.22 to -0.73)
Malawi	Sickle cell disorders	0 (0 to 1)	1 (0 to 1)	0.18 (0.08 to 0.29)	4. 61 (3. 66 to 5. 97)	2.81 (2.23 to 3.64)	-1.78 (-2.05 to -1.5)
Malawi	Sickle cell trait	27 (25 to 31)	32 (29 to 37)	0. 17 (0. 12 to 0. 22)	287. 5 (257. 06 to 327. 54)	173. 99 (155. 53 to 197. 96)	-1.88 (-2.12 to -1.64)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Malawi	G6PD deficiency	48 (37 to 60)	45 (35 to 56)	-0.05 (-0.07 to -0.04)	498. 72 (384. 49 to 624. 52)	244. 27 (189. 09 to 304. 49)	-2.65 (-3.05 to -2.24)
Malawi	G6PD trait	87 (80 to 94)	96 (87 to 104)	0.1 (0.09 to 0.1)	913. 73 (836. 13 to 983. 96)	520. 22 (474. 35 to 562. 61)	-2.11 (-2.37 to -1.85)
Malaysia	Inherited anemias	148 (133 to 166)	94 (84 to 104)	-0.37 (-0.4 to -0.34)	841 (751.66 to 938.62)	299. 22 (267. 46 to 332. 39)	-3.95 (-4.44 to -3.45)
Malaysia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0. 2 (0. 04 to 0. 36)	1.58 (1.27 to 1.99)	1.07 (0.83 to 1.37)	-1.75 (-2.04 to -1.45)
Malaysia	Thalassemi as trait	14 (13 to 16)	18 (16 to 20)	0. 27 (0. 22 to 0. 31)	81. 4 (72. 1 to 90. 61)	58. 33 (51. 46 to 64. 65)	-1.54 (-1.81 to -1.28)
Malaysia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.06 (-0.29 to 0.3)	0. 02 (0. 01 to 0. 02)	0.01 (0.01 to 0.01)	-2.09 (-2.36 to -1.82)
Malaysia	Sickle cell trait	2 (2 to 3)	2 (2 to 3)	0.08 (-0.11 to 0.21)	12.87 (10.36 to 15.33)	7.83 (6.38 to 9.34)	-2.07 (-2.33 to -1.81)
Malaysia	G6PD deficiency	42 (34 to 53)	18 (14 to 22)	-0.58 (-0.62 to -0.53)	240. 65 (190. 77 to 301. 46)	56. 41 (43. 8 to 70. 3)	-5. 29 (-6. 23 to -4. 34)
Malaysia	G6PD trait	89 (82 to 96)	55 (49 to 61)	-0.38 (-0.42 to -0.35)	504. 48 (466. 14 to 542. 06)	175. 57 (156. 88 to 193. 33)	-4.01 (-4.48 to -3.54)
Maldives	Inherited anemias	3 (3 to 4)	3 (3 to 3)	-0.12 (-0.16 to -0.09)	1498. 82 (1359. 28 to 1645. 81)	584.5 (527.89 to 645.75)	-2. 7 (-3 to -2. 39)
Maldives	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.24 to 0.01)	27. 01 (20. 34 to 35. 18)	10. 49 (8. 01 to 13. 62)	-2.77 (-3.12 to -2.43)
Maldives	Thalassemi as trait	1 (1 to 2)	1 (1 to 2)	-0.05 (-0.11 to 0.02)	637. 17 (559. 15 to 723. 49)	269. 41 (236. 96 to 306. 7)	-2.44 (-2.75 to -2.13)
Maldives	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.06 (-0.36 to 0.17)	0.03 (0.02 to 0.04)	0. 01 (0. 01 to 0. 02)	-2.34 (-2.66 to -2.01)
Maldives	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.05 (-0.19 to 0.07)	20. 25 (16. 87 to 24. 48)	8. 61 (7. 15 to 10. 44)	-2.33 (-2.63 to -2.04)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Maldives	G6PD deficiency	1 (0 to 1)	0 (0 to 1)	-0. 19 (-0. 24 to -0. 12)	238. 81 (185. 2 to 301. 31)	86. 43 (66. 59 to 107. 77)	-2. 91 (-3. 26 to -2. 57)
Maldives	G6PD trait	1 (1 to 1)	1 (1 to 1)	-0.18 (-0.21 to -0.16)	575. 54 (518. 83 to 627. 34)	209. 56 (188. 32 to 231. 33)	-2.92 (-3.25 to -2.58)
Mali	Inherited anemias	141 (128 to 154)	302 (276 to 331)	1. 15 (1. 09 to 1. 2)	1622. 17 (1473. 83 to 1778. 26)	1379. 93 (1259. 26 to 1510. 83)	-0.59 (-0.61 to -0.57)
Mali	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 88 (2. 36 to 3. 39)	0. 16 (0. 11 to 0. 22)	0. 24 (0. 15 to 0. 35)	1. 3 (1. 17 to 1. 43)
Mali	Thalassemi as trait	5 (4 to 6)	12 (10 to 14)	1. 57 (1. 42 to 1. 74)	55. 36 (46. 74 to 65. 21)	56. 34 (47. 77 to 65. 97)	-0.03 (-0.07 to 0.02)
Mali	Sickle cell disorders	3 (3 to 3)	6 (5 to 7)	1. 12 (1 to 1. 27)	33. 86 (29. 17 to 39. 24)	28. 43 (24. 48 to 32. 91)	-0.65 (-0.68 to -0.63)
Mali	Sickle cell trait	49 (45 to 54)	105 (95 to 116)	1. 13 (1. 04 to 1. 25)	567. 75 (513. 92 to 628. 11)	479. 53 (432. 18 to 531. 29)	-0.62 (-0.64 to -0.6)
Mali	G6PD deficiency	25 (19 to 31)	52 (40 to 66)	1. 12 (0. 94 to 1. 31)	283. 37 (218. 27 to 353. 9)	237. 94 (183. 94 to 299. 39)	-0.63 (-0.64 to -0.61)
Mali	G6PD trait	59 (53 to 65)	127 (114 to 138)	1. 14 (1. 08 to 1. 2)	681.66 (613.24 to 749.45)	577. 44 (519. 41 to 631. 47)	-0.6 (-0.61 to -0.58)
Malta	Inherited anemias	1 (1 to 1)	1 (1 to 1)	-0.23 (-0.25 to -0.21)	272. 42 (245. 13 to 301. 5)	176. 98 (158. 35 to 196. 44)	-1.34 (-1.68 to -1)
Malta	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.28 (-0.38 to -0.16)	0. 19 (0. 13 to 0. 26)	0. 12 (0. 08 to 0. 17)	-2.38 (-3 to -1.75)
Malta	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0. 22 (-0. 27 to -0. 17)	23. 98 (20. 58 to 27. 51)	15. 74 (13. 65 to 18. 06)	-1.5 (-1.77 to -1.23)
Malta	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.15 (-0.24 to -0.05)	0. 21 (0. 15 to 0. 3)	0. 15 (0. 11 to 0. 22)	-1.03 (-1.32 to -0.74)
Malta	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.19 (-0.24 to -0.14)	32.11 (26.24 to 38.75)	21. 87 (17. 76 to 26. 68)	-1.19 (-1.52 to -0.86)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Malta	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.19 (-0.24 to -0.14)	42.73 (32.96 to 53.14)	29. 05 (22. 33 to 36. 23)	-1.19 (-1.58 to -0.79)
Malta	G6PD trait	1 (1 to 1)	0 (0 to 1)	-0. 25 (-0. 27 to -0. 22)	173. 19 (155. 77 to 191. 36)	110.05 (98.57 to 121.57)	-1.39 (-1.73 to -1.04)
Marshall Islands	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.08 (-0.1 to -0.07)	706. 18 (626. 81 to 790. 95)	523. 78 (462. 99 to 583. 13)	-0.74 (-0.85 to -0.63)
Marshall Islands	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0. 24 (-0. 33 to -0. 14)	3.94 (2.06 to 6.15)	2. 4 (1. 29 to 3. 66)	-0.33 (-1.26 to 0.6)
Marshall Islands	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.19 (-0.24 to -0.15)	115.74 (87.68 to 142)	75. 23 (57. 22 to 91. 49)	-0.78 (-1.16 to -0.4)
Marshall Islands	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.18 to 0.55)	0 (0 to 0)	0 (0 to 0)	-0.87 (-1.04 to -0.7)
Marshall Islands	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.14 (-0.18 to 0.36)	4. 41 (1. 9 to 6. 8)	3.05 (1.26 to 4.62)	-0.96 (-1.11 to -0.82)
Marshall Islands	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0 (-0.06 to 0.05)	145. 54 (111. 78 to 181. 73)	116. 91 (90. 23 to 144. 9)	-0.55 (-0.67 to -0.42)
Marshall Islands	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.07 (-0.08 to -0.07)	436. 56 (392. 47 to 477. 5)	326. 19 (294. 57 to 354. 95)	-0.81 (-0.89 to -0.74)
Mauritania	Inherited anemias	29 (27 to 33)	36 (32 to 40)	0. 22 (0. 19 to 0. 24)	1424. 92 (1283. 95 to 1577. 76)	893. 16 (804. 88 to 986. 19)	-1.57 (-1.69 to -1.45)
Mauritania	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.6 (0.37 to 0.87)	0. 29 (0. 2 to 0. 4)	0. 24 (0. 17 to 0. 33)	-0.69 (-0.79 to -0.59)
Mauritania	Thalassemi as trait	2 (1 to 2)	2 (2 to 3)	0.34 (0.26 to 0.43)	77. 97 (65. 27 to 92. 82)	53. 97 (45. 29 to 64. 53)	-1.26 (-1.38 to -1.15)
Mauritania	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 28 (0. 18 to 0. 4)	8. 22 (6. 5 to 10. 2)	5. 4 (4. 31 to 6. 67)	-1.37 (-1.5 to -1.24)
Mauritania	Sickle cell trait	7 (6 to 8)	9 (8 to 10)	0. 24 (0. 19 to 0. 31)	335. 78 (296. 32 to 377. 8)	215. 16 (190. 81 to 241. 21)	-1.48 (-1.6 to -1.36)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Mauritania	G6PD deficiency	7 (5 to 8)	8 (6 to 10)	0. 17 (0. 09 to 0. 25)	321. 66 (248. 29 to 406. 93)	193. 18 (149. 32 to 239. 38)	-1.68 (-1.83 to -1.53)
Mauritania	G6PD trait	14 (13 to 15)	17 (15 to 19)	0.21 (0.19 to 0.26)	681 (617. 61 to 743. 35)	425. 21 (385. 09 to 462. 01)	-1.61 (-1.73 to -1.49)
Mauritius	Inherited anemias	5 (5 to 6)	3 (3 to 3)	-0.46 (-0.48 to -0.44)	476. 8 (429. 05 to 525. 67)	221. 82 (199. 5 to 244. 63)	-3.01 (-3.19 to -2.83)
Mauritius	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.39 (-0.48 to -0.29)	2.51 (1.86 to 3.43)	1.33 (0.94 to 1.8)	-2.53 (-2.69 to -2.37)
Mauritius	Thalassemi as trait	1 (1 to 1)	1 (1 to 1)	-0.37 (-0.4 to -0.34)	104. 13 (88. 77 to 122. 63)	56. 82 (48. 47 to 66. 22)	-2.42 (-2.57 to -2.27)
Mauritius	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.54 to -0.32)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	-2.76 (-2.9 to -2.62)
Mauritius	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.49 to -0.36)	9.5 (7.97 to 11.35)	4. 72 (3. 95 to 5. 63)	-2.74 (-2.89 to -2.6)
Mauritius	G6PD deficiency	1 (1 to 1)	0 (0 to 1)	-0.41 (-0.45 to -0.37)	72.95 (56.03 to 90.96)	37. 31 (28. 7 to 46. 36)	-2.9 (-3.09 to -2.7)
Mauritius	G6PD trait	3 (3 to 3)	2 (1 to 2)	-0.51 (-0.53 to -0.49)	287. 68 (259. 1 to 313. 84)	121.64 (109.04 to 133.17)	-3.29 (-3.52 to -3.07)
Mexico	Inherited anemias	425 (414 to 436)	245 (238 to 253)	-0.42 (-0.43 to -0.42)	496. 96 (484. 47 to 510. 6)	195.9 (190.21 to 202.59)	-3. 19 (-3. 56 to -2. 82)
Mexico	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.31 (-0.2 to 1.51)	0.02 (0.01 to 0.03)	0. 02 (0. 01 to 0. 02)	-0.41 (-0.59 to -0.23)
Mexico	Thalassemi as trait	10 (6 to 16)	10 (6 to 15)	-0.04 (-0.24 to 0.26)	12. 05 (7. 22 to 18. 54)	7. 9 (5. 04 to 11. 62)	-1.53 (-1.62 to -1.45)
Mexico	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.36 (-0.51 to -0.21)	0.08 (0.05 to 0.13)	0.04 (0.02 to 0.06)	-2.47 (-2.73 to -2.2)
Mexico	Sickle cell trait	20 (15 to 27)	15 (12 to 20)	-0.24 (-0.32 to -0.16)	23.67 (17.61 to 31.43)	12. 26 (9. 54 to 16. 02)	-2. 1 (-2. 18 to -2. 02)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Mexico	G6PD deficiency	54 (51 to 56)	23 (22 to 24)	-0.57 (-0.58 to -0.56)	62.71 (60.17 to 65.08)	18. 45 (17. 54 to 19. 31)	-3.65 (-4.24 to -3.05)
Mexico	G6PD trait	341 (334 to 346)	196 (192 to 200)	-0.42 (-0.43 to -0.42)	398. 44 (390. 86 to 404. 94)	157. 24 (153. 81 to 160. 44)	-3.26 (-3.65 to -2.87)
Micronesia (Federated States of)	Inherited anemias	1 (1 to 1)	0 (0 to 1)	-0.35 (-0.36 to -0.34)	688.71 (613.51 to 766.46)	457. 07 (406. 67 to 510. 72)	-1.38 (-1.61 to -1.14)
Micronesia (Federated States of)	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.49 (-0.57 to -0.41)	3. 99 (2. 09 to 6. 05)	2.06 (1.1 to 3.12)	-1. 22 (-2. 14 to -0. 28)
Micronesia (Federated States of)	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.46 (-0.5 to -0.42)	117. 61 (89. 26 to 142. 36)	65. 08 (49. 9 to 78. 91)	-1.61 (-1.98 to -1.23)
Micronesia (Federated States of)	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.41 (-0.45 to 0.14)	0 (0 to 0)	0 (0 to 0)	-1.63 (-1.77 to -1.5)
Micronesia (Federated States of)	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.45 to 0.12)	4. 46 (1. 82 to 6. 82)	2.66 (1.09 to 4.16)	-1.73 (-1.84 to -1.63)
Micronesia (Federated States of)	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.18 to -0.09)	115.6 (88.8 to 144.18)	102. 26 (79. 24 to 127. 85)	-0.43 (-0.95 to 0.09)
Micronesia (Federated States of)	G6PD trait	0 (0 to 1)	0 (0 to 0)	-0.38 (-0.38 to -0.37)	447. 04 (401. 88 to 488. 9)	285 (258. 07 to 310. 03)	-1.61 (-1.77 to -1.44)
Monaco	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.12 (-0.15 to -0.09)	193. 77 (173. 92 to 214. 12)	137. 46 (122. 97 to 152. 61)	-1.32 (-1.42 to -1.21)
Monaco	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.17 (-0.27 to -0.04)	0. 16 (0. 11 to 0. 22)	0.11 (0.07 to 0.15)	-2.35 (-3.15 to -1.55)
Monaco	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.1 (-0.16 to -0.04)	17.89 (15.52 to 20.58)	13 (11. 25 to 14. 97)	-1.45 (-1.65 to -1.24)
Monaco	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.15 (-0.25 to -0.05)	0. 21 (0. 15 to 0. 28)	0.14 (0.1 to 0.2)	-1.46 (-1.57 to -1.35)
Monaco	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.14 (-0.2 to -0.07)	24.96 (20.43 to 30.3)	17.37 (14.18 to 21.04)	-1.39 (-1.5 to -1.28)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Monaco	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.08 (-0.11 to -0.04)	29. 43 (22. 64 to 36. 67)	21. 92 (16. 84 to 27. 52)	-1.15 (-1.3 to -1.01)
Monaco	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.17 to -0.09)	121. 13 (108. 6 to 134. 13)	84. 92 (76. 01 to 93. 5)	-1.32 (-1.42 to -1.22)
Mongolia	Inherited anemias	11 (10 to 12)	12 (11 to 14)	0. 12 (0. 08 to 0. 15)	519. 01 (464. 99 to 578. 24)	368. 07 (329 to 408. 49)	-0.23 (-0.69 to 0.24)
Mongolia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.12 (-0.22 to 0)	4. 48 (3. 24 to 6. 29)	2.51 (1.82 to 3.43)	-1.02 (-1.51 to -0.54)
Mongolia	Thalassemi as trait	4 (3 to 5)	4 (4 to 5)	0. 12 (0. 04 to 0. 21)	183. 19 (152. 34 to 223. 11)	130.71 (109.27 to 157.63)	-0.23 (-0.71 to 0.24)
Mongolia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.12 (-0.08 to 0.27)	0.02 (0.01 to 0.03)	0.02 (0.01 to 0.02)	-0.22 (-0.69 to 0.25)
Mongolia	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0. 12 (0. 01 to 0. 2)	16. 29 (12. 82 to 20. 19)	11.57 (9.09 to 14.37)	-0.23 (-0.69 to 0.24)
Mongolia	G6PD deficiency	1 (1 to 1)	1 (1 to 1)	0. 13 (0. 05 to 0. 2)	46.68 (36.06 to 59.08)	33. 67 (26. 04 to 42. 66)	-0.11 (-0.59 to 0.38)
Mongolia	G6PD trait	6 (5 to 6)	6 (6 to 7)	0.11 (0.11 to 0.11)	268. 35 (239. 05 to 299. 06)	189. 59 (168. 89 to 211. 29)	-0.23 (-0.69 to 0.24)
Montenegro	Inherited anemias	1 (1 to 2)	1 (1 to 1)	-0. 29 (-0. 3 to -0. 29)	223. 36 (197. 11 to 252. 05)	158. 96 (140. 22 to 179. 87)	-1.31 (-1.38 to -1.24)
Montenegro	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.57 (-0.62 to -0.5)	1. 21 (0. 79 to 1. 89)	0.52 (0.36 to 0.79)	-2. 8 (-2. 84 to -2. 75)
Montenegro	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0. 28 (-0. 33 to -0. 23)	28. 78 (23. 97 to 35. 47)	20.89 (17.5 to 25.05)	-1.07 (-1.11 to -1.02)
Montenegro	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 23 (-0. 3 to -0. 14)	0.13 (0.1 to 0.17)	0.1 (0.07 to 0.13)	-0.88 (-1.08 to -0.67)
Montenegro	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.27 (-0.31 to -0.24)	26. 59 (22. 82 to 30. 69)	19. 48 (16. 72 to 22. 54)	-1.02 (-1.13 to -0.92)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Montenegro	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0. 25 (-0. 26 to -0. 25)	54. 82 (42. 44 to 68. 64)	41. 38 (32. 02 to 51. 8)	-1.86 (-2.2 to -1.51)
Montenegro	G6PD trait	1 (1 to 1)	0 (0 to 1)	-0.32 (-0.32 to -0.32)	111.84 (99.09 to 125.12)	76. 58 (67. 85 to 85. 68)	-1. 2 (-1. 24 to -1. 15)
Morocco	Inherited anemias	261 (238 to 285)	199 (182 to 218)	-0.24 (-0.25 to -0.22)	1030.88 (942.05 to 1126.59)	553.66 (506.5 to 605.88)	-2.04 (-2.22 to -1.85)
Morocco	Thalassemi as	1 (1 to 1)	1 (1 to 1)	-0.23 (-0.3 to -0.15)	3. 69 (2. 93 to 4. 77)	2. 01 (1. 57 to 2. 58)	-2 (-2.19 to -1.8)
Morocco	Thalassemi as trait	56 (51 to 64)	44 (39 to 49)	-0.22 (-0.25 to -0.19)	222. 7 (200. 31 to 251. 51)	122. 1 (109. 07 to 137. 33)	-1.98 (-2.17 to -1.79)
Morocco	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.25 (-0.29 to -0.2)	1. 11 (0. 93 to 1. 31)	0.59 (0.49 to 0.7)	-2.08 (-2.27 to -1.89)
Morocco	Sickle cell trait	29 (27 to 32)	22 (20 to 24)	-0.25 (-0.27 to -0.22)	114. 64 (105. 02 to 125. 02)	60.82 (55.69 to 66.58)	-2.08 (-2.27 to -1.89)
Morocco	G6PD deficiency	45 (35 to 56)	34 (26 to 43)	-0.24 (-0.28 to -0.2)	178.75 (137.69 to 222.85)	95. 31 (73. 67 to 120. 14)	-2.05 (-2.23 to -1.86)
Morocco	G6PD trait	129 (117 to 140)	98 (89 to 107)	-0.24 (-0.26 to -0.22)	510 (462. 17 to 552. 9)	272. 84 (247. 72 to 296. 71)	-2.05 (-2.23 to -1.87)
Mozambique	Inherited anemias	206 (193 to 221)	371 (323 to 422)	0.8 (0.68 to 0.91)	1579. 19 (1473. 38 to 1692. 03)	1255. 2 (1094. 38 to 1429. 86)	-0.9 (-1.08 to -0.72)
Mozambique	Thalassemi as	0 (0 to 0)	0 (0 to 0)	3. 2 (2. 69 to 3. 93)	0. 1 (0. 06 to 0. 15)	0. 18 (0. 1 to 0. 27)	1.71 (1.44 to 1.98)
Mozambique	Thalassemi as trait	4 (3 to 4)	9 (7 to 11)	1.59 (1.41 to 1.8)	27. 2 (21. 46 to 33. 22)	31. 18 (24. 58 to 37. 9)	0.2 (0.02 to 0.38)
Mozambique	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.9 (0.79 to 1.01)	1 (0.81 to 1.21)	0.85 (0.69 to 1.02)	-0.72 (-0.85 to -0.58)
Mozambique	Sickle cell trait	17 (15 to 19)	31 (28 to 35)	0.88 (0.82 to 0.94)	127. 87 (114. 37 to 141. 77)	106. 54 (95. 58 to 117. 8)	-0.76 (-0.9 to -0.62)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Mozambique	G6PD deficiency	75 (69 to 81)	134 (104 to 169)	0. 79 (0. 48 to 1. 11)	570. 42 (526. 84 to 618. 17)	453. 18 (351. 45 to 572. 59)	-0.92 (-1.11 to -0.73)
Mozambique	G6PD trait	111 (102 to 120)	196 (179 to 211)	0.76 (0.72 to 0.79)	852.6 (780.68 to 916.97)	663. 27 (604. 95 to 714. 75)	-0.96 (-1.14 to -0.77)
Myanmar	Inherited anemias	467 (418 to 517)	382 (344 to 422)	-0.18 (-0.21 to -0.16)	1135.73 (1017.39 to 1257.77)	697.79 (629.24 to 771)	-0.84 (-1.28 to -0.39)
Myanmar	Thalassemi as	4 (3 to 5)	5 (4 to 6)	0. 29 (0. 19 to 0. 39)	8.86 (7.03 to 11.31)	8.58 (6.65 to 11.11)	-0.07 (-0.11 to -0.04)
Myanmar	Thalassemi as trait	104 (95 to 115)	96 (87 to 106)	-0.08 (-0.11 to -0.05)	252. 24 (230. 25 to 279. 87)	175.06 (159.55 to 194.15)	-1.23 (-1.26 to -1.2)
Myanmar	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.21 (-0.31 to -0.03)	0.03 (0.02 to 0.04)	0.02 (0.01 to 0.02)	-1.75 (-1.8 to -1.7)
Myanmar	Sickle cell trait	8 (6 to 9)	6 (5 to 7)	-0.21 (-0.26 to -0.12)	18.31 (15.05 to 21.93)	10.83 (8.95 to 12.79)	-1.77 (-1.8 to -1.73)
Myanmar	G6PD deficiency	120 (93 to 150)	94 (73 to 117)	-0.21 (-0.26 to -0.15)	291. 25 (225. 81 to 364. 79)	172. 65 (133. 72 to 214. 17)	0.15 (-0.87 to 1.18)
Myanmar	G6PD trait	232 (212 to 251)	181 (165 to 195)	-0.22 (-0.25 to -0.2)	565. 04 (515. 39 to 610. 37)	330. 65 (302. 27 to 356. 67)	-1.13 (-1.5 to -0.76)
Namibia	Inherited anemias	14 (12 to 16)	18 (16 to 20)	0. 26 (0. 22 to 0. 3)	1008. 23 (884. 88 to 1128. 88)	746. 38 (656. 12 to 843. 43)	-0.91 (-0.98 to -0.84)
Namibia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.74 (1.3 to 2.26)	0.07 (0.05 to 0.1)	0.11 (0.07 to 0.17)	1.47 (1.33 to 1.62)
Namibia	Thalassemi as trait	0 (0 to 0)	1 (0 to 1)	0.68 (0.54 to 0.83)	25. 47 (21. 42 to 29. 81)	25. 07 (20. 46 to 29. 56)	-0.06 (-0.12 to 0)
Namibia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 21 (0. 11 to 0. 3)	0. 27 (0. 2 to 0. 36)	0. 19 (0. 14 to 0. 25)	-0.87 (-1.14 to -0.61)
Namibia	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	0. 25 (0. 19 to 0. 31)	56. 4 (48. 16 to 65. 96)	41. 45 (35. 28 to 48. 25)	-0.85 (-1.01 to -0.69)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Namibia	G6PD deficiency	4 (3 to 5)	5 (4 to 7)	0. 21 (0. 13 to 0. 3)	314. 76 (243. 74 to 388. 48)	223. 09 (172. 9 to 281. 47)	-1.07 (-1.17 to -0.98)
Namibia	G6PD trait	9 (8 to 9)	11 (10 to 12)	0. 27 (0. 23 to 0. 31)	611. 27 (560. 23 to 659. 57)	456. 46 (416. 59 to 495. 47)	-0.88 (-0.94 to -0.82)
Nauru	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0. 23 (-0. 25 to -0. 21)	926. 81 (822. 79 to 1032. 51)	695. 82 (617. 09 to 777. 52)	-0.99 (-1.12 to -0.86)
Nauru	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.37 (-0.44 to -0.27)	5. 43 (3. 01 to 8. 14)	3.31 (1.79 to 5.11)	-0.6 (-1.52 to 0.34)
Nauru	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.33 (-0.36 to -0.28)	153. 61 (118. 26 to 185. 17)	100.75 (77.29 to 123.17)	-1.03 (-1.4 to -0.66)
Nauru	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.28 (-0.31 to 0.08)	0 (0 to 0.01)	0 (0 to 0)	-1.18 (-1.37 to -1)
Nauru	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0. 29 (-0. 31 to -0. 02)	5. 69 (2. 44 to 8. 79)	3. 93 (1. 64 to 5. 97)	-1.25 (-1.39 to -1.11)
Nauru	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.16 (-0.21 to -0.11)	191. 98 (148. 31 to 238. 3)	157. 2 (121. 34 to 198. 57)	-0.77 (-0.95 to -0.59)
Nauru	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0. 22 (-0. 25 to -0. 2)	570. 09 (512. 78 to 623. 39)	430. 63 (389. 59 to 468. 6)	-1.06 (-1.17 to -0.96)
Nepal	Inherited anemias	104 (93 to 116)	82 (74 to 91)	-0.21 (-0.23 to -0.19)	532. 1 (476. 62 to 594. 08)	270. 22 (242. 11 to 300. 64)	-2. 38 (-2. 52 to -2. 24)
Nepal	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0. 23 (0. 13 to 0. 32)	0.78 (0.58 to 1.01)	0. 62 (0. 45 to 0. 82)	-1.11 (-1.22 to -1)
Nepal	Thalassemi as trait	19 (16 to 21)	16 (14 to 18)	-0.13 (-0.16 to -0.1)	95. 3 (83. 47 to 108. 24)	53. 51 (46. 77 to 60. 51)	-2. 26 (-2. 37 to -2. 16)
Nepal	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.08 (-0.23 to 0.16)	0.09 (0.06 to 0.12)	0.05 (0.04 to 0.07)	-1.79 (-1.91 to -1.66)
Nepal	Sickle cell trait	6 (5 to 7)	4 (3 to 6)	-0.25 (-0.3 to -0.18)	30. 16 (23. 53 to 38. 18)	14.53 (11.44 to 18.34)	-2.74 (-2.83 to -2.65)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Nepal	G6PD deficiency	14 (11 to 18)	12 (9 to 15)	-0. 18 (-0. 22 to -0. 12)	73.05 (56.58 to 90.86)	38. 47 (29. 65 to 48. 01)	-1. 99 (-2. 31 to -1. 66)
Nepal	G6PD trait	65 (58 to 72)	50 (44 to 56)	-0. 24 (-0. 27 to -0. 21)	332. 72 (296. 84 to 369. 94)	163. 04 (145. 28 to 182. 61)	-2. 46 (-2. 6 to -2. 33)
Netherlands	Inherited anemias	32 (29 to 36)	29 (26 to 32)	-0.11 (-0.15 to -0.07)	216. 72 (192. 79 to 241. 95)	166. 94 (148. 95 to 186. 74)	-1 (-1.18 to -0.82)
Netherlands	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.19 (-0.33 to -0.03)	0.15 (0.1 to 0.22)	0.11 (0.07 to 0.16)	-2.21 (-3.15 to -1.26)
Netherlands	Thalassemi as trait	3 (2 to 3)	2 (2 to 3)	-0. 1 (-0. 16 to -0. 04)	17.61 (15.09 to 20.3)	13.77 (11.83 to 15.87)	-1.09 (-1.49 to -0.69)
Netherlands	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.09 (-0.19 to 0.03)	0.03 (0.02 to 0.03)	0.02 (0.02 to 0.03)	1. 44 (0. 22 to 2. 67)
Netherlands	Sickle cell trait	1 (1 to 2)	1 (1 to 1)	-0.09 (-0.14 to 0.01)	9. 16 (7. 74 to 10. 98)	7. 22 (6. 14 to 8. 67)	0.58 (-0.2 to 1.37)
Netherlands	G6PD deficiency	5 (4 to 7)	5 (4 to 6)	-0.07 (-0.13 to -0.02)	36. 51 (28. 03 to 45. 89)	29. 56 (22. 97 to 36. 94)	-0.95 (-1.09 to -0.82)
Netherlands	G6PD trait	23 (20 to 25)	20 (18 to 22)	-0.13 (-0.17 to -0.08)	153. 26 (137. 35 to 169. 69)	116. 25 (104. 19 to 128. 74)	-1.13 (-1.27 to -0.98)
New Zealand	Inherited anemias	9 (8 to 11)	7 (6 to 8)	-0.28 (-0.32 to -0.22)	277. 74 (242. 26 to 322. 23)	152. 61 (137. 95 to 170. 27)	-2.18 (-2.87 to -1.49)
New Zealand	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.03 (-0.12 to 0.07)	1.17 (0.8 to 1.8)	0.86 (0.59 to 1.31)	-0.89 (-1.03 to -0.76)
New Zealand	Thalassemi as trait	1 (1 to 1)	1 (1 to 1)	0.07 (0 to 0.15)	26. 39 (22. 13 to 30. 83)	21. 52 (18. 49 to 24. 69)	-0.59 (-0.72 to -0.46)
New Zealand	Sickle cell disorders	0 (0 to 1)	0 (0 to 0)	-0.74 (-0.78 to -0.67)	14.61 (9.56 to 22.07)	2. 93 (2. 07 to 4. 19)	-6.97 (-9.25 to -4.63)
New Zealand	Sickle cell trait	7 (5 to 8)	4 (3 to 5)	-0.39 (-0.44 to -0.34)	190. 97 (160. 2 to 227. 76)	87.86 (75.12 to 104.17)	-3. 29 (-4. 31 to -2. 26)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
New Zealand	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0. 13 (0. 09 to 0. 16)	2. 57 (2. 44 to 2. 72)	2. 2 (2. 08 to 2. 33)	-0.41 (-0.58 to -0.24)
New Zealand	G6PD trait	1 (1 to 2)	2 (2 to 2)	0. 17 (0. 12 to 0. 21)	42.02 (40.03 to 43.91)	37. 23 (35. 72 to 38. 6)	-0.21 (-0.42 to -0.01)
Nicaragua	Inherited anemias	26 (23 to 29)	20 (18 to 23)	-0.21 (-0.23 to -0.18)	659. 48 (579. 1 to 740. 09)	312. 48 (274. 91 to 348. 66)	-2.28 (-2.45 to -2.12)
Nicaragua	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.56 (-0.09 to 2.35)	0.02 (0.01 to 0.03)	0.02 (0.01 to 0.02)	0.02 (-0.14 to 0.19)
Nicaragua	Thalassemi as trait	0 (0 to 1)	0 (0 to 1)	0.14 (-0.09 to 0.57)	10. 03 (7. 17 to 13. 56)	6.82 (5.09 to 8.65)	-1.06 (-1.16 to -0.95)
Nicaragua	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.05 (-0.16 to 0.06)	0. 12 (0. 06 to 0. 19)	0.07 (0.03 to 0.11)	-1.71 (-1.92 to -1.5)
Nicaragua	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.17 (-0.49 to -0.09)	4. 26 (1. 69 to 7. 17)	2. 12 (0. 9 to 3. 41)	-1.92 (-2.16 to -1.67)
Nicaragua	G6PD deficiency	5 (4 to 6)	3 (3 to 4)	-0.32 (-0.35 to -0.28)	132. 08 (101. 62 to 166. 28)	53. 75 (41. 28 to 66. 53)	-2.77 (-3.01 to -2.52)
Nicaragua	G6PD trait	20 (18 to 22)	16 (15 to 18)	-0.18 (-0.21 to -0.16)	512. 97 (461. 36 to 559. 22)	249. 71 (224. 4 to 272. 55)	-2. 2 (-2. 36 to -2. 04)
Niger	Inherited anemias	195 (180 to 212)	494 (453 to 536)	1.53 (1.47 to 1.59)	2436. 43 (2245. 05 to 2644. 02)	2119.65 (1945.98 to 2302.29)	-0.66 (-0.76 to -0.56)
Niger	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.87 (1.59 to 2.19)	1. 32 (1 to 1. 75)	1.31 (1.01 to 1.68)	-0.21 (-0.29 to -0.12)
Niger	Thalassemi as trait	15 (13 to 17)	41 (36 to 46)	1.76 (1.63 to 1.89)	184. 91 (162. 39 to 211. 8)	175. 51 (154. 79 to 199. 03)	-0.36 (-0.45 to -0.26)
Niger	Sickle cell disorders	7 (6 to 8)	13 (11 to 16)	0.94 (0.73 to 1.14)	85. 4 (71. 8 to 100. 28)	56. 92 (46. 71 to 68. 78)	-1.88 (-2.11 to -1.64)
Niger	Sickle cell trait	71 (65 to 79)	178 (161 to 200)	1.5 (1.36 to 1.65)	886. 22 (807. 06 to 979. 78)	762. 55 (689. 58 to 859. 85)	-0.71 (-0.81 to -0.61)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Niger	G6PD deficiency	33 (25 to 42)	82 (63 to 104)	1. 48 (1. 47 to 1. 5)	411.83 (317.54 to 520.67)	352. 2 (272. 47 to 445. 31)	-0.64 (-0.75 to -0.54)
Niger	G6PD trait	70 (63 to 76)	180 (163 to 195)	1.58 (1.56 to 1.61)	866.75 (785.2 to 942.01)	771. 17 (698. 11 to 836. 5)	-0.58 (-0.67 to -0.48)
Nigeria	Inherited anemias	2657 (2472 to 2863)	4519 (4182 to 4891)	0.7 (0.68 to 0.72)	2945. 58 (2740. 66 to 3174. 94)	2103. 52 (1946. 62 to 2276. 91)	-1.04 (-1.18 to -0.91)
Nigeria	Thalassemi as	0 (0 to 0)	0 (0 to 1)	2.13 (1.69 to 2.51)	0. 16 (0. 11 to 0. 23)	0. 22 (0. 14 to 0. 31)	0.69 (0.51 to 0.88)
Nigeria	Thalassemi as trait	50 (43 to 60)	107 (90 to 126)	1.13 (1.04 to 1.22)	55. 92 (47. 19 to 66. 76)	50.04 (42.08 to 58.85)	-0.52 (-0.67 to -0.37)
Nigeria	Sickle cell disorders	128 (94 to 171)	213 (153 to 289)	0.66 (0.58 to 0.74)	141. 93 (104. 68 to 189. 61)	98. 98 (71. 04 to 134. 42)	-1.4 (-1.48 to -1.31)
Nigeria	Sickle cell trait	1005 (858 to 1167)	1798 (1525 to 2090)	0.79 (0.76 to 0.82)	1114.7 (951.59 to 1293.65)	836. 95 (709. 77 to 972. 78)	-1.06 (-1.17 to -0.95)
Nigeria	G6PD deficiency	645 (618 to 670)	1106 (1057 to 1149)	0.71 (0.67 to 0.74)	715. 49 (684. 99 to 742. 83)	514. 72 (492. 11 to 535. 02)	-1.04 (-1.17 to -0.9)
Nigeria	G6PD trait	827 (815 to 838)	1295 (1273 to 1314)	0.56 (0.56 to 0.57)	917. 37 (903. 94 to 928. 92)	602. 62 (592. 72 to 611. 54)	-1.01 (-1.23 to -0.79)
Niue	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.48 (-0.5 to -0.47)	485. 7 (432. 92 to 544. 03)	348. 88 (308. 53 to 390. 86)	-1.18 (-1.43 to -0.93)
Niue	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.59 (-0.64 to -0.54)	2. 19 (1. 21 to 3. 52)	1. 24 (0. 68 to 1. 95)	-0.71 (-1.79 to 0.37)
Niue	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.55 (-0.58 to -0.53)	72.66 (55.82 to 91.15)	45. 14 (34. 57 to 55. 87)	-1.19 (-1.66 to -0.71)
Niue	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.52 (-0.55 to -0.32)	0 (0 to 0)	0 (0 to 0)	-1.57 (-1.71 to -1.42)
Niue	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.53 (-0.54 to -0.36)	2. 9 (1. 27 to 4. 69)	1.91 (0.82 to 3.03)	-1.57 (-1.7 to -1.44)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Niue	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0. 44 (-0. 46 to -0. 42)	100. 12 (77. 28 to 125. 37)	78.07 (60.14 to 96.91)	-0.98 (-1.27 to -0.69)
Niue	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.48 (-0.5 to -0.47)	307. 83 (276. 98 to 338. 44)	222. 51 (200. 82 to 242. 59)	-1.26 (-1.48 to -1.04)
North Macedonia	Inherited anemias	5 (5 to 6)	3 (3 to 4)	-0.35 (-0.36 to -0.34)	258. 91 (229. 08 to 292. 3)	158. 01 (140. 18 to 178. 42)	-1.84 (-2.07 to -1.61)
North Macedonia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.61 (-0.66 to -0.55)	1.58 (1.02 to 2.57)	0.58 (0.39 to 0.89)	-3.31 (-3.57 to -3.05)
North Macedonia	Thalassemi as trait	1 (1 to 1)	0 (0 to 1)	-0.34 (-0.38 to -0.29)	34. 45 (28. 96 to 41. 88)	21. 35 (17. 88 to 25. 54)	-1.61 (-1.88 to -1.33)
North Macedonia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.29 (-0.36 to -0.21)	0. 18 (0. 13 to 0. 23)	0. 12 (0. 09 to 0. 16)	-1.51 (-1.75 to -1.26)
North Macedonia	Sickle cell trait	1 (1 to 1)	0 (0 to 1)	-0.33 (-0.36 to -0.3)	33. 18 (28. 67 to 38. 32)	20.79 (17.91 to 24.01)	-1.61 (-1.85 to -1.36)
North Macedonia	G6PD deficiency	1 (1 to 2)	1 (1 to 1)	-0.32 (-0.32 to -0.31)	62. 94 (48. 69 to 78. 79)	40. 27 (31. 22 to 50. 43)	-2.41 (-2.73 to -2.09)
North Macedonia	G6PD trait	3 (2 to 3)	2 (1 to 2)	-0.37 (-0.38 to -0.35)	126. 58 (112 to 142. 07)	74. 91 (66. 28 to 84. 09)	-1.7 (-1.96 to -1.45)
Northern Mariana Islands	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.56 (-0.56 to -0.55)	580. 54 (515. 32 to 649. 09)	274. 48 (243. 52 to 306. 72)	-3.44 (-4.02 to -2.84)
Northern Mariana Islands	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.65 (-0.7 to -0.61)	2. 44 (1. 29 to 3. 86)	0.91 (0.48 to 1.43)	-3.05 (-3.89 to -2.21)
Northern Mariana Islands	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.62 (-0.64 to -0.6)	83.75 (63.64 to 104.08)	34. 32 (25. 88 to 42. 58)	-3.47 (-4.02 to -2.9)
Northern Mariana Islands	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.6 (-0.61 to -0.5)	0 (0 to 0)	0 (0 to 0)	-3.81 (-4.44 to -3.17)
Northern Mariana Islands	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.6 (-0.61 to -0.54)	3. 41 (1. 49 to 5. 48)	1. 47 (0. 64 to 2. 39)	-3.83 (-4.47 to -3.19)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Northern Mariana Islands	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0. 52 (-0. 54 to -0. 5)	121. 98 (93. 91 to 151. 59)	62. 25 (47. 86 to 77. 75)	-3. 26 (-3. 87 to -2. 64)
Northern Mariana Islands	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.55 (-0.56 to -0.55)	368. 96 (331. 93 to 405. 48)	175. 53 (158. 47 to 191. 09)	-3. 5 (-4. 12 to -2. 88)
Norway	Inherited anemias	11 (11 to 12)	11 (11 to 11)	-0.04 (-0.06 to -0.02)	269. 51 (258. 95 to 281. 55)	206. 11 (197. 93 to 214. 91)	-0.89 (-1.03 to -0.76)
Norway	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.12 (-0.17 to -0.04)	0.65 (0.47 to 0.89)	0.46 (0.34 to 0.6)	-1.45 (-1.7 to -1.2)
Norway	Thalassemi as trait	2 (2 to 2)	2 (2 to 2)	-0.08 (-0.11 to -0.04)	47.61 (40.96 to 55.2)	34.87 (30.25 to 39.8)	-1.15 (-1.26 to -1.03)
Norway	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.93 (0.4 to 1.45)	0. 14 (0. 09 to 0. 22)	0. 22 (0. 13 to 0. 34)	1.59 (0.62 to 2.56)
Norway	Sickle cell trait	1 (1 to 1)	1 (1 to 2)	0.37 (0.16 to 0.55)	22. 79 (17. 13 to 29. 63)	24.75 (19.25 to 31.37)	0.35 (-0.16 to 0.86)
Norway	G6PD deficiency	2 (2 to 2)	2 (1 to 2)	-0.03 (-0.04 to -0.02)	37. 49 (35. 73 to 39. 01)	28. 97 (27. 69 to 30. 16)	-0.88 (-0.97 to -0.79)
Norway	G6PD trait	7 (7 to 7)	6 (6 to 6)	-0.08 (-0.09 to -0.08)	160. 83 (157. 65 to 163. 82)	116.86 (114.53 to 118.97)	-1.04 (-1.17 to -0.92)
Oman	Inherited anemias	37 (35 to 38)	42 (38 to 46)	0.14 (0.04 to 0.25)	1887.85 (1822.21 to 1955.85)	915.61 (829.49 to 1007.03)	-2.23 (-2.42 to -2.03)
Oman	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.32 (0.17 to 0.51)	0.83 (0.6 to 1.17)	0.46 (0.34 to 0.62)	-1.74 (-1.96 to -1.53)
Oman	Thalassemi as trait	2 (2 to 3)	3 (2 to 3)	0. 26 (0. 19 to 0. 33)	115. 19 (98. 62 to 135. 36)	61.41 (52.82 to 71.15)	-1.89 (-2.11 to -1.67)
Oman	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 22 (0. 11 to 0. 33)	17. 63 (14. 99 to 20. 39)	9.09 (7.57 to 10.88)	-1.96 (-2.17 to -1.75)
Oman	Sickle cell trait	9 (8 to 9)	11 (10 to 11)	0. 19 (0. 14 to 0. 24)	454. 47 (421. 83 to 486. 44)	229. 75 (211. 35 to 249. 81)	-2.04 (-2.25 to -1.82)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Oman	G6PD deficiency	11 (10 to 12)	12 (9 to 15)	0. 04 (-0. 19 to 0. 27)	575. 73 (537. 56 to 613. 56)	252. 82 (195. 44 to 317. 05)	-2. 67 (-2. 82 to -2. 52)
Oman	G6PD trait	14 (14 to 14)	17 (15 to 18)	0.18 (0.1 to 0.25)	724 (704. 27 to 741. 71)	362.08 (337.81 to 384.01)	-2.08 (-2.3 to -1.85)
Pakistan	Inherited anemias	815 (751 to 893)	1147 (1059 to 1257)	0.41 (0.38 to 0.43)	722. 34 (665. 95 to 791. 59)	512 (472.63 to 561.06)	-1.33 (-1.46 to -1.2)
Pakistan	Thalassemi as	5 (4 to 8)	7 (5 to 11)	0. 37 (0. 25 to 0. 47)	4. 83 (3. 17 to 7. 41)	3. 32 (2. 17 to 5. 08)	-1.4 (-1.54 to -1.25)
Pakistan	Thalassemi as trait	336 (278 to 411)	460 (380 to 563)	0. 37 (0. 32 to 0. 42)	297. 57 (246. 73 to 364. 2)	205. 09 (169. 61 to 251. 3)	-1.39 (-1.54 to -1.24)
Pakistan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.36 (0.24 to 0.56)	0.03 (0.02 to 0.04)	0.02 (0.01 to 0.03)	-1.42 (-1.6 to -1.24)
Pakistan	Sickle cell trait	21 (17 to 25)	28 (23 to 34)	0.36 (0.3 to 0.49)	18. 41 (15. 09 to 22. 31)	12. 65 (10. 38 to 15. 24)	-1. 4 (-1. 57 to -1. 23)
Pakistan	G6PD deficiency	147 (140 to 154)	214 (205 to 224)	0.46 (0.43 to 0.49)	129. 92 (123. 98 to 136. 11)	95. 53 (91. 29 to 99. 86)	-1.52 (-1.79 to -1.26)
Pakistan	G6PD trait	306 (297 to 315)	438 (423 to 455)	0.43 (0.41 to 0.46)	271. 58 (263. 59 to 279. 24)	195. 39 (188. 74 to 202. 9)	-1.17 (-1.41 to -0.94)
Palau	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.43 (-0.45 to -0.41)	506. 62 (452. 17 to 565. 89)	246. 48 (218. 51 to 274. 43)	-2.35 (-2.57 to -2.12)
Palau	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.54 (-0.6 to -0.48)	2. 2 (1. 22 to 3. 39)	0.86 (0.47 to 1.32)	-1. 9 (-3. 03 to -0. 75)
Palau	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0. 5 (-0. 53 to -0. 47)	73.89 (56.95 to 90.97)	31. 3 (24. 06 to 38. 21)	-2.35 (-2.89 to -1.81)
Palau	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.49 (-0.51 to -0.42)	0 (0 to 0)	0 (0 to 0)	-2.73 (-2.94 to -2.51)
Palau	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.49 (-0.49 to -0.44)	2. 98 (1. 3 to 4. 85)	1. 3 (0. 57 to 2. 11)	-2.76 (-2.98 to -2.55)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Palau	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0. 38 (-0. 43 to -0. 34)	106. 66 (82. 71 to 132. 67)	56. 32 (43. 62 to 69. 97)	-2. 15 (-2. 34 to -1. 95)
Palau	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.43 (-0.45 to -0.41)	320. 89 (289. 18 to 351. 54)	156.69 (141.9 to 170.1)	-2. 43 (-2. 59 to -2. 26)
Palestine	Inherited anemias	32 (29 to 35)	43 (39 to 46)	0.33 (0.31 to 0.36)	1545. 18 (1403. 63 to 1689. 88)	859. 69 (782. 61 to 937. 47)	-2.09 (-2.26 to -1.93)
Palestine	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0. 4 (0. 22 to 0. 58)	3. 18 (2. 09 to 4. 82)	1.85 (1.25 to 2.76)	-1.91 (-2.07 to -1.75)
Palestine	Thalassemi as trait	5 (4 to 6)	7 (6 to 9)	0.38 (0.29 to 0.46)	253 (209. 84 to 306. 53)	145.39 (121.06 to 174.99)	-1.95 (-2.12 to -1.78)
Palestine	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.4 (0.29 to 0.51)	4. 82 (3. 67 to 6. 11)	2.81 (2.14 to 3.6)	-2.42 (-2.66 to -2.18)
Palestine	Sickle cell trait	6 (5 to 7)	8 (7 to 9)	0.35 (0.3 to 0.4)	287. 33 (252. 16 to 323. 31)	161.89 (142.13 to 183.01)	-2.26 (-2.44 to -2.07)
Palestine	G6PD deficiency	5 (4 to 7)	7 (5 to 9)	0.31 (0.24 to 0.38)	260. 43 (201. 06 to 324. 38)	142.51 (110.16 to 179.19)	-2.08 (-2.24 to -1.91)
Palestine	G6PD trait	15 (14 to 17)	20 (18 to 22)	0.32 (0.31 to 0.33)	736. 42 (667. 84 to 799. 48)	405. 24 (367. 49 to 439. 01)	-2.08 (-2.24 to -1.92)
Panama	Inherited anemias	11 (9 to 12)	12 (10 to 13)	0.13 (0.1 to 0.15)	441. 15 (386. 84 to 494. 72)	285. 61 (251. 68 to 321. 87)	-1. 4 (-1. 53 to -1. 28)
Panama	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1. 22 (0. 29 to 3. 74)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.02)	0.84 (0.61 to 1.06)
Panama	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.62 (0.29 to 1.22)	6. 53 (4. 65 to 8. 79)	6.06 (4.47 to 7.8)	-0.21 (-0.3 to -0.12)
Panama	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.31 (0.14 to 0.54)	0.06 (0.03 to 0.11)	0.05 (0.03 to 0.08)	-0.95 (-1.06 to -0.84)
Panama	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0. 22 (-0. 23 to 0. 29)	2. 68 (1. 1 to 4. 23)	1.87 (0.82 to 3.04)	-1.05 (-1.17 to -0.94)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Panama	G6PD deficiency	2 (2 to 3)	2 (2 to 3)	-0.03 (-0.07 to 0.02)	89. 53 (69. 2 to 112. 95)	49. 77 (38. 26 to 62. 55)	-1.89 (-2.14 to -1.64)
Panama	G6PD trait	8 (7 to 9)	9 (9 to 10)	0.16 (0.13 to 0.19)	342. 33 (308. 21 to 373. 07)	227. 84 (204. 76 to 251. 56)	-1.32 (-1.42 to -1.21)
Papua New Guinea	Inherited anemias	40 (37 to 43)	95 (86 to 105)	1.37 (1.27 to 1.49)	984. 1 (909. 67 to 1060. 2)	967.75 (869.59 to 1068.84)	-0.18 (-0.34 to -0.01)
Papua New Guinea	Thalassemi as	0 (0 to 0)	1 (0 to 1)	1.06 (0.87 to 1.27)	7. 44 (4. 99 to 10. 24)	6. 35 (4. 31 to 8. 9)	0.35 (-0.37 to 1.08)
Papua New Guinea	Thalassemi as trait	12 (11 to 14)	27 (23 to 31)	1.18 (1.1 to 1.27)	302. 19 (261. 47 to 344. 91)	273. 17 (235. 45 to 313. 31)	-0.11 (-0.31 to 0.09)
Papua New Guinea	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	1. 32 (1. 21 to 2. 4)	0 (0 to 0.01)	0 (0 to 0.01)	-0.06 (-0.16 to 0.05)
Papua New Guinea	Sickle cell trait	0 (0 to 0)	0 (0 to 1)	1. 28 (1. 21 to 2. 17)	5. 27 (2. 28 to 8. 76)	4. 99 (2. 09 to 8. 64)	-0.14 (-0.22 to -0.06)
Papua New Guinea	G6PD deficiency	10 (9 to 11)	18 (14 to 23)	0.85 (0.48 to 1.23)	242. 23 (224. 09 to 260. 24)	185. 22 (143. 19 to 231. 7)	-0.94 (-1.19 to -0.68)
Papua New Guinea	G6PD trait	17 (16 to 19)	49 (44 to 54)	1.82 (1.74 to 1.91)	426. 95 (382. 22 to 472. 04)	498. 01 (450. 43 to 545. 96)	0.08 (-0.18 to 0.33)
Paraguay	Inherited anemias	23 (20 to 25)	23 (20 to 25)	0 (-0.02 to 0.04)	558. 38 (497. 58 to 621. 15)	327. 34 (292. 2 to 364. 94)	-1.71 (-1.81 to -1.62)
Paraguay	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.36 (-0.07 to 1.08)	0.03 (0.02 to 0.04)	0.02 (0.01 to 0.03)	-0.68 (-0.79 to -0.57)
Paraguay	Thalassemi as trait	1 (1 to 1)	1 (1 to 1)	0.1 (-0.06 to 0.29)	18. 11 (15. 42 to 21. 31)	11.6 (9.8 to 13.44)	-1.38 (-1.43 to -1.32)
Paraguay	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.05 (-0.04 to 0.15)	0. 6 (0. 47 to 0. 76)	0.37 (0.28 to 0.47)	-2 (-2.21 to -1.79)
Paraguay	Sickle cell trait	3 (3 to 4)	3 (3 to 4)	0.02 (-0.03 to 0.08)	75. 78 (65. 55 to 87. 73)	45. 28 (38. 89 to 52. 38)	-1.9 (-2.04 to -1.75)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Paraguay	G6PD deficiency	4 (3 to 5)	4 (3 to 5)	-0.01 (-0.04 to 0.03)	95. 03 (72. 85 to 119. 42)	55. 14 (42. 41 to 69. 12)	-1.69 (-1.79 to -1.6)
Paraguay	G6PD trait	15 (13 to 16)	15 (13 to 16)	0 (-0.03 to 0.03)	368. 83 (329. 86 to 407. 56)	214. 93 (192. 94 to 237. 63)	-1.7 (-1.79 to -1.6)
Peru	Inherited anemias	103 (93 to 114)	113 (99 to 127)	0.09 (0.05 to 0.13)	475. 11 (426. 74 to 525. 42)	331. 3 (292. 57 to 373. 64)	-1.54 (-1.64 to -1.44)
Peru	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.35 (-0.04 to 1.1)	0.03 (0.02 to 0.04)	0.02 (0.02 to 0.03)	-0.45 (-0.59 to -0.3)
Peru	Thalassemi as trait	4 (3 to 5)	4 (4 to 5)	0.07 (-0.07 to 0.24)	19.02 (16.01 to 22.4)	13 (10.87 to 15.19)	-1.25 (-1.29 to -1.21)
Peru	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.02 (-0.12 to 0.07)	0.16 (0.11 to 0.22)	0.1 (0.07 to 0.14)	-1.41 (-1.48 to -1.34)
Peru	Sickle cell trait	9 (8 to 11)	9 (7 to 11)	-0.03 (-0.08 to 0.01)	42.58 (35.35 to 50.91)	26. 44 (21. 85 to 31. 64)	-1.51 (-1.55 to -1.47)
Peru	G6PD deficiency	10 (8 to 13)	25 (19 to 31)	1.4 (1.23 to 1.55)	48.03 (37.48 to 60.01)	73. 57 (57. 18 to 92. 44)	-0.85 (-1.54 to -0.16)
Peru	G6PD trait	79 (71 to 88)	74 (66 to 82)	-0.07 (-0.1 to -0.02)	365. 29 (327. 83 to 404. 83)	218. 17 (194. 98 to 241. 3)	-1.7 (-1.73 to -1.67)
Philippines	Inherited anemias	400 (377 to 430)	485 (455 to 526)	0.21 (0.2 to 0.23)	631. 29 (595. 33 to 679. 73)	432. 76 (406. 12 to 468. 75)	-1.14 (-1.24 to -1.04)
Philippines	Thalassemi as	2 (2 to 4)	4 (3 to 5)	0. 44 (0. 39 to 0. 49)	3. 92 (2. 79 to 5. 58)	3. 18 (2. 27 to 4. 51)	-0.5 (-0.64 to -0.37)
Philippines	Thalassemi as trait	135 (114 to 163)	182 (154 to 219)	0.35 (0.33 to 0.37)	213. 21 (179. 59 to 256. 83)	162. 43 (137. 09 to 195. 4)	-0.82 (-0.89 to -0.75)
Philippines	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 22 (0. 06 to 0. 33)	0.03 (0.02 to 0.04)	0.02 (0.01 to 0.03)	-1.3 (-1.38 to -1.23)
Philippines	Sickle cell trait	11 (10 to 14)	14 (12 to 17)	0. 25 (0. 17 to 0. 31)	18. 14 (15. 29 to 21. 44)	12.79 (10.91 to 15.01)	-1.19 (-1.23 to -1.15)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Philippines	G6PD deficiency	50 (48 to 52)	62 (59 to 64)	0. 24 (0. 22 to 0. 26)	78.71 (75.13 to 81.97)	55. 11 (52. 57 to 57. 33)	-1.02 (-1.1 to -0.93)
Philippines	G6PD trait	201 (197 to 204)	223 (219 to 227)	0. 11 (0. 11 to 0. 12)	317. 29 (310. 81 to 322. 78)	199. 24 (195. 02 to 202. 84)	-1.41 (-1.57 to -1.26)
Poland	Inherited anemias	76 (74 to 79)	53 (52 to 55)	-0.3 (-0.3 to -0.3)	199. 93 (193. 09 to 207. 3)	138. 87 (134. 27 to 143. 96)	-0.89 (-1.23 to -0.55)
Poland	Thalassemi as	0 (0 to 1)	0 (0 to 0)	-0.58 (-0.6 to -0.55)	1. 22 (0. 81 to 1. 92)	0.51 (0.35 to 0.77)	-2. 4 (-2. 76 to -2. 03)
Poland	Thalassemi as trait	10 (9 to 13)	7 (6 to 9)	-0.29 (-0.32 to -0.27)	26. 73 (22. 34 to 32. 85)	18. 73 (15. 78 to 22. 56)	-0.66 (-1.02 to -0.3)
Poland	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.28 (-0.31 to -0.25)	0.13 (0.1 to 0.17)	0.09 (0.07 to 0.12)	-0.95 (-1.26 to -0.64)
Poland	Sickle cell trait	10 (8 to 11)	7 (6 to 8)	-0.3 (-0.31 to -0.29)	25. 09 (21. 71 to 28. 7)	17. 45 (15. 02 to 20. 07)	-0.83 (-1.16 to -0.51)
Poland	G6PD deficiency	18 (17 to 19)	13 (13 to 14)	-0. 26 (-0. 27 to -0. 26)	47. 22 (45. 1 to 49. 25)	34. 61 (33. 01 to 36. 06)	-1.44 (-1.86 to -1.01)
Poland	G6PD trait	38 (37 to 39)	26 (25 to 27)	-0.32 (-0.32 to -0.32)	99. 53 (97. 3 to 101. 73)	67. 47 (65. 97 to 68. 97)	-0.72 (-1.08 to -0.36)
Portugal	Inherited anemias	24 (22 to 27)	16 (15 to 18)	-0.33 (-0.35 to -0.3)	240. 16 (218. 39 to 263. 32)	153. 59 (139. 11 to 168. 36)	-1.65 (-1.82 to -1.47)
Portugal	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.34 (-0.45 to -0.24)	0.13 (0.08 to 0.18)	0.08 (0.05 to 0.12)	-2.72 (-3.85 to -1.58)
Portugal	Thalassemi as trait	1 (1 to 1)	1 (1 to 1)	-0. 29 (-0. 35 to -0. 22)	11. 2 (9. 44 to 13. 01)	7.56 (6.31 to 9.06)	-1.78 (-2.29 to -1.27)
Portugal	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.44 (-0.53 to -0.34)	1.61 (1.13 to 2.28)	0.86 (0.61 to 1.2)	-2.43 (-2.58 to -2.29)
Portugal	Sickle cell trait	8 (7 to 10)	5 (4 to 6)	-0.38 (-0.43 to -0.33)	80. 23 (67. 21 to 95. 41)	47. 32 (39. 59 to 56. 17)	-1.97 (-2.07 to -1.86)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Portugal	G6PD deficiency	1 (1 to 2)	1 (1 to 2)	-0.07 (-0.15 to 0)	13.95 (11.46 to 16.9)	12. 39 (9. 52 to 15. 74)	-0.84 (-1.11 to -0.57)
Portugal	G6PD trait	13 (12 to 15)	9 (8 to 10)	-0.33 (-0.35 to -0.3)	133.04 (119.6 to 147)	85. 38 (76. 45 to 94. 51)	-1.55 (-1.75 to -1.35)
Puerto Rico	Inherited anemias	16 (14 to 18)	6 (6 to 7)	-0.6 (-0.62 to -0.59)	444. 38 (390. 44 to 503. 75)	180. 24 (158. 19 to 204. 37)	-3. 19 (-3. 41 to -2. 97)
Puerto Rico	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.37 (-0.61 to 0.36)	0.01 (0 to 0.01)	0 (0 to 0.01)	-1.75 (-2.2 to -1.31)
Puerto Rico	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.54 (-0.61 to -0.4)	5. 99 (4. 58 to 7. 46)	2.81 (2.19 to 3.43)	-2.76 (-3.06 to -2.45)
Puerto Rico	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.56 (-0.61 to -0.5)	2. 77 (2. 05 to 3. 62)	1. 25 (0. 91 to 1. 68)	-2.89 (-3 to -2.78)
Puerto Rico	Sickle cell trait	4 (4 to 5)	2 (2 to 2)	-0.59 (-0.61 to -0.56)	124. 26 (105. 23 to 144. 52)	52. 2 (43. 53 to 61. 35)	-3.09 (-3.25 to -2.92)
Puerto Rico	G6PD deficiency	5 (4 to 6)	2 (2 to 2)	-0.61 (-0.64 to -0.59)	141.96 (109.7 to 177.5)	56. 52 (43. 45 to 69. 89)	-3. 24 (-3. 5 to -2. 99)
Puerto Rico	G6PD trait	6 (5 to 7)	2 (2 to 3)	-0.61 (-0.62 to -0.6)	169. 4 (150. 71 to 189. 03)	67. 46 (60. 02 to 75. 22)	-3.24 (-3.48 to -3)
Qatar	Inherited anemias	3 (3 to 4)	9 (8 to 9)	1.58 (1.52 to 1.64)	757. 46 (688. 61 to 830. 24)	303. 1 (275. 42 to 331. 44)	-3.17 (-3.36 to -2.97)
Qatar	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1. 78 (1. 45 to 2. 16)	0. 62 (0. 42 to 0. 89)	0. 27 (0. 19 to 0. 37)	-3 (-3.19 to -2.8)
Qatar	Thalassemi as trait	0 (0 to 0)	1 (1 to 1)	1.69 (1.54 to 1.85)	82.07 (68.85 to 97.53)	34. 27 (28. 88 to 40. 36)	-3.07 (-3.27 to -2.87)
Qatar	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	1.55 (1.36 to 1.73)	2. 72 (2. 1 to 3. 47)	1. 08 (0. 83 to 1. 37)	-3. 15 (-3. 37 to -2. 93)
Qatar	Sickle cell trait	1 (1 to 1)	2 (2 to 2)	1.54 (1.44 to 1.63)	154. 23 (136. 04 to 173. 99)	60.84 (53.62 to 68.66)	-3. 19 (-3. 4 to -2. 98)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Qatar	G6PD deficiency	1 (0 to 1)	2 (1 to 2)	1.55 (1.43 to 1.68)	136.83 (105.46 to 169.9)	54. 21 (41. 92 to 68. 26)	-3.19 (-3.39 to -3)
Qatar	G6PD trait	2 (2 to 2)	4 (4 to 5)	1.57 (1.51 to 1.66)	380. 99 (345. 93 to 413. 41)	152. 44 (138. 89 to 164. 74)	-3.17 (-3.36 to -2.97)
Republic of Korea	Inherited anemias	52 (46 to 58)	30 (26 to 33)	-0.43 (-0.45 to -0.4)	116.68 (103.36 to 131.16)	55. 53 (49. 26 to 62. 14)	-2.96 (-3.06 to -2.85)
Republic of Korea	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.5 (-0.56 to -0.41)	0.69 (0.46 to 1.07)	0. 29 (0. 2 to 0. 43)	-3. 12 (-3. 27 to -2. 97)
Republic of Korea	Thalassemi as trait	3 (3 to 4)	3 (3 to 4)	0.07 (-0.05 to 0.19)	7. 18 (5. 66 to 8. 86)	6. 36 (4. 85 to 7. 78)	-0.67 (-0.96 to -0.39)
Republic of Korea	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.49 to -0.33)	0. 02 (0. 01 to 0. 02)	0.01 (0.01 to 0.01)	-2. 44 (-2. 7 to -2. 19)
Republic of Korea	Sickle cell trait	3 (3 to 4)	2 (2 to 2)	-0.42 (-0.46 to -0.33)	7. 44 (6. 02 to 9. 14)	3. 6 (2. 88 to 4. 35)	-2.51 (-2.72 to -2.3)
Republic of Korea	G6PD deficiency	3 (3 to 4)	2 (1 to 2)	-0.52 (-0.56 to -0.49)	7. 82 (5. 93 to 10. 02)	3. 1 (2. 33 to 3. 99)	-4.77 (-5.23 to -4.31)
Republic of Korea	G6PD trait	41 (36 to 47)	23 (20 to 26)	-0.46 (-0.48 to -0.43)	93.53 (81.89 to 105.49)	42. 17 (36. 67 to 47. 82)	-3.11 (-3.21 to -3.01)
Republic of Moldova	Inherited anemias	10 (9 to 11)	4 (4 to 5)	-0.57 (-0.58 to -0.57)	223. 49 (198. 54 to 250. 51)	114.65 (102.07 to 128.35)	-1.57 (-1.9 to -1.25)
Republic of Moldova	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.71 (-0.74 to -0.67)	1.06 (0.73 to 1.55)	0. 37 (0. 27 to 0. 53)	-2.81 (-3.14 to -2.47)
Republic of Moldova	Thalassemi as trait	2 (2 to 2)	1 (1 to 1)	-0.56 (-0.59 to -0.53)	45. 71 (38 to 55. 49)	24. 24 (20. 21 to 29)	-1.46 (-1.77 to -1.14)
Republic of Moldova	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.56 (-0.62 to -0.47)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	-1.5 (-1.79 to -1.21)
Republic of Moldova	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.57 (-0.6 to -0.53)	8. 59 (6. 85 to 10. 52)	4. 42 (3. 56 to 5. 4)	-1.54 (-1.85 to -1.22)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Republic of Moldova	G6PD deficiency	2 (1 to 2)	1 (1 to 1)	-0.55 (-0.55 to -0.55)	34. 85 (26. 75 to 43. 36)	18. 87 (14. 49 to 23. 48)	-1.7 (-2.02 to -1.37)
Republic of Moldova	G6PD trait	6 (5 to 7)	2 (2 to 3)	-0.58 (-0.58 to -0.58)	133. 28 (118. 43 to 149. 2)	66. 75 (59. 31 to 74. 72)	-1.58 (-1.91 to -1.24)
Romania	Inherited anemias	35 (31 to 40)	25 (22 to 28)	-0.3 (-0.32 to -0.29)	151.06 (134.31 to 169.07)	128. 03 (112. 78 to 144. 34)	-0.54 (-0.74 to -0.33)
Romania	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.64 (-0.68 to -0.59)	1. 17 (0. 74 to 1. 87)	0.51 (0.33 to 0.8)	-2.3 (-2.48 to -2.12)
Romania	Thalassemi as trait	3 (2 to 3)	2 (2 to 2)	-0.34 (-0.4 to -0.27)	12.11 (10.26 to 14.51)	9.67 (8.24 to 11.28)	-0.31 (-0.5 to -0.12)
Romania	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.29 (-0.36 to -0.21)	0.13 (0.1 to 0.17)	0.11 (0.08 to 0.15)	-0.19 (-0.37 to -0.01)
Romania	Sickle cell trait	5 (5 to 6)	4 (3 to 4)	-0.35 (-0.38 to -0.31)	23. 11 (19. 85 to 26. 67)	18. 23 (15. 56 to 21. 15)	-0.37 (-0.54 to -0.2)
Romania	G6PD deficiency	6 (4 to 7)	7 (5 to 8)	0.14 (0.06 to 0.21)	24.86 (19.07 to 30.92)	34. 38 (26. 38 to 42. 93)	-1.09 (-1.87 to -0.29)
Romania	G6PD trait	21 (19 to 23)	13 (11 to 14)	-0. 4 (-0. 4 to -0. 4)	89.68 (79.11 to 100.41)	65. 13 (57. 46 to 72. 93)	-0.52 (-0.71 to -0.33)
Russian Federation	Inherited anemias	241 (231 to 253)	215 (206 to 225)	-0.11 (-0.11 to -0.1)	159.55 (153.01 to 167.71)	146. 34 (140. 38 to 153. 57)	1.3 (0.78 to 1.82)
Russian Federation	Thalassemi as	1 (1 to 2)	1 (1 to 1)	-0.41 (-0.45 to -0.35)	0.81 (0.56 to 1.18)	0.49 (0.36 to 0.7)	-0.07 (-0.59 to 0.45)
Russian Federation	Thalassemi as trait	50 (41 to 61)	45 (38 to 55)	-0.09 (-0.11 to -0.06)	32.96 (27.43 to 40.3)	30. 95 (25. 92 to 37. 62)	1.38 (0.87 to 1.89)
Russian Federation	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.09 (-0.13 to -0.01)	0.01 (0.01 to 0.01)	0.01 (0.01 to 0.01)	1. 33 (0. 85 to 1. 82)
Russian Federation	Sickle cell trait	9 (8 to 11)	8 (7 to 10)	-0.11 (-0.13 to -0.07)	6. 2 (5. 01 to 7. 54)	5. 69 (4. 66 to 6. 93)	1. 32 (0. 82 to 1. 83)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Russian Federation	G6PD deficiency	37 (35 to 38)	35 (33 to 36)	-0.06 (-0.06 to -0.06)	24. 32 (23. 21 to 25. 35)	23. 52 (22. 45 to 24. 52)	1. 18 (0. 68 to 1. 68)
Russian Federation	G6PD trait	144 (141 to 147)	126 (123 to 128)	-0.13 (-0.13 to -0.13)	95. 26 (93. 1 to 97. 25)	85. 67 (83. 75 to 87. 47)	1.31 (0.78 to 1.84)
Rwanda	Inherited anemias	70 (62 to 78)	70 (63 to 79)	0.01 (-0.02 to 0.04)	972.78 (861.79 to 1092.44)	554. 94 (495. 17 to 622. 33)	-1.95 (-2.13 to -1.77)
Rwanda	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1. 52 (1. 21 to 2. 1)	0.09 (0.05 to 0.13)	0. 12 (0. 07 to 0. 19)	0.8 (0.57 to 1.03)
Rwanda	Thalassemi as trait	2 (1 to 2)	3 (2 to 3)	0. 62 (0. 51 to 0. 84)	21.65 (17.04 to 26.91)	19.84 (15.25 to 24.83)	-0.56 (-0.72 to -0.4)
Rwanda	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.03 (-0.07 to 0.14)	1. 16 (0. 86 to 1. 54)	0.68 (0.5 to 0.91)	-1.75 (-2.21 to -1.3)
Rwanda	Sickle cell trait	10 (9 to 12)	11 (9 to 12)	0.07 (0.01 to 0.12)	139. 12 (120. 14 to 160. 92)	83. 98 (72. 1 to 97. 77)	-1.73 (-2.01 to -1.44)
Rwanda	G6PD deficiency	16 (13 to 20)	13 (10 to 17)	-0.17 (-0.23 to -0.1)	225. 8 (174. 42 to 283. 79)	105.61 (81.84 to 132.01)	-2.47 (-2.76 to -2.18)
Rwanda	G6PD trait	42 (38 to 46)	44 (39 to 48)	0.04 (0.01 to 0.08)	584. 96 (525. 49 to 638. 97)	344.7 (309.55 to 381)	-1.89 (-2.02 to -1.76)
Saint Kitts and Nevis	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0. 2 (-0. 23 to -0. 17)	570.75 (503.15 to 646.04)	317. 02 (278. 36 to 358. 03)	-2.03 (-2.06 to -2.01)
Saint Kitts and Nevis	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.28 (-0.23 to 1.5)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.01)	-0.5 (-0.79 to -0.2)
Saint Kitts and Nevis	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.08 (-0.23 to 0.15)	8. 05 (6. 24 to 10. 17)	5. 14 (4. 02 to 6. 25)	-1.58 (-1.71 to -1.45)
Saint Kitts and Nevis	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.1 (-0.2 to 0.01)	5. 82 (4. 23 to 7. 79)	3. 65 (2. 59 to 4. 94)	-1.71 (-1.87 to -1.56)
Saint Kitts and Nevis	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.17 (-0.22 to -0.12)	182. 98 (152. 32 to 215. 71)	105.89 (87.87 to 126.49)	-1.91 (-1.97 to -1.86)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Saint Kitts and Nevis	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0. 22 (-0. 29 to -0. 15)	170. 17 (131. 37 to 211. 35)	91.74 (70.87 to 113.56)	-2. 12 (-2. 18 to -2. 06)
Saint Kitts and Nevis	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0. 22 (-0. 25 to -0. 18)	203. 71 (182. 03 to 224. 53)	110. 59 (98. 5 to 123. 18)	-2. 1 (-2. 15 to -2. 06)
Saint Lucia	Inherited anemias	1 (1 to 1)	0 (0 to 1)	-0.53 (-0.55 to -0.52)	757. 24 (667. 25 to 856. 73)	279 (245. 86 to 314. 91)	-3.58 (-3.72 to -3.44)
Saint Lucia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.23 (-0.53 to 0.54)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	-1.95 (-2.13 to -1.77)
Saint Lucia	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.45 (-0.53 to -0.29)	9. 93 (7. 53 to 12. 75)	4. 3 (3. 34 to 5. 21)	-2.99 (-3.04 to -2.93)
Saint Lucia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.51 (-0.57 to -0.44)	9. 1 (6. 59 to 12. 23)	3. 51 (2. 5 to 4. 66)	-3.77 (-4.14 to -3.39)
Saint Lucia	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.53 (-0.56 to -0.5)	253. 67 (210. 32 to 298. 6)	93. 25 (77. 6 to 109. 73)	-3.75 (-4 to -3.51)
Saint Lucia	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.54 (-0.56 to -0.5)	220. 73 (170. 43 to 278. 26)	80.71 (62.34 to 99.95)	-3.51 (-3.6 to -3.43)
Saint Lucia	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.53 (-0.56 to -0.51)	263. 8 (234. 77 to 294. 71)	97. 22 (86. 71 to 106. 93)	-3.49 (-3.59 to -3.4)
Saint Vincent and the Grenadines	Inherited anemias	1 (1 to 1)	0 (0 to 0)	-0.44 (-0.46 to -0.42)	679. 95 (603. 66 to 768. 78)	369. 83 (325. 38 to 417. 44)	-2. 09 (-2. 16 to -2. 02)
Saint Vincent and the Grenadines	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.04 (-0.43 to 0.84)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.02)	-0.44 (-0.68 to -0.19)
Saint Vincent and the Grenadines	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.32 (-0.43 to -0.15)	8. 92 (6. 94 to 11. 23)	5. 89 (4. 59 to 7. 15)	-1.52 (-1.6 to -1.45)
Saint Vincent and the Grenadines	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.46 (-0.52 to -0.39)	8. 93 (6. 47 to 12. 2)	4. 7 (3. 34 to 6. 36)	-2. 12 (-2. 43 to -1. 81)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Saint				-0. 47	239. 89	124. 5	-2. 17
Vincent and the	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	(-0.5 to -0.44)	(200. 09 to 287. 38)	(103. 26 to 148. 03)	(-2.35 to -1.99)
Grenadines Saint							
Vincent and the Grenadines	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0. 43 (-0. 47 to -0. 4)	193. 14 (149. 67 to 241. 61)	106. 56 (82. 39 to 133. 6)	-2. 08 (-2. 11 to -2. 05)
Saint Vincent and the Grenadines	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.45 to -0.4)	229. 07 (204. 62 to 254. 14)	128. 17 (114. 29 to 142. 09)	-2.04 (-2.07 to -2.01)
Samoa	Inherited anemias	1 (1 to 1)	1 (1 to 1)	0. 26 (0. 24 to 0. 29)	398. 49 (354. 89 to 445. 34)	389. 96 (346. 72 to 436. 58)	0.17 (-0.15 to 0.49)
Samoa	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.02 (-0.09 to 0.17)	1. 98 (1. 08 to 3. 07)	1. 57 (0. 87 to 2. 41)	0.56 (-0.48 to 1.61)
Samoa	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.1 (0.04 to 0.17)	62. 37 (48. 02 to 76. 16)	53. 21 (41. 03 to 64. 8)	0.12 (-0.36 to 0.61)
Samoa	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 23 (0. 13 to 1. 78)	0 (0 to 0)	0 (0 to 0)	0.01 (-0.32 to 0.34)
Samoa	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0. 21 (0. 13 to 1. 27)	2. 37 (1. 03 to 3. 83)	2. 23 (0. 96 to 3. 43)	-0.04 (-0.35 to 0.26)
Samoa	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0.37 (0.31 to 0.46)	82.67 (63.91 to 102.53)	87. 89 (68. 1 to 109. 55)	0.38 (0.01 to 0.75)
Samoa	G6PD trait	0 (0 to 0)	1 (0 to 1)	0. 27 (0. 25 to 0. 3)	249. 1 (223. 93 to 272. 51)	245. 06 (222. 19 to 266. 49)	0.09 (-0.2 to 0.39)
San Marino	Inherited anemias	0 (0 to 0)	0 (0 to 0)	0. 17 (0. 14 to 0. 2)	200. 39 (179. 41 to 222. 43)	167. 17 (149. 56 to 186. 1)	-0.85 (-1.04 to -0.67)
San Marino	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.11 (-0.06 to 0.27)	0. 14 (0. 1 to 0. 2)	0.11 (0.08 to 0.15)	-1.84 (-2.74 to -0.92)
San Marino	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0. 2 (0. 13 to 0. 28)	17.71 (15.35 to 20.34)	15. 16 (13. 04 to 17. 41)	-0.95 (-1.28 to -0.61)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
San Marino	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 09 (-0. 02 to 0. 2)	0. 16 (0. 11 to 0. 21)	0. 12 (0. 09 to 0. 16)	-1.15 (-1.36 to -0.93)
San Marino	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0.12 (0.04 to 0.18)	21.87 (17.68 to 26.05)	17.41 (14.33 to 20.95)	-1.04 (-1.24 to -0.84)
San Marino	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0.23 (0.2 to 0.28)	31. 37 (24. 12 to 39. 07)	27. 55 (21. 18 to 34. 55)	-0.68 (-0.83 to -0.54)
San Marino	G6PD trait	0 (0 to 0)	0 (0 to 0)	0. 16 (0. 12 to 0. 21)	129. 14 (115. 68 to 142. 89)	106. 82 (95. 51 to 118. 18)	-0.85 (-1.03 to -0.67)
Sao Tome and Principe	Inherited anemias	2 (2 to 2)	2 (2 to 2)	-0.07 (-0.1 to -0.05)	1714. 01 (1547. 72 to 1887. 84)	940. 34 (852. 04 to 1025. 99)	-2.15 (-2.44 to -1.85)
Sao Tome and Principe	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.3 (0.12 to 0.51)	0. 26 (0. 18 to 0. 38)	0. 2 (0. 14 to 0. 28)	-1.02 (-1.26 to -0.77)
Sao Tome and Principe	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.1 (0.04 to 0.17)	69.96 (58.25 to 84.58)	45. 62 (38. 27 to 54. 58)	-1.58 (-1.82 to -1.33)
Sao Tome and Principe	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.29 (-0.37 to -0.19)	40.46 (30.52 to 52.9)	17.01 (12.74 to 22.12)	-2.98 (-3.49 to -2.47)
Sao Tome and Principe	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	-0.16 (-0.2 to -0.1)	680. 97 (597. 13 to 773. 93)	338. 83 (291. 94 to 386. 61)	-2.45 (-2.82 to -2.08)
Sao Tome and Principe	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.04 (-0.11 to 0.03)	304. 6 (235. 47 to 377. 86)	172. 83 (133. 49 to 214. 68)	-1.99 (-2.26 to -1.73)
Sao Tome and Principe	G6PD trait	1 (1 to 1)	1 (1 to 1)	0 (-0.03 to 0.03)	617. 77 (560. 24 to 670. 66)	365. 85 (332. 1 to 397. 06)	-1.92 (-2.16 to -1.67)
Saudi Arabia	Inherited anemias	306 (297 to 314)	211 (192 to 230)	-0.31 (-0.37 to -0.25)	1904.66 (1852.19 to 1956.93)	589. 5 (538. 6 to 643. 96)	-4.05 (-4.27 to -3.84)
Saudi Arabia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.11 (-0.19 to 0)	2. 05 (1. 55 to 2. 57)	0.82 (0.63 to 1.06)	-3.17 (-3.24 to -3.1)
Saudi Arabia	Thalassemi as trait	28 (25 to 31)	25 (22 to 28)	-0.11 (-0.15 to -0.06)	174. 44 (153. 36 to 194. 23)	69.38 (61.41 to 78.72)	-3.19 (-3.26 to -3.13)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Saudi Arabia	Sickle cell disorders	8 (7 to 8)	1 (1 to 2)	-0.81 (-0.84 to -0.78)	47. 19 (43. 53 to 50. 81)	4 (3. 3 to 4. 78)	-9. 51 (-10. 43 to -8. 57)
Saudi Arabia	Sickle cell trait	111 (107 to 115)	48 (44 to 52)	-0.57 (-0.6 to -0.53)	692. 78 (668. 55 to 714. 87)	134. 07 (122. 55 to 145. 92)	-6.16 (-6.63 to -5.7)
Saudi Arabia	G6PD deficiency	51 (48 to 55)	45 (35 to 57)	-0.12 (-0.31 to 0.09)	320. 81 (299. 99 to 344. 04)	126. 83 (97. 64 to 159. 62)	-2.01 (-2.59 to -1.42)
Saudi Arabia	G6PD trait	107 (104 to 110)	91 (84 to 97)	-0.15 (-0.21 to -0.1)	667. 39 (649. 7 to 685. 3)	254.4 (234.96 to 271.58)	-3.33 (-3.39 to -3.27)
Senegal	Inherited anemias	159 (152 to 167)	211 (190 to 235)	0. 33 (0. 21 to 0. 45)	2092. 52 (1992. 41 to 2186. 83)	1396.93 (1257.59 to 1551.14)	-1.34 (-1.64 to -1.03)
Senegal	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1. 25 (0. 91 to 1. 65)	0.16 (0.11 to 0.21)	0. 18 (0. 12 to 0. 24)	0.44 (0.34 to 0.54)
Senegal	Thalassemi as trait	4 (3 to 5)	7 (6 to 8)	0.6 (0.51 to 0.7)	54.66 (45.91 to 64.66)	43. 92 (37. 13 to 51. 7)	-0.67 (-0.75 to -0.59)
Senegal	Sickle cell disorders	2 (1 to 2)	2 (2 to 3)	0.35 (0.24 to 0.47)	23. 15 (18. 59 to 27. 96)	15. 76 (12. 69 to 19. 07)	-1.22 (-1.32 to -1.13)
Senegal	Sickle cell trait	42 (38 to 47)	57 (51 to 64)	0.35 (0.29 to 0.42)	555. 23 (492. 95 to 614. 38)	378. 27 (334. 67 to 420. 02)	-1.21 (-1.3 to -1.11)
Senegal	G6PD deficiency	47 (43 to 50)	59 (46 to 74)	0.27 (0.01 to 0.56)	611.95 (560.43 to 661.88)	391. 42 (302. 25 to 487. 81)	-1.58 (-2.39 to -0.77)
Senegal	G6PD trait	65 (63 to 66)	86 (79 to 92)	0.33 (0.22 to 0.43)	847. 37 (822. 03 to 869. 98)	567. 39 (519. 08 to 611. 14)	-1.31 (-1.59 to -1.03)
Serbia	Inherited anemias	20 (18 to 23)	12 (11 to 14)	-0. 4 (-0. 42 to -0. 39)	215. 37 (190. 77 to 241. 91)	138. 4 (122. 26 to 155. 22)	-1.64 (-1.87 to -1.41)
Serbia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.64 (-0.68 to -0.59)	1. 27 (0. 82 to 2. 01)	0. 49 (0. 34 to 0. 74)	-3. 12 (-3. 37 to -2. 86)
Serbia	Thalassemi as trait	3 (2 to 3)	2 (1 to 2)	-0.39 (-0.43 to -0.35)	28. 42 (23. 9 to 34. 6)	18.6 (15.48 to 22.54)	-1.39 (-1.66 to -1.13)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Serbia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.37 (-0.43 to -0.31)	0. 14 (0. 11 to 0. 19)	0. 1 (0. 07 to 0. 13)	-1.39 (-1.69 to -1.09)
Serbia	Sickle cell trait	3 (2 to 3)	2 (1 to 2)	-0. 4 (-0. 42 to -0. 37)	27.56 (23.83 to 31.8)	17.85 (15.14 to 20.64)	-1.44 (-1.71 to -1.17)
Serbia	G6PD deficiency	5 (4 to 6)	3 (2 to 4)	-0.37 (-0.41 to -0.32)	51. 69 (40. 02 to 64. 75)	35. 14 (27. 21 to 43. 66)	-2. 2 (-2. 53 to -1. 87)
Serbia	G6PD trait	10 (9 to 11)	6 (5 to 6)	-0.42 (-0.42 to -0.42)	106. 28 (94. 06 to 118. 18)	66. 23 (58. 5 to 73. 73)	-1.51 (-1.76 to -1.25)
Seychelles	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.21 (-0.23 to -0.19)	612. 8 (546. 84 to 682. 25)	345. 62 (310. 26 to 384. 69)	-1.85 (-1.95 to -1.74)
Seychelles	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.06 (-0.2 to 0.07)	3. 03 (2. 26 to 4. 19)	2. 03 (1. 45 to 2. 78)	-1.3 (-1.39 to -1.2)
Seychelles	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.03 (-0.08 to 0.01)	121.77 (103.96 to 141.47)	84.34 (71.93 to 97.89)	-1.15 (-1.23 to -1.07)
Seychelles	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.12 (-0.26 to 0.07)	0. 02 (0. 01 to 0. 02)	0.01 (0.01 to 0.01)	-1.48 (-1.57 to -1.38)
Seychelles	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.2 to -0.04)	11. 25 (9. 39 to 13. 32)	7.03 (5.8 to 8.4)	-1.49 (-1.57 to -1.4)
Seychelles	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.27 (-0.28 to -0.25)	138. 52 (106. 67 to 174. 37)	72. 57 (55. 97 to 90. 45)	-2.08 (-2.23 to -1.93)
Seychelles	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0. 26 (-0. 28 to -0. 23)	338. 22 (305. 37 to 367. 93)	179.64 (161.35 to 198.54)	-2.05 (-2.18 to -1.92)
Sierra Leone	Inherited anemias	89 (82 to 96)	151 (139 to 163)	0.7 (0.65 to 0.74)	2435. 17 (2250. 94 to 2624. 74)	1820. 84 (1678. 31 to 1962. 05)	-1 (-1.17 to -0.82)
Sierra Leone	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1. 22 (0. 92 to 1. 56)	0. 38 (0. 27 to 0. 57)	0.38 (0.26 to 0.53)	-0.06 (-0.23 to 0.11)
Sierra Leone	Thalassemi as trait	3 (3 to 4)	6 (5 to 8)	0.9 (0.8 to 1)	91. 25 (76. 29 to 111. 83)	76. 4 (63. 78 to 91. 17)	-0.62 (-0.79 to -0.44)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Sierra Leone	Sickle cell disorders	4 (4 to 5)	7 (6 to 9)	0.66 (0.5 to 0.8)	120. 57 (99. 96 to 147. 69)	88 (71.64 to 106.62)	-1.08 (-1.25 to -0.9)
Sierra Leone	Sickle cell trait	42 (39 to 47)	72 (65 to 78)	0. 68 (0. 61 to 0. 75)	1163. 42 (1065. 57 to 1276. 13)	863. 46 (785. 13 to 946. 56)	-1.03 (-1.2 to -0.85)
Sierra Leone	G6PD deficiency	13 (10 to 16)	21 (16 to 26)	0.65 (0.6 to 0.72)	345. 66 (267. 3 to 430. 92)	251.05 (193.65 to 314.88)	-1.05 (-1.25 to -0.85)
Sierra Leone	G6PD trait	26 (24 to 28)	45 (41 to 49)	0.72 (0.68 to 0.78)	713. 88 (647. 79 to 775. 13)	541.55 (490.87 to 587.94)	-0.96 (-1.13 to -0.79)
Singapore	Inherited anemias	3 (3 to 4)	3 (3 to 4)	0.01 (-0.05 to 0.07)	107.75 (94.61 to 122.41)	58. 58 (50. 28 to 67. 27)	-2. 13 (-2. 29 to -1. 97)
Singapore	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.23 (-0.35 to -0.08)	0.56 (0.39 to 0.83)	0. 23 (0. 17 to 0. 33)	-3. 1 (-3. 34 to -2. 85)
Singapore	Thalassemi as trait	0 (0 to 0)	1 (0 to 1)	0.61 (0.45 to 0.78)	11.69 (10.03 to 13.48)	10.14 (8.46 to 12.01)	-0.65 (-0.88 to -0.42)
Singapore	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.12 (-0.08 to 0.68)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.01)	-1.47 (-1.85 to -1.1)
Singapore	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0. 1 (0. 01 to 0. 42)	7. 6 (6. 02 to 9. 15)	4. 49 (3. 54 to 5. 47)	-1.68 (-1.99 to -1.37)
Singapore	G6PD deficiency	1 (1 to 1)	1 (1 to 1)	-0.09 (-0.21 to 0.05)	27. 05 (22. 18 to 32. 87)	13. 3 (10. 2 to 16. 71)	-2.38 (-2.76 to -2)
Singapore	G6PD trait	2 (2 to 2)	2 (1 to 2)	-0.07 (-0.14 to 0)	60. 84 (52 to 70. 79)	30. 42 (25. 19 to 35. 87)	-2.44 (-2.6 to -2.28)
Slovakia	Inherited anemias	11 (10 to 13)	8 (7 to 9)	-0.28 (-0.29 to -0.26)	212. 92 (188. 28 to 240. 51)	149. 51 (131. 55 to 168. 26)	-0.86 (-1.25 to -0.48)
Slovakia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.56 (-0.61 to -0.51)	1. 18 (0. 79 to 1. 84)	0.5 (0.34 to 0.76)	-2.35 (-2.75 to -1.95)
Slovakia	Thalassemi as trait	1 (1 to 2)	1 (1 to 1)	-0.27 (-0.31 to -0.22)	27. 85 (23. 25 to 33. 74)	19.8 (16.57 to 23.82)	-0.61 (-1.02 to -0.2)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Slovakia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 28 (-0. 34 to -0. 22)	0.13 (0.1 to 0.16)	0.09 (0.07 to 0.11)	-0.96 (-1.37 to -0.55)
Slovakia	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	-0. 28 (-0. 31 to -0. 25)	24. 43 (20. 97 to 28. 1)	17 (14.61 to 19.61)	-0.81 (-1.2 to -0.42)
Slovakia	G6PD deficiency	3 (2 to 3)	2 (2 to 3)	-0. 23 (-0. 3 to -0. 17)	51. 49 (39. 81 to 64. 26)	38. 32 (29. 6 to 47. 69)	-1.41 (-1.86 to -0.95)
Slovakia	G6PD trait	6 (5 to 6)	4 (4 to 4)	-0.3 (-0.3 to -0.3)	107. 84 (95. 28 to 120. 82)	73. 8 (65. 21 to 82. 69)	-0.7 (-1.1 to -0.3)
Slovenia	Inherited anemias	3 (3 to 4)	3 (2 to 3)	-0.12 (-0.13 to -0.1)	157. 25 (138. 08 to 177. 63)	132. 23 (116. 39 to 148. 75)	-0.03 (-0.34 to 0.28)
Slovenia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.48 (-0.55 to -0.4)	0.77 (0.51 to 1.21)	0.38 (0.26 to 0.57)	-1.6 (-1.92 to -1.28)
Slovenia	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.1 (-0.16 to -0.04)	19.04 (15.61 to 23.38)	16. 21 (13. 56 to 19. 39)	0.22 (-0.09 to 0.52)
Slovenia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.03 (-0.13 to 0.07)	0.08 (0.06 to 0.1)	0.07 (0.05 to 0.09)	0.38 (0.07 to 0.69)
Slovenia	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.09 (-0.14 to -0.04)	17. 61 (15. 15 to 20. 29)	15.21 (13.07 to 17.5)	0.23 (-0.08 to 0.54)
Slovenia	G6PD deficiency	1 (1 to 1)	1 (1 to 1)	-0.07 (-0.14 to -0.02)	39. 17 (30. 04 to 49. 12)	34. 51 (26. 61 to 42. 98)	-0.63 (-1.07 to -0.19)
Slovenia	G6PD trait	2 (1 to 2)	1 (1 to 2)	-0.14 (-0.14 to -0.14)	80. 58 (71. 37 to 90. 62)	65.84 (58.32 to 74.05)	0. 12 (-0. 2 to 0. 43)
Solomon Islands	Inherited anemias	4 (4 to 5)	6 (6 to 7)	0.5 (0.45 to 0.56)	1246. 39 (1085. 28 to 1421. 76)	972.06 (842.39 to 1107.94)	-0.73 (-0.97 to -0.49)
Solomon Islands	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.34 (0.14 to 0.56)	5. 38 (2. 9 to 7. 98)	3.75 (2.1 to 5.69)	-0.22 (-1.12 to 0.69)
Solomon Islands	Thalassemi as trait	1 (0 to 1)	1 (1 to 1)	0. 42 (0. 32 to 0. 52)	154. 73 (119. 71 to 186. 64)	114.22 (89.46 to 138.81)	-0.64 (-1 to -0.27)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Solomon Islands	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 53 (0. 44 to 2. 12)	0 (0 to 0.01)	0 (0 to 0.01)	-0.66 (-0.79 to -0.53)
Solomon Islands	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0.51 (0.44 to 1.84)	5. 9 (2. 47 to 8. 93)	4.61 (1.94 to 7.12)	-0.79 (-0.91 to -0.67)
Solomon Islands	G6PD deficiency	1 (1 to 2)	2 (2 to 3)	0.61 (0.49 to 0.75)	435. 76 (337. 96 to 550. 26)	364. 93 (282. 1 to 450. 53)	-0.34 (-0.79 to 0.11)
Solomon Islands	G6PD trait	2 (2 to 2)	3 (3 to 3)	0.45 (0.4 to 0.49)	644.62 (582.6 to 704.86)	484. 56 (438. 12 to 526. 09)	-1.06 (-1.21 to -0.92)
Somalia	Inherited anemias	104 (92 to 118)	248 (218 to 279)	1. 37 (1. 32 to 1. 43)	1460.54 (1281.99 to 1646.07)	1217.7 (1074.06 to 1371.27)	-0.66 (-0.87 to -0.45)
Somalia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	4. 84 (4. 22 to 6. 02)	0. 1 (0. 06 to 0. 15)	0. 2 (0. 11 to 0. 3)	2. 12 (1. 88 to 2. 37)
Somalia	Thalassemi as trait	2 (2 to 2)	7 (6 to 9)	2. 61 (2. 36 to 2. 96)	27. 57 (21. 68 to 33. 65)	34. 94 (27. 69 to 42. 54)	0. 62 (0. 47 to 0. 78)
Somalia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	1.64 (1.41 to 1.89)	0. 41 (0. 27 to 0. 62)	0.38 (0.25 to 0.58)	-0.34 (-0.47 to -0.22)
Somalia	Sickle cell trait	6 (5 to 7)	15 (12 to 19)	1.62 (1.5 to 1.76)	80. 35 (63. 1 to 102. 09)	73. 97 (58. 29 to 94. 25)	-0.36 (-0.48 to -0.23)
Somalia	G6PD deficiency	35 (27 to 44)	74 (57 to 92)	1.11 (1.07 to 1.16)	489. 42 (378. 49 to 610. 64)	363. 44 (281. 54 to 451. 2)	-1.06 (-1.38 to -0.74)
Somalia	G6PD trait	62 (57 to 66)	152 (139 to 163)	1.46 (1.4 to 1.52)	862. 69 (792. 16 to 926. 16)	744.77 (681.67 to 803.17)	-0.52 (-0.69 to -0.36)
South Africa	Inherited anemias	274 (266 to 280)	283 (276 to 290)	0.03 (0.03 to 0.04)	743. 27 (723. 26 to 760. 41)	509. 49 (496. 12 to 521. 49)	-1.11 (-1.22 to -1.01)
South Africa	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1. 24 (0. 97 to 1. 53)	0.06 (0.04 to 0.09)	0.09 (0.05 to 0.13)	1. 26 (1. 09 to 1. 43)
South Africa	Thalassemi as trait	8 (6 to 9)	10 (8 to 12)	0. 37 (0. 28 to 0. 45)	20. 5 (17. 35 to 23. 99)	18.63 (15.26 to 21.99)	-0.26 (-0.35 to -0.18)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
South Africa	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.06 (0.02 to 0.1)	0. 08 (0. 06 to 0. 12)	0.06 (0.04 to 0.09)	-1. 08 (-1. 14 to -1. 02)
South Africa	Sickle cell trait	9 (7 to 12)	10 (8 to 13)	0.07 (0.05 to 0.1)	25. 15 (19. 58 to 32. 37)	17. 86 (13. 85 to 22. 87)	-1.04 (-1.11 to -0.98)
South Africa	G6PD deficiency	86 (83 to 90)	86 (82 to 89)	-0.01 (-0.02 to 0)	234. 76 (224. 11 to 244. 17)	153. 91 (146. 83 to 160. 4)	-1.27 (-1.41 to -1.13)
South Africa	G6PD trait	170 (168 to 173)	177 (174 to 180)	0.04 (0.03 to 0.05)	462. 72 (455. 13 to 469. 62)	318.94 (313.59 to 323.69)	-1.08 (-1.17 to -0.99)
South Sudan	Inherited anemias	85 (75 to 96)	112 (100 to 125)	0. 32 (0. 29 to 0. 36)	1450. 82 (1281. 55 to 1630. 98)	1208.88 (1075.05 to 1350.27)	-0.63 (-0.87 to -0.38)
South Sudan	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 24 (1. 88 to 2. 9)	0.09 (0.05 to 0.13)	0. 18 (0. 1 to 0. 28)	2. 17 (1. 91 to 2. 42)
South Sudan	Thalassemi as trait	1 (1 to 2)	3 (2 to 4)	1 (0.87 to 1.19)	25. 29 (20. 08 to 30. 72)	31. 97 (25. 31 to 39. 14)	0.65 (0.48 to 0.83)
South Sudan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.36 (0.22 to 0.54)	2.01 (1.4 to 2.74)	1.72 (1.23 to 2.4)	-0.52 (-0.66 to -0.38)
South Sudan	Sickle cell trait	10 (9 to 12)	15 (12 to 17)	0. 4 (0. 33 to 0. 49)	177. 46 (148. 21 to 207. 68)	156. 73 (132. 77 to 185. 72)	-0.43 (-0.58 to -0.29)
South Sudan	G6PD deficiency	26 (20 to 33)	31 (24 to 39)	0. 18 (0. 12 to 0. 24)	446. 21 (342. 81 to 560. 36)	331. 28 (256. 5 to 417. 37)	-1.03 (-1.4 to -0.66)
South Sudan	G6PD trait	47 (43 to 51)	64 (58 to 69)	0.36 (0.32 to 0.42)	799. 76 (732. 43 to 862. 15)	686. 99 (627. 78 to 742. 85)	-0.51 (-0.71 to -0.31)
Spain	Inherited anemias	47 (42 to 52)	42 (37 to 46)	-0.11 (-0.14 to -0.08)	121. 19 (109. 05 to 133. 84)	90.68 (81.22 to 100.63)	-0.42 (-0.76 to -0.07)
Spain	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.15 (-0.31 to -0.02)	0. 1 (0. 07 to 0. 15)	0.07 (0.05 to 0.11)	-1.73 (-2.81 to -0.64)
Spain	Thalassemi as trait	3 (3 to 4)	3 (2 to 4)	-0.05 (-0.13 to 0.03)	8. 17 (6. 57 to 9. 84)	6.56 (5.34 to 7.86)	-0.72 (-1.28 to -0.15)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Spain	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 34 (-0. 42 to -0. 25)	0. 22 (0. 15 to 0. 3)	0. 12 (0. 09 to 0. 16)	-0.6 (-1.12 to -0.08)
Spain	Sickle cell trait	10 (8 to 12)	7 (6 to 9)	-0.26 (-0.31 to -0.2)	25.64 (20.65 to 31.04)	15. 94 (13. 05 to 19. 27)	-0.48 (-0.91 to -0.04)
Spain	G6PD deficiency	4 (3 to 5)	4 (3 to 5)	-0.01 (-0.09 to 0.06)	10. 58 (8. 15 to 13. 24)	8.82 (6.76 to 11.11)	-0.15 (-0.46 to 0.17)
Spain	G6PD trait	30 (26 to 33)	27 (24 to 31)	-0.08 (-0.12 to -0.04)	76. 48 (68. 05 to 85. 31)	59. 17 (52. 5 to 66. 32)	-0. 4 (-0. 74 to -0. 06)
Sri Lanka	Inherited anemias	104 (90 to 119)	79 (68 to 90)	-0.24 (-0.26 to -0.23)	603. 63 (522. 64 to 692. 85)	359. 31 (310. 94 to 413. 1)	-1.48 (-1.77 to -1.18)
Sri Lanka	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.37 (-0.45 to -0.28)	1.53 (1.08 to 2.27)	0.76 (0.57 to 1.05)	-2.07 (-2.27 to -1.87)
Sri Lanka	Thalassemi as trait	10 (9 to 11)	9 (8 to 10)	-0.11 (-0.15 to -0.08)	58.36 (51.39 to 66.56)	40.7 (36 to 45.86)	-0.92 (-1.14 to -0.71)
Sri Lanka	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.17 (-0.36 to 0.06)	0. 01 (0. 01 to 0. 02)	0.01 (0.01 to 0.01)	-1.16 (-1.36 to -0.95)
Sri Lanka	Sickle cell trait	2 (1 to 2)	1 (1 to 2)	-0.17 (-0.27 to -0.06)	9. 92 (8. 27 to 11. 81)	6. 47 (5. 33 to 7. 77)	-1.17 (-1.38 to -0.95)
Sri Lanka	G6PD deficiency	40 (31 to 51)	32 (25 to 40)	-0.21 (-0.22 to -0.2)	233. 19 (180. 32 to 293. 39)	145. 34 (112. 33 to 183. 03)	-1.3 (-1.55 to -1.05)
Sri Lanka	G6PD trait	52 (47 to 56)	36 (33 to 40)	-0.3 (-0.32 to -0.28)	300. 62 (270. 91 to 327. 74)	166.03 (149.07 to 181.79)	-1.75 (-2.11 to -1.39)
Sudan	Inherited anemias	348 (325 to 375)	402 (375 to 432)	0. 15 (0. 13 to 0. 18)	1724. 65 (1607. 14 to 1856. 54)	985. 55 (919. 32 to 1059. 48)	-2.22 (-2.45 to -2)
Sudan	Thalassemi as	1 (1 to 2)	1 (1 to 2)	0. 17 (0. 06 to 0. 29)	5. 74 (4. 44 to 7. 54)	3. 33 (2. 6 to 4. 3)	-1.92 (-2.06 to -1.78)
Sudan	Thalassemi as trait	72 (64 to 82)	85 (76 to 97)	0. 18 (0. 13 to 0. 24)	357. 55 (317. 75 to 405. 22)	209. 48 (187. 19 to 236. 89)	-1.9 (-2.04 to -1.76)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Sudan	Sickle cell disorders	5 (4 to 6)	5 (4 to 7)	0. 12 (0. 02 to 0. 22)	23. 41 (18. 58 to 29. 52)	12. 99 (10. 31 to 16. 31)	-2. 36 (-3. 07 to -1. 65)
Sudan	Sickle cell trait	131 (118 to 146)	149 (134 to 166)	0.13 (0.08 to 0.18)	649. 74 (584. 81 to 724. 9)	364. 15 (327. 18 to 405. 76)	-2.17 (-2.56 to -1.77)
Sudan	G6PD deficiency	24 (18 to 29)	27 (21 to 34)	0.16 (0.08 to 0.23)	116. 45 (90. 55 to 145. 15)	66. 62 (51. 18 to 83. 32)	-2.81 (-3.06 to -2.57)
Sudan	G6PD trait	115 (103 to 127)	134 (120 to 148)	0. 16 (0. 12 to 0. 21)	571.77 (511.41 to 628.3)	328. 98 (294. 41 to 363. 72)	-2.41 (-2.56 to -2.26)
Suriname	Inherited anemias	3 (2 to 3)	3 (2 to 3)	-0.04 (-0.08 to -0.01)	703.6 (616.02 to 797.19)	451.11 (396.38 to 507.81)	-1.39 (-1.49 to -1.29)
Suriname	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.57 (-0.05 to 2.05)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.02)	0.25 (-0.04 to 0.54)
Suriname	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.13 (-0.05 to 0.43)	9. 42 (7. 19 to 11. 9)	7. 13 (5. 53 to 8. 56)	-0.86 (-0.99 to -0.72)
Suriname	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.11 (-0.02 to 0.28)	8. 27 (6. 05 to 10. 99)	6. 17 (4. 35 to 8. 46)	-0.99 (-1.22 to -0.76)
Suriname	Sickle cell trait	1 (1 to 1)	1 (1 to 1)	0.02 (-0.06 to 0.1)	223. 76 (187. 98 to 265. 83)	152. 96 (125. 08 to 182. 44)	-1.2 (-1.35 to -1.06)
Suriname	G6PD deficiency	1 (1 to 1)	1 (1 to 1)	-0.13 (-0.21 to -0.06)	223. 25 (172. 67 to 279. 18)	131.13 (100.99 to 161.89)	-1.62 (-1.77 to -1.47)
Suriname	G6PD trait	1 (1 to 1)	1 (1 to 1)	-0.04 (-0.07 to -0.01)	238. 88 (213. 25 to 264. 87)	153. 71 (136. 79 to 171. 3)	-1.4 (-1.5 to -1.3)
Sweden	Inherited anemias	22 (21 to 23)	21 (21 to 22)	-0.03 (-0.04 to -0.01)	256. 43 (248. 35 to 264. 81)	209. 14 (201. 94 to 216. 96)	-0.2 (-0.54 to 0.15)
Sweden	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.22 to -0.04)	0. 19 (0. 13 to 0. 26)	0.14 (0.1 to 0.19)	-1.43 (-2.14 to -0.72)
Sweden	Thalassemi as trait	2 (2 to 2)	2 (2 to 2)	-0.05 (-0.1 to 0)	23. 26 (20. 08 to 26. 56)	18.54 (16.11 to 21.17)	-0.46 (-0.77 to -0.16)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Sweden	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 5 (0. 36 to 0. 68)	0. 21 (0. 15 to 0. 3)	0. 27 (0. 19 to 0. 38)	1. 1 (0. 73 to 1. 46)
Sweden	Sickle cell trait	3 (2 to 3)	3 (3 to 4)	0. 2 (0. 14 to 0. 28)	32. 17 (26. 6 to 39. 01)	32. 52 (26. 91 to 38. 78)	0.46 (0.11 to 0.8)
Sweden	G6PD deficiency	3 (3 to 3)	3 (3 to 3)	-0.01 (-0.03 to 0.01)	37.84 (36.08 to 39.51)	31. 43 (29. 98 to 32. 75)	-0.13 (-0.5 to 0.25)
Sweden	G6PD trait	14 (14 to 14)	13 (13 to 13)	-0.08 (-0.09 to -0.06)	162. 76 (159. 36 to 166. 02)	126. 23 (123. 7 to 128. 68)	-0.32 (-0.68 to 0.04)
Switzerland	Inherited anemias	15 (14 to 17)	16 (14 to 17)	0.02 (0 to 0.05)	223. 22 (200. 84 to 248. 11)	178.8 (160.04 to 198.01)	-0.78 (-0.99 to -0.57)
Switzerland	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.04 (-0.17 to 0.09)	0.16 (0.1 to 0.21)	0. 12 (0. 08 to 0. 17)	-1.84 (-2.48 to -1.2)
Switzerland	Thalassemi as trait	1 (1 to 2)	1 (1 to 2)	0.04 (-0.02 to 0.11)	19.72 (17.09 to 22.38)	16. 1 (13. 96 to 18. 51)	-0.91 (-1.09 to -0.74)
Switzerland	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 17 (0. 05 to 0. 28)	0.31 (0.23 to 0.4)	0. 28 (0. 21 to 0. 36)	-0.4 (-0.64 to -0.16)
Switzerland	Sickle cell trait	2 (1 to 2)	2 (1 to 2)	0.02 (-0.04 to 0.08)	24.65 (20.07 to 29.64)	19.65 (16.1 to 23.69)	-0.79 (-1 to -0.57)
Switzerland	G6PD deficiency	2 (2 to 3)	3 (2 to 3)	0.08 (0.03 to 0.15)	34.6 (26.67 to 43.37)	29. 22 (22. 48 to 36. 46)	-0.61 (-0.87 to -0.35)
Switzerland	G6PD trait	10 (9 to 11)	10 (9 to 11)	0.01 (-0.02 to 0.04)	143. 78 (128. 77 to 158. 87)	113. 43 (101. 59 to 125. 33)	-0.8 (-1.02 to -0.59)
Syrian Arab Republic	Inherited anemias	157 (144 to 171)	72 (66 to 78)	-0.54 (-0.55 to -0.53)	1221.06 (1118.79 to 1327.49)	496 (455. 34 to 537. 4)	-3.09 (-3.32 to -2.86)
Syrian Arab Republic	Thalassemi as	1 (0 to 1)	0 (0 to 0)	-0.53 (-0.58 to -0.49)	4. 75 (3. 67 to 6. 19)	1. 97 (1. 54 to 2. 55)	-3.09 (-3.32 to -2.86)
Syrian Arab Republic	Thalassemi as trait	36 (32 to 41)	17 (15 to 19)	-0.53 (-0.55 to -0.51)	280. 27 (249. 61 to 316. 96)	116. 39 (103. 71 to 130. 99)	-3. 07 (-3. 3 to -2. 84)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Syrian Arab Republic	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 54 (-0. 57 to -0. 51)	1.36 (1.09 to 1.65)	0.55 (0.45 to 0.67)	-3. 15 (-3. 37 to -2. 94)
Syrian Arab Republic	Sickle cell trait	18 (16 to 20)	8 (7 to 9)	-0.55 (-0.56 to -0.53)	141.86 (126.81 to 156.43)	57. 08 (51. 29 to 63. 1)	-3. 16 (-3. 39 to -2. 94)
Syrian Arab Republic	G6PD deficiency	21 (16 to 26)	9 (7 to 12)	-0.55 (-0.57 to -0.53)	159. 44 (122. 6 to 200. 2)	64. 14 (49. 44 to 79. 83)	-2.87 (-3.13 to -2.6)
Syrian Arab Republic	G6PD trait	82 (74 to 89)	37 (34 to 40)	-0.55 (-0.56 to -0.53)	633. 39 (574. 63 to 690. 69)	255. 88 (232. 42 to 277. 01)	-3.13 (-3.35 to -2.92)
Taiwan (Province of China)	Inherited anemias	55 (50 to 60)	29 (26 to 33)	-0. 47 (-0. 5 to -0. 44)	269. 44 (246. 88 to 294. 44)	123. 06 (109. 61 to 137. 75)	-2.74 (-3.12 to -2.37)
Taiwan (Province of China)	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.62 (-0.66 to -0.58)	0.64 (0.5 to 0.85)	0. 21 (0. 17 to 0. 26)	-3.88 (-4.29 to -3.46)
Taiwan (Province of China)	Thalassemi as trait	8 (7 to 9)	4 (4 to 5)	-0.46 (-0.5 to -0.41)	37. 55 (32. 87 to 43. 07)	17. 63 (15. 9 to 19. 49)	-2.64 (-3.06 to -2.23)
Taiwan (Province of China)	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.17 (-0.3 to -0.01)	0.04 (0.03 to 0.05)	0.03 (0.02 to 0.03)	-0.8 (-1.47 to -0.12)
Taiwan (Province of China)	Sickle cell trait	3 (3 to 3)	2 (2 to 2)	-0.35 (-0.39 to -0.28)	14.39 (12.35 to 16.89)	8. 13 (7. 1 to 9. 25)	-1.84 (-2.35 to -1.32)
Taiwan (Province of China)	G6PD deficiency	10 (9 to 12)	5 (4 to 7)	-0.48 (-0.56 to -0.39)	51. 13 (44. 49 to 58. 33)	22. 95 (17. 68 to 28. 72)	-2.85 (-3.29 to -2.41)
Taiwan (Province of China)	G6PD trait	34 (30 to 37)	18 (16 to 19)	-0.48 (-0.51 to -0.45)	165. 71 (149. 06 to 183. 03)	74. 12 (66. 07 to 82. 44)	-2.82 (-3.16 to -2.48)
Tajikistan	Inherited anemias	34 (31 to 37)	42 (38 to 46)	0. 24 (0. 21 to 0. 26)	624. 59 (567. 65 to 684. 56)	437. 42 (398 to 479. 79)	-0.85 (-1.08 to -0.62)
Tajikistan	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.05 (-0.06 to 0.18)	6. 26 (4. 84 to 8. 11)	3. 73 (2. 92 to 4. 78)	-1.39 (-1.63 to -1.16)
Tajikistan	Thalassemi as trait	13 (12 to 15)	17 (15 to 19)	0. 26 (0. 2 to 0. 32)	246. 68 (217. 58 to 278. 04)	176. 18 (156. 47 to 200. 38)	-0.8 (-1.03 to -0.57)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Tajikistan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 23 (0. 15 to 0. 42)	0. 02 (0. 02 to 0. 04)	0.02 (0.01 to 0.03)	-0.87 (-1.11 to -0.64)
Tajikistan	Sickle cell trait	1 (1 to 1)	1 (1 to 2)	0. 23 (0. 22 to 0. 33)	18. 3 (14. 29 to 22. 7)	12. 74 (9. 91 to 15. 84)	-0.88 (-1.11 to -0.65)
Tajikistan	G6PD deficiency	3 (2 to 4)	4 (3 to 5)	0. 25 (0. 19 to 0. 33)	53. 61 (41. 13 to 66. 76)	37. 91 (29. 36 to 48. 29)	-0.76 (-0.98 to -0.54)
Tajikistan	G6PD trait	16 (14 to 18)	20 (17 to 22)	0. 22 (0. 22 to 0. 22)	299. 72 (266. 93 to 332. 69)	206. 84 (184. 21 to 229. 59)	-0.9 (-1.13 to -0.67)
Thailand	Inherited anemias	307 (291 to 324)	178 (163 to 195)	-0.42 (-0.45 to -0.39)	540. 17 (510. 97 to 568. 92)	253. 95 (232. 07 to 278. 11)	-2.51 (-2.59 to -2.42)
Thailand	Thalassemi as	17 (14 to 22)	8 (7 to 9)	-0.53 (-0.6 to -0.47)	29. 28 (23. 89 to 37. 95)	11. 08 (9. 29 to 13. 47)	-3.25 (-3.32 to -3.18)
Thailand	Thalassemi as trait	114 (105 to 124)	72 (66 to 79)	-0.36 (-0.39 to -0.34)	200. 02 (183. 79 to 218. 84)	103. 13 (94. 43 to 112. 91)	-2. 2 (-2. 27 to -2. 12)
Thailand	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.46 (-0.58 to -0.39)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	-2.72 (-2.79 to -2.65)
Thailand	Sickle cell trait	5 (4 to 6)	3 (2 to 4)	-0.45 (-0.51 to -0.41)	9. 3 (7. 58 to 11. 36)	4. 12 (3. 37 to 4. 99)	-2.7 (-2.77 to -2.63)
Thailand	G6PD deficiency	54 (50 to 59)	33 (25 to 41)	-0. 4 (-0. 52 to -0. 28)	95.71 (87.83 to 103.71)	46.64 (36.06 to 58.4)	-2. 23 (-2. 44 to -2. 03)
Thailand	G6PD trait	117 (109 to 125)	62 (56 to 68)	-0.47 (-0.51 to -0.43)	205. 84 (190. 79 to 220. 26)	88.98 (79.74 to 97.4)	-2.87 (-2.93 to -2.81)
Timor-Leste	Inherited anemias	11 (10 to 12)	10 (9 to 11)	-0.07 (-0.09 to -0.04)	1380. 62 (1232. 49 to 1529. 03)	755. 06 (678. 46 to 835. 57)	-2.37 (-2.51 to -2.23)
Timor-Leste	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.06 (-0.08 to 0.2)	11. 17 (8. 42 to 15. 2)	6. 92 (5. 1 to 9. 05)	-1.96 (-2.07 to -1.85)
Timor-Leste	Thalassemi as trait	3 (2 to 3)	3 (3 to 4)	0.11 (0.05 to 0.16)	352.55 (301.66 to 408)	229. 47 (197. 2 to 265. 79)	-1.79 (-1.89 to -1.68)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Timor-Leste	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 01 (-0. 21 to 0. 16)	0.04 (0.03 to 0.06)	0.03 (0.02 to 0.04)	-2. 05 (-2. 14 to -1. 97)
Timor-Leste	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0.02 (-0.09 to 0.09)	27. 26 (22. 54 to 32. 42)	16. 24 (13. 33 to 19. 32)	-2.05 (-2.14 to -1.96)
Timor-Leste	G6PD deficiency	2 (2 to 3)	2 (1 to 2)	-0.15 (-0.21 to -0.08)	288. 53 (223. 36 to 358. 18)	144. 48 (111. 7 to 180. 19)	-2.65 (-2.84 to -2.46)
Timor-Leste	G6PD trait	5 (5 to 6)	5 (4 to 5)	-0.13 (-0.16 to -0.09)	701. 07 (634. 82 to 762. 43)	357. 91 (321. 49 to 395. 6)	-2. 6 (-2. 78 to -2. 42)
Togo	Inherited anemias	76 (70 to 83)	110 (101 to 119)	0.44 (0.4 to 0.48)	2081.8 (1921.66 to 2261.14)	1386.94 (1272.93 to 1507.7)	-1.18 (-1.35 to -1.01)
Togo	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.01 (0.63 to 1.52)	0. 27 (0. 14 to 0. 53)	0. 25 (0. 14 to 0. 42)	0.05 (-0.14 to 0.24)
Togo	Thalassemi as trait	3 (2 to 4)	4 (3 to 6)	0.64 (0.54 to 0.77)	73. 55 (50. 96 to 106. 74)	55. 93 (39. 78 to 77. 32)	-0.69 (-0.86 to -0.51)
Togo	Sickle cell disorders	3 (3 to 4)	5 (4 to 6)	0. 44 (0. 31 to 0. 57)	91. 04 (80. 1 to 105. 35)	60. 54 (51. 14 to 70. 69)	-1.16 (-1.35 to -0.97)
Togo	Sickle cell trait	32 (29 to 35)	45 (41 to 49)	0. 42 (0. 34 to 0. 5)	869. 08 (803. 64 to 943. 45)	569. 74 (512. 65 to 621. 71)	-1.22 (-1.39 to -1.06)
Togo	G6PD deficiency	13 (10 to 16)	18 (14 to 22)	0.41 (0.33 to 0.48)	342.64 (265.06 to 429)	222. 66 (172. 08 to 281)	-1.23 (-1.43 to -1.03)
Togo	G6PD trait	26 (24 to 28)	38 (34 to 41)	0.47 (0.44 to 0.5)	705. 23 (641. 81 to 766. 02)	477. 82 (433. 77 to 521. 36)	-1.15 (-1.32 to -0.98)
Tokelau	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.34 (-0.35 to -0.33)	791. 83 (704. 15 to 884. 8)	628.71 (558.08 to 701.1)	-0.83 (-1.05 to -0.61)
Tokelau	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.46 (-0.53 to -0.38)	4. 13 (2. 25 to 6. 42)	2.65 (1.44 to 4.05)	-0.47 (-1.45 to 0.52)
Tokelau	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.45 to -0.38)	125. 87 (97. 9 to 153. 71)	87. 04 (66. 79 to 106. 27)	-0.89 (-1.32 to -0.45)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Tokelau	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 4 (-0. 41 to -0. 18)	0 (0 to 0.01)	0 (0 to 0)	-1.04 (-1.24 to -0.84)
Tokelau	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0. 4 (-0. 41 to -0. 23)	4. 88 (2. 01 to 7. 66)	3. 53 (1. 52 to 5. 44)	-1.11 (-1.26 to -0.95)
Tokelau	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0. 28 (-0. 3 to -0. 27)	163. 57 (126. 26 to 203. 65)	141. 26 (109. 11 to 175. 93)	-0.62 (-0.88 to -0.36)
Tokelau	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.33 (-0.34 to -0.32)	493. 37 (444. 07 to 542. 2)	394. 24 (356. 04 to 429)	-0.9 (-1.09 to -0.71)
Tonga	Inherited anemias	1 (0 to 1)	1 (0 to 1)	0 (-0.02 to 0.03)	545.71 (486.07 to 612.09)	517. 02 (459. 71 to 577)	-0.02 (-0.12 to 0.09)
Tonga	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.19 (-0.3 to -0.07)	2. 79 (1. 56 to 4. 26)	2. 14 (1. 16 to 3. 22)	0.4 (-0.58 to 1.39)
Tonga	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.12 (-0.18 to -0.07)	86. 57 (67. 34 to 105. 4)	71. 76 (55. 04 to 86. 75)	-0.04 (-0.44 to 0.35)
Tonga	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.01 (-0.1 to 0.95)	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.25 to -0.01)
Tonga	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.04 (-0.1 to 0.45)	3. 4 (1. 5 to 5. 26)	3. 09 (1. 27 to 4. 84)	-0.24 (-0.33 to -0.15)
Tonga	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0.09 (0.02 to 0.17)	110.99 (85.41 to 140.5)	114. 17 (88. 45 to 144. 15)	0. 19 (0. 06 to 0. 32)
Tonga	G6PD trait	0 (0 to 0)	0 (0 to 0)	0.01 (-0.01 to 0.03)	341.96 (307.87 to 376.93)	325. 85 (294. 77 to 354. 77)	-0.09 (-0.15 to -0.03)
Trinidad and Tobago	Inherited anemias	6 (6 to 7)	4 (4 to 5)	-0.32 (-0.34 to -0.29)	532. 8 (470. 78 to 603. 1)	315.06 (279.05 to 356.29)	-1.09 (-1.37 to -0.81)
Trinidad and Tobago	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.09 (-0.35 to 1.22)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	0.32 (0.08 to 0.56)
Trinidad and Tobago	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.22 (-0.34 to 0)	6. 99 (5. 32 to 8. 93)	4. 72 (3. 63 to 5. 74)	-0.74 (-0.94 to -0.55)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Trinidad and Tobago	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 25 (-0. 34 to -0. 17)	6. 54 (4. 73 to 8. 82)	4. 24 (2. 98 to 5. 76)	-0.66 (-1.14 to -0.19)
Trinidad and Tobago	Sickle cell trait	2 (2 to 3)	2 (1 to 2)	-0. 3 (-0. 35 to -0. 26)	184. 55 (154. 26 to 216. 5)	111. 28 (92. 73 to 131. 72)	-0.94 (-1.31 to -0.57)
Trinidad and Tobago	G6PD deficiency	2 (1 to 2)	1 (1 to 2)	-0.31 (-0.38 to -0.25)	149. 72 (115. 44 to 187. 65)	89. 19 (68. 94 to 111. 02)	-1.09 (-1.35 to -0.84)
Trinidad and Tobago	G6PD trait	2 (2 to 2)	1 (1 to 2)	-0.34 (-0.37 to -0.32)	184. 99 (164. 99 to 203. 53)	105. 63 (94. 18 to 116. 43)	-1. 27 (-1. 5 to -1. 03)
Tunisia	Inherited anemias	89 (82 to 98)	61 (55 to 66)	-0.32 (-0.34 to -0.3)	1057. 92 (970. 61 to 1158. 8)	523. 1 (476. 61 to 574. 07)	-2.14 (-2.26 to -2.01)
Tunisia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.42 (-0.49 to -0.35)	3. 73 (2. 77 to 4. 95)	1. 57 (1. 19 to 2. 03)	-2.46 (-2.73 to -2.18)
Tunisia	Thalassemi as trait	18 (15 to 20)	12 (10 to 13)	-0.35 (-0.38 to -0.31)	209. 85 (183 to 240. 43)	99.86 (87.87 to 112.8)	-2.17 (-2.36 to -1.98)
Tunisia	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.45 (-0.5 to -0.41)	3. 81 (3. 11 to 4. 65)	1.52 (1.2 to 1.9)	-2.38 (-2.68 to -2.09)
Tunisia	Sickle cell trait	17 (15 to 19)	10 (9 to 12)	-0.38 (-0.41 to -0.36)	200. 49 (181. 98 to 220. 9)	90. 26 (80. 79 to 100. 92)	-2.21 (-2.41 to -2.01)
Tunisia	G6PD deficiency	16 (13 to 20)	12 (9 to 14)	-0.28 (-0.34 to -0.22)	190. 92 (150. 89 to 240. 78)	99.82 (76.77 to 124.97)	-2.32 (-2.49 to -2.15)
Tunisia	G6PD trait	38 (34 to 41)	27 (24 to 29)	-0.3 (-0.32 to -0.27)	449. 12 (407. 63 to 488. 14)	230. 08 (209. 29 to 250. 88)	-2.01 (-2.14 to -1.88)
Turkey	Inherited anemias	572 (554 to 589)	325 (296 to 358)	-0.43 (-0.48 to -0.38)	956. 81 (926. 94 to 985. 17)	399. 9 (363. 36 to 439. 6)	-2. 9 (-3. 23 to -2. 57)
Turkey	Thalassemi as	1 (1 to 1)	1 (0 to 1)	-0.25 (-0.34 to -0.15)	1. 32 (1 to 1. 72)	0.73 (0.55 to 0.94)	-2.24 (-2.56 to -1.93)
Turkey	Thalassemi as trait	77 (68 to 88)	51 (45 to 58)	-0.33 (-0.37 to -0.29)	129. 16 (113. 15 to 147. 9)	63. 27 (55. 66 to 71. 67)	-2.77 (-2.98 to -2.56)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Turkey	Sickle cell disorders	1 (1 to 1)	0 (0 to 0)	-0.69 (-0.71 to -0.66)	1. 58 (1. 34 to 1. 88)	0.36 (0.31 to 0.42)	-5. 9 (-6. 32 to -5. 48)
Turkey	Sickle cell trait	75 (69 to 82)	32 (29 to 34)	-0.58 (-0.6 to -0.56)	125. 53 (115. 45 to 137. 34)	38. 77 (35. 94 to 41. 85)	-4.7 (-5 to -4.39)
Turkey	G6PD deficiency	113 (107 to 119)	66 (52 to 84)	-0.41 (-0.54 to -0.26)	188. 66 (178. 76 to 198. 78)	81.64 (63.66 to 103.33)	-1.89 (-2.45 to -1.33)
Turkey	G6PD trait	305 (299 to 311)	175 (161 to 188)	-0.43 (-0.47 to -0.38)	510. 57 (499. 54 to 519. 99)	215. 12 (197. 28 to 231. 41)	-2. 84 (-3. 23 to -2. 45)
Turkmenista n	Inherited anemias	20 (18 to 22)	17 (15 to 19)	-0.15 (-0.17 to -0.13)	535. 74 (479. 69 to 594. 26)	330. 6 (295. 23 to 368. 11)	-1.18 (-1.55 to -0.81)
Turkmenista n	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.32 (-0.4 to -0.22)	4. 28 (3. 08 to 5. 91)	2. 12 (1. 51 to 2. 96)	-1.98 (-2.34 to -1.61)
Turkmenista n	Thalassemi as trait	7 (6 to 8)	6 (5 to 7)	-0.14 (-0.19 to -0.08)	181. 22 (151. 21 to 220. 77)	113. 9 (94. 5 to 138. 32)	-1.16 (-1.53 to -0.8)
Turkmenista n	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.16 (-0.27 to -0.03)	0. 02 (0. 01 to 0. 03)	0.01 (0.01 to 0.02)	-1.17 (-1.55 to -0.79)
Turkmenista n	Sickle cell trait	1 (0 to 1)	1 (0 to 1)	-0.16 (-0.22 to -0.09)	17.01 (13.4 to 21.1)	10. 47 (8. 24 to 13. 03)	-1.17 (-1.55 to -0.8)
Turkmenista n	G6PD deficiency	2 (1 to 2)	2 (1 to 2)	-0.14 (-0.19 to -0.09)	50. 13 (38. 64 to 63. 73)	31. 53 (24. 26 to 39. 62)	-1.04 (-1.44 to -0.65)
Turkmenista n	G6PD trait	10 (9 to 12)	9 (8 to 10)	-0.16 (-0.18 to -0.16)	283. 07 (252. 27 to 317. 08)	172. 57 (153. 87 to 192. 26)	-1.21 (-1.58 to -0.84)
Tuvalu	Inherited anemias	0 (0 to 0)	0 (0 to 0)	-0.19 (-0.21 to -0.18)	683. 21 (605. 24 to 763. 66)	435. 91 (385. 58 to 484. 93)	-1.5 (-1.78 to -1.21)
Tuvalu	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.33 (-0.42 to -0.24)	3. 87 (2. 1 to 5. 85)	2. 05 (1. 14 to 3. 15)	-1.09 (-2.04 to -0.13)
Tuvalu	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.29 (-0.34 to -0.24)	112. 35 (86. 79 to 136. 29)	63. 24 (48. 94 to 77. 56)	-1.54 (-1.96 to -1.11)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Tuvalu	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.19 (-0.28 to 1.05)	0 (0 to 0)	0 (0 to 0)	-1.43 (-1.65 to -1.21)
Tuvalu	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.22 (-0.28 to 0.67)	4. 28 (1. 82 to 6. 56)	2.65 (1.13 to 4.53)	-1.6 (-1.8 to -1.41)
Tuvalu	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0.13 (-0.18 to -0.08)	140. 46 (108. 48 to 176. 68)	97. 3 (75. 45 to 120. 99)	-1.29 (-1.63 to -0.94)
Tuvalu	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0. 19 (-0. 2 to -0. 18)	422. 25 (380. 12 to 464. 03)	270. 67 (244. 46 to 294. 49)	-1.57 (-1.84 to -1.3)
Uganda	Inherited anemias	437 (398 to 477)	776 (702 to 857)	0.78 (0.71 to 0.83)	2521. 18 (2300. 3 to 2753)	1887.75 (1706.89 to 2084.47)	-1.27 (-1.38 to -1.17)
Uganda	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 81 (2. 32 to 3. 66)	0. 11 (0. 07 to 0. 16)	0. 18 (0. 1 to 0. 27)	1. 22 (0. 99 to 1. 46)
Uganda	Thalassemi as trait	5 (4 to 7)	13 (10 to 16)	1.36 (1.19 to 1.62)	31. 6 (25. 19 to 38. 37)	31. 35 (24. 7 to 38. 36)	-0.26 (-0.41 to -0.12)
Uganda	Sickle cell disorders	6 (5 to 8)	9 (7 to 11)	0. 4 (0. 15 to 0. 66)	35. 32 (28. 23 to 46. 4)	20. 83 (16. 22 to 25. 69)	-2.29 (-2.48 to -2.1)
Uganda	Sickle cell trait	139 (125 to 157)	216 (192 to 238)	0.55 (0.42 to 0.68)	801. 22 (724. 19 to 909)	524. 36 (467. 09 to 578. 72)	-1.73 (-1.83 to -1.63)
Uganda	G6PD deficiency	93 (72 to 116)	209 (161 to 260)	1. 26 (1. 13 to 1. 38)	535. 6 (413. 96 to 670. 91)	508. 79 (392. 74 to 631. 39)	-0.69 (-0.88 to -0.49)
Uganda	G6PD trait	193 (179 to 206)	330 (305 to 351)	0.71 (0.7 to 0.71)	1117. 32 (1033. 75 to 1190. 74)	802. 25 (742. 63 to 854. 51)	-1.27 (-1.37 to -1.16)
Ukraine	Inherited anemias	82 (78 to 86)	51 (48 to 53)	-0.38 (-0.39 to -0.37)	155. 35 (148. 69 to 162. 97)	114.72 (109.98 to 120.18)	-0.02 (-0.45 to 0.42)
Ukraine	Thalassemi as	0 (0 to 1)	0 (0 to 0)	-0.58 (-0.63 to -0.52)	0.76 (0.53 to 1.11)	0.38 (0.27 to 0.55)	-1.26 (-1.72 to -0.81)
Ukraine	Thalassemi as trait	17 (14 to 21)	11 (9 to 13)	-0.36 (-0.4 to -0.31)	31.96 (26.35 to 39.07)	24. 42 (20. 29 to 29. 32)	0.12 (-0.31 to 0.55)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Ukraine	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 38 (-0. 48 to -0. 24)	0.01 (0.01 to 0.01)	0.01 (0 to 0.01)	-0.02 (-0.45 to 0.42)
Ukraine	Sickle cell trait	3 (3 to 4)	2 (2 to 2)	-0.39 (-0.44 to -0.32)	6. 05 (4. 84 to 7. 42)	4. 42 (3. 54 to 5. 38)	-0.01 (-0.45 to 0.42)
Ukraine	G6PD deficiency	13 (12 to 13)	8 (8 to 9)	-0.35 (-0.36 to -0.34)	23. 99 (22. 85 to 25. 06)	18.65 (17.76 to 19.43)	-0.14 (-0.57 to 0.29)
Ukraine	G6PD trait	49 (48 to 50)	29 (29 to 30)	-0. 4 (-0. 4 to -0. 4)	92. 59 (90. 32 to 94. 69)	66. 85 (65. 22 to 68. 36)	-0.02 (-0.47 to 0.42)
United Arab Emirates	Inherited anemias	17 (16 to 18)	20 (18 to 22)	0. 18 (0. 08 to 0. 26)	897. 72 (841. 26 to 944. 8)	214. 58 (193. 63 to 236. 6)	-4.38 (-4.58 to -4.17)
United Arab Emirates	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.31 (0.15 to 0.47)	2. 24 (1. 65 to 3. 01)	0.6 (0.45 to 0.82)	-3.98 (-4.2 to -3.77)
United Arab Emirates	Thalassemi as trait	3 (2 to 3)	4 (3 to 4)	0. 28 (0. 21 to 0. 35)	152. 31 (132. 08 to 174. 82)	39. 58 (34. 77 to 45. 67)	-4.07 (-4.29 to -3.85)
United Arab Emirates	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 19 (0. 12 to 0. 28)	0.73 (0.6 to 0.88)	0. 18 (0. 14 to 0. 21)	-4.52 (-4.75 to -4.29)
United Arab Emirates	Sickle cell trait	2 (1 to 2)	2 (2 to 2)	0. 2 (0. 16 to 0. 24)	83. 27 (75. 85 to 91. 33)	20. 25 (18. 42 to 22. 21)	-4.39 (-4.61 to -4.17)
United Arab Emirates	G6PD deficiency	4 (4 to 5)	5 (4 to 6)	0.05 (-0.16 to 0.26)	233. 69 (198. 76 to 260. 3)	49. 72 (38. 43 to 62. 8)	-4.88 (-5.02 to -4.74)
United Arab Emirates	G6PD trait	8 (8 to 8)	10 (9 to 10)	0. 21 (0. 12 to 0. 3)	425. 47 (408. 17 to 447. 7)	104. 27 (95. 15 to 112. 51)	-4.23 (-4.47 to -3.99)
United Kingdom	Inherited anemias	146 (138 to 156)	148 (142 to 155)	0.01 (-0.01 to 0.03)	254. 85 (240. 95 to 271. 5)	220. 32 (210. 67 to 231. 06)	-0.23 (-0.43 to -0.03)
United Kingdom	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0.06 (-0.13 to -0.01)	0.08 (0.06 to 0.11)	0.06 (0.04 to 0.09)	-0.63 (-0.78 to -0.49)
United Kingdom	Thalassemi as trait	11 (10 to 14)	11 (9 to 14)	-0.01 (-0.04 to 0.01)	19.88 (16.67 to 24.38)	16.77 (13.91 to 20.71)	-0.4 (-0.56 to -0.24)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
United Kingdom	Sickle cell disorders	1 (0 to 1)	1 (0 to 1)	0.04 (-0.08 to 0.16)	1. 1 (0. 77 to 1. 55)	0. 98 (0. 72 to 1. 29)	-0.12 (-0.4 to 0.16)
United Kingdom	Sickle cell trait	31 (24 to 40)	30 (24 to 36)	-0.05 (-0.13 to 0.04)	54. 28 (42. 14 to 69. 23)	43. 97 (35. 93 to 52. 88)	-0.37 (-0.59 to -0.15)
United Kingdom	G6PD deficiency	12 (11 to 12)	19 (18 to 20)	0.63 (0.61 to 0.66)	20.57 (19.6 to 21.51)	28. 72 (27. 44 to 29. 88)	1.45 (0.86 to 2.06)
United Kingdom	G6PD trait	91 (90 to 93)	87 (86 to 89)	-0.04 (-0.05 to -0.04)	158. 94 (155. 75 to 161. 99)	129. 82 (127. 29 to 132. 13)	-0.44 (-0.64 to -0.25)
United Republic of Tanzania	Inherited anemias	553 (501 to 607)	877 (797 to 960)	0.59 (0.55 to 0.62)	2134. 49 (1934. 72 to 2344. 4)	1546.02 (1404.45 to 1691.26)	-1.07 (-1.26 to -0.89)
United Republic of Tanzania	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2.81 (2.3 to 3.48)	0. 1 (0. 06 to 0. 15)	0. 17 (0. 09 to 0. 25)	1.63 (1.42 to 1.85)
United Republic of Tanzania	Thalassemi as trait	7 (6 to 9)	17 (13 to 21)	1.35 (1.17 to 1.55)	27. 8 (22. 03 to 33. 89)	29. 77 (23. 38 to 36. 25)	0. 12 (0 to 0. 25)
United Republic of Tanzania	Sickle cell disorders	7 (6 to 9)	13 (10 to 16)	0.79 (0.62 to 0.99)	27. 74 (21. 73 to 34. 23)	22. 7 (18. 12 to 28. 1)	-0.71 (-0.92 to -0.5)
United Republic of Tanzania	Sickle cell trait	173 (155 to 191)	301 (271 to 332)	0.74 (0.66 to 0.82)	669. 22 (598. 21 to 738. 77)	530. 17 (478. 51 to 585. 45)	-0.8 (-0.94 to -0.66)
United Republic of Tanzania	G6PD deficiency	134 (104 to 166)	177 (137 to 223)	0.32 (0.24 to 0.41)	515.96 (400.06 to 641.5)	311.79 (241.04 to 392.18)	-1.68 (-2.03 to -1.33)
United Republic of Tanzania	G6PD trait	231 (212 to 249)	370 (337 to 399)	0.6 (0.59 to 0.61)	893. 68 (819. 86 to 960. 59)	651. 43 (594. 23 to 703. 22)	-1.02 (-1.17 to -0.87)
United States of America	Inherited anemias	1295 (1231 to 1367)	781 (761 to 800)	-0. 4 (-0. 43 to -0. 37)	510. 73 (485. 32 to 539. 15)	238. 02 (232. 03 to 243. 78)	-1.85 (-2.29 to -1.42)
United States of America	Thalassemi as	1 (1 to 1)	1 (1 to 1)	-0.02 (-0.11 to 0.09)	0. 43 (0. 32 to 0. 57)	0. 32 (0. 26 to 0. 42)	-0.65 (-0.82 to -0.48)
United States of America	Thalassemi as trait	89 (76 to 103)	87 (78 to 98)	-0.02 (-0.07 to 0.04)	35.03 (29.99 to 40.8)	26. 53 (23. 67 to 29. 74)	-0.68 (-0.82 to -0.54)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
United States of America	Sickle cell disorders	44 (33 to 58)	2 (2 to 2)	-0.96 (-0.97 to -0.95)	17. 25 (12. 87 to 22. 9)	0. 52 (0. 46 to 0. 57)	-8. 16 (-10. 5 to -5. 75)
United States of America	Sickle cell trait	524 (470 to 583)	117 (110 to 125)	-0.78 (-0.8 to -0.75)	206. 67 (185. 41 to 229. 82)	35.81 (33.61 to 38.24)	-4.17 (-5.15 to -3.19)
United States of America	G6PD deficiency	212 (204 to 220)	163 (156 to 170)	-0.23 (-0.26 to -0.21)	83.66 (80.4 to 86.79)	49.78 (47.48 to 51.98)	-1.92 (-2.97 to -0.85)
United States of America	G6PD trait	425 (418 to 432)	410 (402 to 418)	-0.04 (-0.05 to -0.02)	167. 7 (164. 73 to 170. 39)	125. 07 (122. 55 to 127. 39)	-0.83 (-1 to -0.67)
United States Virgin Islands	Inherited anemias	1 (0 to 1)	0 (0 to 0)	-0.43 (-0.45 to -0.41)	532. 53 (468. 36 to 605. 39)	311.7 (273.61 to 352.89)	-1.86 (-1.89 to -1.84)
United States Virgin Islands	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0. 08 (-0. 45 to 0. 87)	0.01 (0.01 to 0.02)	0.01 (0 to 0.01)	-0.36 (-0.6 to -0.12)
United States Virgin Islands	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	-0.34 (-0.45 to -0.16)	7. 28 (5. 62 to 9. 1)	4. 9 (3. 86 to 5. 97)	-1.43 (-1.5 to -1.35)
United States Virgin Islands	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.35 (-0.43 to -0.27)	3.7 (2.69 to 4.92)	2. 43 (1. 72 to 3. 39)	-1.53 (-1.71 to -1.36)
United States Virgin Islands	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0. 4 (-0. 44 to -0. 36)	153. 34 (128. 96 to 179. 6)	93. 39 (75. 9 to 112. 08)	-1.75 (-1.83 to -1.66)
United States Virgin Islands	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	-0. 44 (-0. 49 to -0. 39)	167. 27 (129. 48 to 210. 3)	95. 25 (73. 3 to 118. 27)	-1.95 (-1.97 to -1.92)
United States Virgin Islands	G6PD trait	0 (0 to 0)	0 (0 to 0)	-0.44 (-0.46 to -0.4)	200. 93 (178. 92 to 224. 01)	115. 72 (102. 98 to 129. 04)	-1.91 (-1.93 to -1.9)
Uruguay	Inherited anemias	6 (5 to 6)	4 (4 to 5)	-0. 22 (-0. 25 to -0. 19)	177. 74 (156. 31 to 201. 29)	127. 06 (111. 76 to 143. 92)	-1.25 (-1.34 to -1.15)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Uruguay	Thalassemi as	0 (0 to 0)	0 (0 to 0)	-0. 23 (-0. 37 to 0. 01)	0. 23 (0. 14 to 0. 36)	0. 16 (0. 11 to 0. 23)	-1.31 (-1.69 to -0.93)
Uruguay	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.61 (0.36 to 0.94)	7 (5.73 to 8.4)	10. 29 (8. 74 to 12. 11)	1.61 (1.17 to 2.05)
Uruguay	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.12 (-0.16 to 0.32)	0 (0 to 0)	0 (0 to 0)	-0.75 (-0.82 to -0.68)
Uruguay	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	-0.12 (-0.16 to 0.23)	3. 24 (1. 83 to 4. 84)	2. 59 (1. 46 to 3. 91)	-0.79 (-0.88 to -0.7)
Uruguay	G6PD deficiency	1 (1 to 1)	1 (1 to 1)	-0.22 (-0.26 to -0.17)	28. 08 (21. 75 to 34. 99)	20. 13 (15. 59 to 25. 54)	-1.3 (-1.39 to -1.22)
Uruguay	G6PD trait	4 (4 to 5)	3 (3 to 4)	-0.26 (-0.3 to -0.23)	139. 2 (124. 27 to 155. 06)	93. 89 (83. 1 to 105. 08)	-1.45 (-1.55 to -1.35)
Uzbekistan	Inherited anemias	92 (83 to 101)	92 (83 to 102)	0 (-0.01 to 0.02)	436. 95 (394. 14 to 483. 45)	272. 24 (244. 98 to 301. 41)	-1.21 (-1.49 to -0.92)
Uzbekistan	Thalassemi as	1 (0 to 1)	0 (0 to 1)	-0.28 (-0.36 to -0.19)	2. 59 (1. 85 to 3. 75)	1. 16 (0. 86 to 1. 58)	-2.32 (-2.61 to -2.03)
Uzbekistan	Thalassemi as trait	22 (19 to 26)	23 (20 to 26)	0.04 (-0.01 to 0.1)	106. 2 (92. 88 to 122. 15)	68.92 (60.66 to 77.95)	-1. 1 (-1. 39 to -0. 81)
Uzbekistan	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.02 (-0.13 to 0.22)	0.02 (0.01 to 0.03)	0.01 (0.01 to 0.02)	-1.13 (-1.42 to -0.84)
Uzbekistan	Sickle cell trait	3 (3 to 4)	3 (3 to 4)	0.01 (-0.08 to 0.11)	15.68 (12.39 to 19.54)	9.89 (7.81 to 12.33)	-1.16 (-1.45 to -0.88)
Uzbekistan	G6PD deficiency	10 (7 to 12)	10 (8 to 13)	0.03 (-0.03 to 0.1)	46.6 (35.69 to 59.31)	29. 94 (23. 04 to 37. 98)	-1.04 (-1.34 to -0.74)
Uzbekistan	G6PD trait	56 (50 to 62)	55 (49 to 61)	-0.02 (-0.02 to -0.02)	265. 85 (236. 39 to 297. 92)	162.32 (144.33 to 181.91)	-1.27 (-1.56 to -0.99)
Vanuatu	Inherited anemias	1 (1 to 1)	2 (2 to 2)	0.42 (0.36 to 0.49)	837. 72 (770. 22 to 908. 99)	612.08 (543.98 to 681.91)	-1.06 (-1.17 to -0.95)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Vanuatu	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0. 19 (0. 01 to 0. 37)	4. 74 (2. 62 to 7. 24)	2.89 (1.58 to 4.3)	-0.58 (-1.52 to 0.38)
Vanuatu	Thalassemi as trait	0 (0 to 0)	0 (0 to 0)	0.28 (0.2 to 0.37)	135. 19 (103. 75 to 164. 79)	89. 28 (68. 81 to 107. 4)	-0.99 (-1.37 to -0.6)
Vanuatu	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0.44 (0.32 to 1.85)	0 (0 to 0.01)	0 (0 to 0)	-1.01 (-1.11 to -0.9)
Vanuatu	Sickle cell trait	0 (0 to 0)	0 (0 to 0)	0.4 (0.32 to 1.17)	5. 1 (2. 19 to 7. 86)	3.67 (1.49 to 5.87)	-1.13 (-1.21 to -1.05)
Vanuatu	G6PD deficiency	0 (0 to 0)	0 (0 to 0)	0.34 (0.1 to 0.58)	193. 29 (178. 92 to 208. 08)	132. 78 (102. 5 to 165. 37)	-1.36 (-1.4 to -1.31)
Vanuatu	G6PD trait	1 (1 to 1)	1 (1 to 1)	0. 49 (0. 45 to 0. 54)	499.39 (449.04 to 544.7)	383. 46 (346. 14 to 417. 43)	-0.99 (-1.11 to -0.87)
Venezuela (Bolivarian Republic of)	Inherited anemias	117 (105 to 130)	82 (73 to 91)	-0. 3 (-0. 32 to -0. 28)	623.71 (557.42 to 691.53)	292. 36 (260. 36 to 325. 68)	-2.14 (-2.36 to -1.92)
Venezuela (Bolivarian Republic of)	Thalassemi as	0 (0 to 0)	0 (0 to 0)	0.42 (-0.15 to 1.84)	0.01 (0.01 to 0.02)	0.01 (0.01 to 0.02)	0.25 (-0.07 to 0.57)
Venezuela (Bolivarian Republic of)	Thalassemi as trait	2 (1 to 2)	2 (2 to 2)	0.02 (-0.15 to 0.31)	10. 22 (7. 96 to 12. 78)	7. 02 (5. 46 to 8. 57)	-0.84 (-1.05 to -0.63)
Venezuela (Bolivarian Republic of)	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0. 59 (-0. 65 to -0. 52)	1. 29 (1. 03 to 1. 58)	0.36 (0.27 to 0.45)	-4. 24 (-4. 54 to -3. 94)
Venezuela (Bolivarian Republic of)	Sickle cell trait	17 (15 to 20)	7 (6 to 8)	-0.58 (-0.61 to -0.55)	92. 5 (81. 89 to 105. 05)	26. 24 (22. 84 to 30. 24)	-4. 25 (-4. 56 to -3. 95)
Venezuela (Bolivarian Republic of)	G6PD deficiency	20 (16 to 25)	13 (10 to 16)	-0.36 (-0.39 to -0.32)	108. 26 (83. 15 to 135. 29)	46. 66 (36. 05 to 58. 04)	-2.37 (-2.76 to -1.97)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Venezuela (Bolivarian Republic of)	G6PD trait	77 (70 to 85)	60 (54 to 65)	-0. 23 (-0. 25 to -0. 21)	411. 43 (370. 73 to 451. 25)	212.07 (191.01 to 232.26)	-1.77 (-2.03 to -1.52)
Viet Nam	Inherited anemias	449 (409 to 490)	306 (280 to 334)	-0.32 (-0.34 to -0.3)	660. 5 (602. 22 to 721. 6)	317. 58 (290. 51 to 346. 36)	-2.11 (-2.32 to -1.9)
Viet Nam	Thalassemi as	5 (4 to 6)	4 (3 to 4)	-0.3 (-0.37 to -0.22)	7.5 (6.24 to 9.22)	3. 7 (3. 15 to 4. 4)	-1.99 (-2.16 to -1.83)
Viet Nam	Thalassemi as trait	122 (111 to 134)	101 (93 to 111)	-0.17 (-0.2 to -0.14)	179. 54 (163. 98 to 197. 16)	105. 25 (96. 12 to 115. 22)	-1.41 (-1.57 to -1.25)
Viet Nam	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.25 (-0.44 to -0.05)	0.02 (0.01 to 0.03)	0.01 (0.01 to 0.01)	-1.69 (-1.89 to -1.5)
Viet Nam	Sickle cell trait	9 (7 to 11)	7 (6 to 8)	-0.25 (-0.35 to -0.16)	13. 38 (10. 9 to 16. 06)	7. 04 (5. 73 to 8. 51)	-1.73 (-1.91 to -1.56)
Viet Nam	G6PD deficiency	56 (43 to 70)	34 (26 to 42)	-0. 4 (-0. 43 to -0. 36)	82.84 (63.76 to 103.03)	35 (27.14 to 43.69)	-2.62 (-2.89 to -2.34)
Viet Nam	G6PD trait	256 (231 to 280)	161 (144 to 176)	-0.37 (-0.4 to -0.35)	377. 23 (340. 71 to 411. 8)	166. 58 (149. 83 to 182. 99)	-2. 4 (-2. 64 to -2. 15)
Yemen	Inherited anemias	221 (200 to 243)	313 (283 to 345)	0.42 (0.39 to 0.44)	1609. 29 (1454. 34 to 1769. 64)	994. 97 (897. 64 to 1094. 65)	-1.53 (-1.77 to -1.29)
Yemen	Thalassemi as	1 (0 to 1)	1 (1 to 1)	0. 49 (0. 33 to 0. 7)	4. 84 (3. 2 to 7. 19)	3. 14 (2. 17 to 4. 57)	-1.43 (-1.65 to -1.2)
Yemen	Thalassemi as trait	44 (36 to 53)	65 (55 to 77)	0.47 (0.39 to 0.56)	320. 4 (264. 93 to 386. 3)	205. 31 (173. 14 to 244. 51)	-1.44 (-1.68 to -1.21)
Yemen	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	0. 4 (0. 32 to 0. 49)	1. 59 (1. 34 to 1. 87)	0. 97 (0. 82 to 1. 17)	-1.58 (-1.83 to -1.33)
Yemen	Sickle cell trait	23 (22 to 26)	33 (30 to 36)	0. 4 (0. 36 to 0. 44)	170. 78 (156. 82 to 185. 96)	103. 84 (95. 57 to 114. 3)	-1.58 (-1.83 to -1.33)
Yemen	G6PD deficiency	42 (33 to 53)	59 (46 to 74)	0.39 (0.32 to 0.46)	309. 42 (239. 56 to 387. 94)	187. 22 (144. 98 to 235. 59)	-1.61 (-1.86 to -1.35)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Yemen	G6PD trait	110 (100 to 120)	156 (142 to 169)	0. 41 (0. 4 to 0. 44)	802. 25 (729. 52 to 874)	494. 49 (449. 75 to 536. 35)	-1. 53 (-1. 76 to -1. 3)
Zambia	Inherited anemias	210 (188 to 232)	316 (284 to 349)	0.51 (0.45 to 0.56)	2637. 68 (2370. 15 to 2917. 04)	1732. 24 (1559. 13 to 1914. 22)	-1.47 (-1.64 to -1.3)
Zambia	Thalassemi as	0 (0 to 0)	0 (0 to 0)	2. 47 (2. 04 to 3. 08)	0.1 (0.06 to 0.16)	0.15 (0.09 to 0.23)	1.09 (0.86 to 1.32)
Zambia	Thalassemi as trait	2 (2 to 3)	5 (4 to 6)	1.17 (1.02 to 1.36)	29. 01 (22. 77 to 35. 5)	27. 38 (21. 75 to 33. 29)	-0.38 (-0.53 to -0.23)
Zambia	Sickle cell disorders	4 (3 to 5)	5 (4 to 6)	0. 28 (0. 08 to 0. 5)	50. 15 (38. 96 to 66. 63)	28. 05 (22. 65 to 35. 11)	-1.83 (-2.28 to -1.38)
Zambia	Sickle cell trait	70 (62 to 80)	100 (91 to 111)	0. 43 (0. 32 to 0. 54)	881.5 (785.04 to 1005.69)	549.76 (498.96 to 610.93)	-1.58 (-1.84 to -1.32)
Zambia	G6PD deficiency	57 (44 to 71)	86 (67 to 106)	0.51 (0.39 to 0.62)	719.65 (558.35 to 893.7)	472. 22 (365. 39 to 583. 62)	-1.51 (-1.65 to -1.36)
Zambia	G6PD trait	76 (70 to 81)	119 (110 to 128)	0.57 (0.52 to 0.62)	957. 27 (880. 26 to 1025. 9)	654. 67 (603. 12 to 701. 92)	-1.36 (-1.48 to -1.25)
Zimbabwe	Inherited anemias	125 (111 to 140)	138 (122 to 154)	0.1 (0.07 to 0.12)	1210. 48 (1071. 29 to 1356. 02)	917. 68 (813. 25 to 1023. 71)	-0.67 (-0.81 to -0.53)
Zimbabwe	Thalassemi as	0 (0 to 0)	0 (0 to 0)	1.43 (1.04 to 1.97)	0.08 (0.05 to 0.12)	0.14 (0.08 to 0.21)	1.81 (1.64 to 1.98)
Zimbabwe	Thalassemi as trait	3 (3 to 4)	4 (4 to 5)	0.48 (0.35 to 0.64)	29. 12 (24. 46 to 34. 81)	29. 72 (24. 26 to 35. 38)	0. 29 (0. 17 to 0. 41)
Zimbabwe	Sickle cell disorders	0 (0 to 0)	0 (0 to 0)	-0.08 (-0.19 to 0.02)	1.69 (1.3 to 2.24)	1. 07 (0. 8 to 1. 42)	-1.9 (-2.1 to -1.7)
Zimbabwe	Sickle cell trait	16 (14 to 18)	16 (14 to 19)	0.03 (-0.04 to 0.08)	153. 73 (134. 56 to 177. 18)	108. 56 (94. 28 to 125. 73)	-1.21 (-1.31 to -1.12)
Zimbabwe	G6PD deficiency	36 (28 to 46)	39 (30 to 49)	0.06 (0.03 to 0.1)	352. 6 (271. 28 to 441. 64)	258. 58 (198. 98 to 324. 49)	-0.75 (-0.94 to -0.56)

Regions	Causes	Cases in 1990 No.×103 (95% UI)	Cases in 2019 No.×103 (95% UI)	Change in absolute number (%)	Rates in 1990 per 100000 (95% UI)	Rates in 2019 per 100000 (95% UI)	EAPC from 1990 and 2019 (95%CI)
Zimbabwe	G6PD trait	70 (64 to 75)	78 (71 to 84)	0. 12 (0. 09 to 0. 15)	673. 26 (615. 69 to 728. 09)	519.61 (473.24 to 561.3)	-0. 56 (-0. 7 to -0. 42)

Abbreviations: EAPC, estimated annual percentage change; UI, uncertainty interval. CI, confidence interval.